Study on the prevalence of drug use, including intravenous drug use, and blood-borne viruses among the Irish prisoner population. by Drummond, Anne et al.
Study on the prevalence of drug use, 
including intravenous drug use, and 
blood-borne viruses among 
the Irish prisoner population
1Study on the prevalence of drug use, including intravenous drug use, 
and blood-borne viruses among the Irish prisoner population
Executive Summary
Background
Accurate up-to-date data on the extent of drug use and the prevalence of blood-borne viruses among the prisoner population 
are a necessary pre-requisite for health and social service planning and policy development. The most recent national study 
assessing the prevalence of blood-borne viruses, along with self-reported drug use within Irish prisons (Allwright et al., 1999), 
was carried out over a decade ago. This study was commissioned by the National Advisory Committee on Drugs (NACD)* 
in 2010 with the following objectives: to describe the nature, extent and pattern of consumption for different drugs among 
the prisoner population; to describe methods of drug use, including intravenous drug use, among the prisoner population; 
to estimate the prevalence of blood-borne viruses among the prisoner population and to identify associated risk behaviours; 
and to measure the uptake of individual drug treatment and harm reduction interventions (including hepatitis B vaccination) 
in prison.
Methods
An observational cross-sectional study, targeting all prisons and prisoners in Ireland, was carried out in early 2011. Prisoners 
were selected at random in proportion to the population in each prison. A detailed, validated and piloted self-completion 
questionnaire was administered to prisoners under the supervision of the research team. Oral fluid samples were taken 
for assessment of drugs of abuse and blood-borne viruses. Overall 824 prisoners participated, with a final response rate of 
49.5%.
Results
Results reveal lifetime, last year and last month prevalence rates for drug use that greatly exceed those of the general 
population but which are broadly consistent with findings from prison studies internationally. For example, lifetime cannabis 
use among all prisoners was 87%, last year use was 69% and last month use was 43%. Likewise, lifetime heroin use was 
43%, last year use was 30% and last month use was 11%. Women were significantly more likely to use drugs, including 
injecting drugs. Despite there being a high prevalence (26%) of ever injecting drugs among prisoners, last month injecting 
prevalence was low (2%). Prevalence of HIV was 2%. Prevalence rates for hepatitis C (13%) and hepatitis B (0.3%) were 
lower than expected. By far the most important factors associated with blood-borne viruses in this prison population were 
ever having used drugs IV and ever having shared IV drug equipment. Older age and having had a tattoo done in prison 
were associated with hepatitis C. Female prisoners were at greater risk of having hepatitis C and HIV and male-to-male sexual 
contact was confirmed as a risk factor for HIV. The need for drug treatment and harm reduction services was identified in 
different prison categories, with a pattern of very high uptake of services when they are available.
Summary
This study confirms that drug use, including injecting drug use, is a significant problem among prisoners in Ireland and 
suggests that drug-related factors are important in the acquisition of blood-borne viruses. The findings also show that 
prisoners who need services, such as the range of addiction services and detoxification, are very willing to use them when 
they are available. ‘In-prison’ uptake of testing and vaccination services confirms that prisons are appropriate settings for the 
provision of preventive, diagnostic and treatment services for drug users. It is hoped that the evidence provided in this study 
will facilitate service and policy development in this important area.
* In 2013 the remit of the NACD was extended to include alcohol and is now called the National Advisory Committee on Drugs and Alcohol (NACDA).
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Chapter 1 Introduction
1.1 Background
The National Advisory Committee on Drugs (NACD)* was established in July 2000 to advise the Government in 
relation to the prevalence, prevention, treatment/rehabilitation and consequences of problem drug use in Ireland, 
based on the analysis of research findings and information. The Committee oversees the delivery of a work 
programme on the extent, nature, causes and effects of drug use in Ireland.
A Steering Group, set up under the auspices of the former National Drug Strategy Team, carried out an assessment 
of the need for prison-based needle exchange in Ireland in 2009. The primary conclusions were that prison needle-
exchange constitutes a viable, effective means of addressing the drug problem and associated health risks within 
Irish prisons. However, it was acknowledged that data measuring the prevalence of drug use, including intravenous 
drug use, among the prison population is either dated or based on a proxy approach. The Steering Group therefore 
recommended that a study should be carried out to measure the extent of drug use, including intravenous drug 
use, and the prevalence of blood-borne viruses among the prisoner population before consideration is given to 
introducing needle exchange into a prison setting.
1.2 Aim and Objectives
Against this background the National Advisory Committee on Drugs commissioned University College Dublin (UCD) 
to undertake this study. The study aimed to estimate the prevalence of drug use, including intravenous drug use, 
among the prisoner population in Ireland in order to determine the need for drug treatment and harm reduction 
(including needle exchange) services in Irish prisons.
The project objectives are:
1. To describe the nature, extent and pattern of consumption for different drugs among the prisoner population;
2. To describe methods of drug use, including intravenous drug use, among the prisoner population;
3. To estimate the prevalence of blood-borne viruses among the prisoner population and to identify associated risk 
behaviours;
4. To measure the uptake of individual drug treatment and harm reduction interventions (including hepatitis B 
vaccination) in prison.
The study was jointly funded by the NACD and the Irish Prison Service.
This is the first dedicated national drug prevalence study of the prisoner population in Ireland, which includes 
detailed questions on thirteen individual drugs and biological sampling for drugs. It will provide a benchmark for 
future studies of this type.
This study did not set out to address the prevalence or the different patterns of drug use that may exist among the 
larger throughput of committals.
1.3 Prevalence
This is a prevalence study of drug use and of blood-borne virus status among prisoners. The definitions of lifetime, 
last year and last month prevalence adopted for this study are those used by the National Advisory Committee on 
Drugs that define prevalence as follows:
• Prevalence refers to the proportion of a population who have used a drug over a particular time period.
• Lifetime prevalence refers to the proportion of the sample that reported ever having used the named 
drug at the time they were surveyed. A person who records lifetime prevalence may – or may not – be 
currently using the drug. Lifetime prevalence should not be interpreted as meaning that people have 
necessarily used a drug over a period of time or that they will use the drug in the future.
* In 2013 the remit of the NACD was extended to include alcohol and is now called the National Advisory Committee on Drugs and Alcohol (NACDA).
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Chapter 1 Introduction
• Last year prevalence refers to the proportion of the sample that reported using a named drug in the year 
prior to the survey. For this reason, last year prevalence is often referred to as recent use.
• Last month prevalence refers to the proportion of the sample that reported using a named drug in the  
30 day period prior to the survey. Last month prevalence is often referred to as current use. A proportion  
of those reporting current use may be occasional (or first-time) users who happen to have used in the 
period leading up to the survey – it should therefore be appreciated that current use is not synonymous 
with regular use.
1.4 Report Outline
This report is structured in the following manner. Chapter 2 sets the context for this study by examining the existing 
literature on both drug use and blood-borne viruses within prisons. A review of the literature on drug policies in 
prisons within Ireland and internationally is also provided. A reference list is provided at the end of the report.
Chapter 3 describes in detail the methods employed in the study. This includes the sampling strategy and 
procedure, development and piloting of the study materials and data collection methods, data entry and data 
analysis.
Chapter 4 provides a socio-demographic over-view of the sample along with a discussion of the representativeness 
of the sample. Following this the prevalence rates for lifetime, last year and last month drug use and injecting drug 
use among prisoners are presented. Chapter 4 also presents the nature and patterns of drug use including drug use 
initiating in prison as well as use in prison within the last year. Methods of use for different drugs are explored along 
with the prevalence rates for blood-borne viruses, namely hepatitis C, hepatitis B and the Human Immunodeficiency 
Virus (HIV). Models of the socio-demographic, behavioural and drug-related factors associated with hepatitis C, HIV 
and co-infection of blood-borne viruses are provided. Lastly, the need for and availability and uptake of a range of 
drug treatment and harm reduction services in the prison setting are described.
For comparison purposes, it should be noted that two previous national Irish studies of prison inmates have 
included a small number of questions about the prevalence of drug use. A prevalence study of Blood-Borne Viruses 
(BBVs) asked a question on last year heroin use and a question on ever injection (Allwright et al, 1999) in addition 
to questions associated with BBV risk behaviours, such as injecting drug use and sharing works. However, because 
six of the then 15 prisons were not included in that study, excluding in particular three prisons perceived as low 
risk for BBVs, direct comparison of results may be misleading. The general healthcare study of prisoners (Centre for 
Health Promotion Studies, 2000) included 13 of 15 prisons, and it is not known which two prisons were excluded. 
Drug questions in that study included a small number of comparable questions on cannabis, cocaine and heroin. 
Methodological differences, or lack of methodological detail, in published international prison drug studies also 
preclude direct comparison. In interpreting results therefore, while comparisons are made with previous Irish and 
other studies, these limitations should be borne in mind and are highlighted in Chapter 4 where appropriate.  
In order to provide a context for comparison, for some drugs, prevalence rates for the general population are 
referred to.
Chapter 5 discusses the study findings. Discussion focuses on generalisability of the findings, the prevalence and 
methods of drug use, prevalence of blood-borne viruses, and the uptake and utilisation of prison drug treatment 
and harm reduction services. Finally, the policy implications of these findings are discussed.
Tables of prevalence are provided in the appendix. These include prevalence rates and confidence intervals for total, 
age and gender for self-reported lifetime, last year and last month prevalence for drug use and intravenous drug use 
for individual drugs, and for blood-borne virus status. Tables are also provided for prevalence based on the results of 
oral fluid analysis for drugs and for blood-borne viruses.
A separate Technical Report contains additional detail on the methods employed and the logistics of fieldwork. The 
appendices of the Technical Report contain copies of advance documentation and information provided to prisoners 
and staff including leaflets, poster, participant information sheets, consent form and questionnaire.
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Chapter 2 Literature Review
2.1 Introduction
Substance abuse and associated harm from their problematic use is a major problem in prisons globally. In order 
to ensure evidence-based decision-making when determining the need for drug treatment and harm reduction 
services in Irish prisons it is necessary to have reliable up-to-date data on the extent of drug use and the prevalence 
of blood-borne viruses among the prisoner population. To set the context for this study it is necessary to discuss the 
findings from studies, both within Ireland and internationally, which have analysed both drug use and blood-borne 
viruses within prisons. This is done by firstly looking at substance abuse in prisons before turning to blood-borne 
viruses in prisons. Finally, a brief review of the literature on drug policies in prisons within Ireland and internationally 
is also provided.
2.2 Prisoner Health
A distinguishing feature amongst prison populations, both in Ireland and internationally, is that they are among the 
most socio-economically deprived communities (O’Mahony, 2002; Jenkins et al., 2005). Prison populations are 
characterised by high unemployment, early school leaving, poor housing and family breakdown (Sugrue, 2006). 
Indeed the Prison Adult Literacy Survey found that a significant number of prisoners in Ireland have virtually no 
literacy skills. There was also a large number of prisoners who have limited skills of a kind that would enable them 
to meet the challenges of modern day living (Morgan and Kett, 2003).
In tandem with experiencing socio-economic deprivation and exclusion prison populations are also known to 
experience poorer physical and mental health, including both acute and long standing physical and mental illness 
and disability, drug and alcohol dependency, sexual health problems, suicide and self-harm when compared to 
the general population (Hannon et al., 2007; Barry et al., 2010). The general healthcare study of the Irish prisoner 
population (Centre for Health Promotion Studies, NUI Galway, 2000) found that reported levels of excellent or 
very good health amongst prisoners (29% for males, 16% for females) which they noted were lower than that 
of the general population (47% of similar aged males in SLÁN). The study also found high levels of life time drug 
use when compared to the general population (72% for males compared to 14% for males in SLÁN), high levels 
of alcohol consumption (25% of males and 39% of females drank daily outside of prison) and cigarette smoking 
(91% of males and 100% of females).
2.3 Substance Abuse in Prison
Over the past two decades the presence of illicit drugs and the associated harm from their problematic use has 
changed considerably the reality of prisons throughout Europe and the rest of the world (WHO, 2005). Prison 
populations are well known to have personal histories of drug use and have a high concentration of injecting drug 
use when compared to the general population (Singleton et al., 1999; Boys et al., 2002; Lukasiewicz et al., 2007; 
Dolan et al., 2007). For example, in a major national survey of a random sample of all 131 prisons in England and 
Wales, Boys et al. (2002) found the prevalence of heroin use in UK prisons was approximately forty times what 
would be expected from a random population sample. It is therefore understandable that, despite methodological 
differences, a number of studies internationally have found relatively high rates of drug use and drug dependence 
within the prison population both before entering prison and within prison (Singleton et al., 1999; Sleiman, 
2004; Lukasiewicz et al., 2007; Graham, 2007; Scottish Prison Service, 2008 and 2009). Table 2.2 highlights the 
prevalence of drug use within prisons as found from a selection of international studies. As can be seen from 
the table, in each study the most prevalent drug used in prison was Cannabis, followed by Benzodiazepines and 
Opiates. It is also possible to see that there are marginal differences in the prevalence of Benzodiazepines and 
Opiates reported within each study.
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Table 2.1 Findings from international studies on prevalence of drug use within prisons
Author Year Country Sample (n) Drug use in prison 
included
Reported prevalence
Singleton 
et al.
1999 England & Wales 3,142 Use in prison during 
current sentence, not 
specific to any time 
period.
Cannabis: 36% for male remand, 46% 
for male sentenced, 19% for female 
remand, 31% for female sentenced. 
Methadone (non-prescribed): 1% for 
male remand, 2% for male sentenced, 
2% for female remand, 3% for female 
sentenced. 
Benzodiazepines: not reported 
Heroin: 12% for male remand, 19% 
for male sentenced, 17% for female 
remand, 20% for female sentenced. 
Cocaine: 2% for male remand, 4% for 
male sentenced, 1% for female remand, 
2% for female sentenced.
Sleiman 2004 Belgium 886 Ever use in prison, not 
specific to any time 
period.
Cannabis: 28.9% 
Methadone: 5.8% 
Benzodiazepines: 11.8% 
Heroin: 13.3% 
Cocaine: 11.1%
Lukasiewicz 
et al.
2007 France 998 Use in previous 12 
months, aggregating 
both prior and during 
prison sentence use.
Cannabis: 26.7% 
Methadone: not reported 
Benzodiazepines: not reported 
Opiates: 2.7% 
Cocaine: 5.5%
Scottish 
Prison 
Service
2008 Scotland Census of 
all Scottish 
prisoners (n not 
specified) 62% 
response rate
Use in the month 
prior to the survey 
while in prison
Proportion using each drug among those 
who reported having used the drug in 
prison: 
Heroin: 69% 
Cannabis: 66% 
Benzodiazepines: 45% 
Cocaine: 19% 
Methadone (non-prescribed): 17%
Scottish 
Prison 
Service
2009 Scotland Census of 
all Scottish 
prisoners (n not 
specified) 62% 
response
Use in the month 
prior to the survey 
while in prison
Proportion using each drug among those 
who reported having used the drug in 
prison: 
Heroin: 70% 
Cannabis: 61% 
Cocaine: 17% 
Methadone (non-prescribed): 18%
In her 2001 exploratory study within the Mountjoy Prison Complex in Ireland, Dillon found that for prisoners with 
a history of drug use the perceived benefits of drug use were reinforced in the prison environment. Drugs were 
seen to alleviate some of the problems associated with prison, such as boredom and depression (Dillon, 2001). 
As O’Mahony (2008) describes, the specific realities of prison life mean that for many prisoners drugs are never 
more attractive than in prisons. The stress, idleness, boredom and ubiquitous petty coercion of prison life make the 
pleasure, release and oblivion provided by the opiate fix or other powerful drugs especially attractive (O’Mahony, 
2008:7).
The prison environment has also been found to affect both the type of drug and method of use. In terms of the 
type of drug used, in the same study respondents argued that the effects of heroin and cannabis were more 
suited to the prison environment than stimulants (Dillon, 2001). Bullock (2003) also found a greater tendency 
to use depressants rather than stimulants in prisons in England, again the most frequently cited reasons for using 
depressants were relaxation and relief of boredom. In a study of prisons in the UK, Boys et al. (2002) found similar 
proportions of respondents who had ever used cannabis and heroin who also reported use in prison (64% for 
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cannabis, n=1,538/2,411; 62% for heroin, n=743/1203), whereas less than a quarter (24%, n=351/1,442) of 
those who had ever used cocaine reported having used while incarcerated. More recently, in Canada, Zakaria et al. 
(2010) found that the proportion of prisoners who reported cocaine as one of their most frequently used drugs 
declined considerably in prison compared to the community for both men (3% vs 34%) and women (6% vs 
46%), whereas opiate use declined the least in prison compared to the community (7% vs 9%).
In terms of the affect the prison environment has on the method of drug use, both Dillion (2001) and Long et 
al. (2004) report that respondents described how low availability of heroin encouraged a shift from smoking, 
which was perceived as wasteful, to injecting. Similarly, Malliori et al. (1998) found that in Greece more than half 
(57.8%, n=153) of those who admitted drug use in prison reported injection as the route of administration. This is 
not to say that injecting drug use has been found to be greater in prison than in the community; a decline in the 
proportion of men and women who inject in prison compared to the community has been reported in a number of 
studies (Bullock, 2003; Poulin et al., 2007; Zakaria et al., 2010). However, given limited quantities available injecting 
was seen as more ‘efficient’.
Considering the scarcity of injecting equipment elevated rates of sharing works in prison has been observed in a 
number of studies. As Malliori et al. (1998) report, injecting drug users inject less but share more in prison. The 
degree to which this occurs varies from study to study and there would appear to be a downward trend in the 
proportion sharing works over time. For example, the Malliori et al. (1998) study in Greece found that of those who 
injected 91.5% (n=119) were sharing works; whereas, for Koulierakis et al. (2000), again in Greece, this rate was 
83% (n=145). In Scotland, Graham (2007) reported 71% (n=79) of prisoners who inject sharing works, while in 
Canada Werb et al. (2008) reported 60.9% (n=56) of injectors sharing works. Most recently, Zakaria et al. (2010) 
found 44% of those who injected in prison shared works.
Within the Irish context a number of studies between 1984 and 2000, particularly focusing on prisons within 
Dublin, showed that there was a continued growth in the extent of drug use, especially injecting heroin (O’Mahony, 
1984; O’Mahony, 1997; Carmody and McEvoy, 1996; Allwright et al., 1999; Long et al., 2000). Reported use of 
heroin in these studies increased from 3.8% of prisoners in the O’Mahony study (1984) to 35.5% in the work of 
Long et al. (2000).
Furthermore, the more recent of these studies found higher prevalence rates for hepatitis B, hepatitis C and HIV 
in prisoners than in the general population (Allwright et al., 1999; Long et al., 2000). However, these studies were 
carried out over a decade ago. In the interim there is evidence of an increase in both the incidence and prevalence 
of treated drug use in the community (Alcohol and Drug Research Unit of the Health Research Board 2009a, 
2009b). The European Committee for the Prevention of Torture (CPT) fifth visit to Ireland in 2010 observed that 
drug-misuse remains a major challenge in all of the six prisons visited. The delegation reported that management 
and health-care staff in most prisons visited acknowledged both the rising numbers of prisoners with a substance 
abuse problem and the widespread availability of drugs (CPT, 2011).
Between 2001 and 2007 no studies were conducted to estimate the prevalence of drug use in Irish prisons. A 
2005 survey of the psychiatric status of Irish prisoners found that 59% (n=235) of male sentenced prisoners had 
a drug dependency problem and 45% (n=200) had an alcohol dependency problem based on the Severity of 
Dependence Questionnaire which is concerned with the psychological components of dependence (Kennedy et 
al., 2005). Long (2008) analysed information on drug testing, conducted to monitor drug use and response to 
treatment in prisons, from 2005 to 2007 as a proxy for drug use in prisons. More than 20,000 voluntary tests were 
carried out each year to monitor drug use and responses to treatment, however, these tests included those carried 
out on committals as well as existing inmates, therefore some of the positive test results could relate to drugs 
consumed outside of prison. It is noted that between one-third and half of those screened tested positive for at 
least one drug. More up-to-date information is found in the Irish Focal Point (2010) national report to the European 
Monitoring Centre for Drugs and Drugs Addiction (EMCDDA) on 2009 drug tests, excluding methadone, which 
again notes that committals are included. In Irish prisons it was found that between one-tenth and two-fifths tested 
positive for at least one drug.
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2.4 Blood-Borne Viruses in Prisons
The link between injecting drug use and blood-borne infections is a major concern. As discussed above, prisoner 
populations are recognised for engaging in illicit drug use, particularly injecting drug use, both in and out of prison, 
placing them at increased risk of exposure to blood-borne viruses (Australian Federation of AIDS Organisations, 
2007; Butler et al., 2007; Kirwan et al., 2011). Hepatitis C, hepatitis B and HIV prevalence has been found, in a 
number of studies, to be disproportionately higher among injecting drug prisoners than the general community. 
For example, Christensen et al., (2000) found that injecting drug users in prisons in Denmark have an incidence 
of hepatitis B and C 100 times higher than reported in the general Danish population (Christensen et al., 2000). 
Concurrently, Wong et al. (2006) report that the prevalence of hepatitis C in Canadian federal penitentiaries (17%-
40%) are estimated to be 20 to 50 times higher than among the general Canadian population (0.8%), while HIV 
rates are 5 to 40 times higher (1%-8% vs 0.2%).
A number of studies have analysed independent risk factors associated with hepatitis C, hepatitis B and HIV 
infection amongst prisoner populations. The significance of a history of injecting drug use is quite apparent from 
these studies. Indeed, a history of injecting drug use is the most commonly reported risk factor (Butler et al., 1997 
& 2007; Ford et al., 2000; Weild et al., 2000; Champion et al., 2004). Prior imprisonment has also been found 
to be independently associated with blood-borne infections (Butler et al., 1997 & 2007; Christensen et al., 2000; 
Guimarães et al., 2001). Guimarães et al. (2001) also found that the longer time spent in prison the greater the 
chance of acquiring infection. Older prisoners would appear to be more at risk, according to the multivariate models 
by Butler et al. (1997 & 2007). However, age was not found to be a significant predictor according to the logistic 
regression model cited in Christensen et al. (2000). Acquiring tattoos in prison was a risk factor, independent of a 
history of injecting drug use, for Hellard et al. (2007). In contrast, Butler et al. (1997), and Champion et al. (2004) 
found that neither tattoos in prison and sexual behaviour were significant predictors for blood-borne infections.
It is thus understandable that in many western countries prisoners have a higher prevalence of HIV, hepatitis B and 
hepatitis C than in the general population (Weild et al., 2000). For example, Christensen et al. (2000) found that 
the incidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among Danish prisoners was more than 100 
times higher than the reported incidence in the general Danish population. More recently, Wong et al. (2006)  
report that the prevalence of hepatitis C in Canadian federal penitentiaries (17%-40%) are estimated to be 20  
to 50 times higher than among the general Canadian population (0.8%), while HIV rates are 5 to 40 times higher  
(1%-8% vs 0.2%).
Table 2.2 highlights the prevalence of blood-borne viruses within prisons as found from a selection of international 
studies. The publication dates of these studies range from 1997 to 2011. While not directly comparable due to 
different methodologies, prevalence rates for hepatitis B range from 57.6% (antibody) in a study from Greece 
published in 1998 (Malliori et al., 1998) to 2.4% (antibody) from a study in Lebanon published in 2010  
(Mahfoud et al., 2010).
Prevalence rates for hepatitis C range from 82% in a study in Germany published in 2006 (Stark et al., 2006) to 
1.1% from the study in Northern Ireland published in 2007 (Danis et al., 2007).
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Table 2.2 Findings from international studies on prevalence of blood-borne viruses within prisons
Author Year Country Sample (n) Reported prevalence
Butler et al. 1997 Australia 408 Hepatitis B: 31% (core antibody) 
3.2% (surface antigen). 
Hepatitis C: 37% 
HIV: not available.
Malliori 
et al.
1998 Greece 544 questionnaires and 
533 blood samples.
Hepatitis B: 57.6% (antibody) 
6.5% (antigen). 
Hepatitis C: 58.2%. 
HIV: 0.19%.
Allwright 
et al.
1999 Ireland 1,205 questionnaires; 
1,193 samples
Hepatitis B: 9% (antibody). Hepatitis C: 37% 
HIV: 2%.
Weild et al. 2000 England & Wales 3,942 Hepatitis B: 8% (antibody). 
Hepatitis C: 7%. 
HIV: 0.4%.
Ford et al. 2000 Canada 355 blood samples; 350 
questionnaires
Hepatitis B: not available. 
Hepatitis C: 33%. 
HIV: 2%.
Long et al. 2000 Ireland 607 Hepatitis B: 6% (antibody). 
Hepatitis C: 22%. 
HIV: 2%.
Guimaires 
et al.
2001 Brazil 756 Hepatitis B: 30.6% (antigen) and 37.5% (antibody). 
Hepatitis C: 41%. 
HIV: 13.7%.
Champion 
et al.
2004 Scotland 612 Hepatitis B: not available. 
Hepatitis C: 16% (antibody). 
HIV: not available.
Stark et al. 2006 Germany 174 Hepatitis B: 53% (antigen and antigen). 
Hepatitis C: 82%. 
HIV: 18%.
Butler et al. 2007 Australia 672 Hepatitis B: 20% (core antibody) 24% (surface 
antibody) and 3% (surface antigen). 
Hepatitis C: 34%. 
HIV: 1%.
Danis et al. 2007 Northern Ireland 663 for the questionnaire 
and 
658 samples
Hepatitis B: 0.75% (antibody). 
Hepatitis C: 1.1%. 
HIV: 0.0%.
Radun et 
al. Cited in 
Klempova & 
Wiessing
2008 Germany 1,582 Hepatitis B: 10.4% (antibody) and 2.5% (antigen 
Hepatitis C: 17.6%. 
HIV: 0.8%.
Mahfoud 
et al.
2010 Lebanon 580 Hepatitis B: 2.4% (antibody) and 2.4% (antigen). 
Hepatitis C: 3.4% 
HIV: 0.17%.
Kazi et al. 2010 Pakistan 357 Hepatitis B: 5.9% (antigen) 
Hepatitis C: 15.2%. 
HIV: 2%.
Kirwan et al. 2011 England 10,723 Hepatitis B: 13.9% (antibody) and 2.4% (antigen) 
Hepatitis C: 24.2%. 
HIV: not available.
Saiz de la 
Hoya et al.
2011 Spain 378 Hepatitis B: 2.6% (antigen) 
Hepatitis C: 22.7%. 
HIV: not available.
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The last prevalence study of blood-borne viruses amongst the prisoner population in Ireland was conducted over 
a decade ago. The study was designed in two phases: a survey of sentenced prisoners (inmates) (Allwright et al., 
1999) and a survey of committal prisoners (entrants) (Long et al., 2000). The Allwright et al. (1999) study found 
that amongst sentenced prisoners the overall prevalence of infection with hepatitis B was 9% (n=104), hepatitis 
C 37% (n=442) and HIV 2% (n=24). Long et al. (2000) found that among committal prisoners prevalence of 
hepatitis B and C was much lower, at 6% (n=37) and 22% (n=130) respectively, while HIV was the same at 2% 
(n=12).
Both studies found prevalence rates were considerably higher among injecting drug users. Allwright et al. (1999) 
found prevalence of hepatitis B was 19% (n=94), hepatitis C 81% (n=414) and HIV 4% (n=18) among injecting 
drug users. Long et al. (2000) found prevalence of hepatitis B was 18% (n=31), hepatitis C 72% (n=72), and HIV 
6% (n=10) among (ever) injecting drug users.
Consistent with findings from international studies, Allwright et al. (1999) found a large proportion of the prison 
population reported a history of drug use, with 52% (n=630) reporting heroin use and 43% (n=514) reported 
ever injecting drugs. For those who inject, the differences in sharing practices between the community and prison 
would also appear to reflect findings from other international studies. Allwright et al. (1999) found just over a third 
(37%), of respondents had shared injecting works (needles, syringes, filters, spoons) before committal to prison, 
whereas, of those who injected in prison 58% had shared injecting works. Long et al. (2000) found that of injecting 
drug users who had previously been imprisoned, 54% (n=85) reported sharing needles while imprisoned, while 
22% (n=35) of these reported to not have shared works in the month before committal.
Multivariate logistic regression analyses in both studies showed that injecting drug use was the most important 
predictor for both hepatitis B and C infection, whereas a history of anal sex with men was the strongest predictor 
of HIV in the Allwright et al. (1999) study, though the numbers testing positive for HIV were very small (n=24). 
After taking into account differences between respondents, Allwright et al. (1999) found those who reported 
ever injecting drugs were 22 times more likely to be hepatitis B positive than those who did not inject (adjusted 
Odds Ratio (OR) 21.6, Confidence Interval (CI) 95% 10.9–47.6), while those who reported ever injecting drugs 
were 81 times more likely to be hepatitis C positive (adjusted OR 80.8, CI 95% 47.9–143). Similarly, Long et al. 
(2000) found those committal prisoners who reported injecting drugs were 89 times more likely to have hepatitis 
C antibodies (adjusted OR 89.1, CI 95% 37.4–255.3) and 16 times more likely to have hepatitis B core antibodies 
than non-injectors (adjusted OR 15.9, CI 95% 6.5–47.6).
2.5 Drug Policy in Prison
Since the beginning of the 1990s drug treatment has increased in volume and variety in prisons throughout Europe 
(Kolind et al., 2010). This development is in line with the EU action plan on drugs, which emerged in response 
to the large number of inmates with drug and health problems, and is also consistent with international agendas 
on health and prisoners’ rights (Bruce and Schleifer, 2008; European Monitoring Centre for Drugs and Drugs 
Addiction (EMCDDA), 2006a; Kerr et al., 2004, Møller et al., 2007). Harm reduction initiatives, drug-free wings and 
substitution treatment was made available, although cross-European differences exist (Stallwitz and Stöver, 2007).
Within the Irish context, there has been a significant improvement in medical services for the prison population over 
the last two decades. The Irish Prison Service (IPS) has committed considerable investment, over €8 million since 
1999, towards healthcare services for prisoners (Ailbhe Jordan, Medical Independent 10th June 2010). In 2000 and 
2001 the IPS introduced drug treatment service plans in addition to health care plans; the hepatitis B vaccine was 
made available; methadone therapy was introduced; drug-free units were expanded; and registered nurses were 
employed.
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In 2006 the Irish Prison Service (IPS) published a drugs policy and strategy paper, “Keeping drugs out of prison”, 
which remains the reference document for the approach being adopted by the IPS in respect of drugs in prisons. 
The document details how the IPS has adopted a two-pronged approach: elimination of supply and reduction 
of demand for drugs. To effect supply elimination, prisons have introduced body orifice security scanner chairs, 
detection dogs, closed circuit television cameras, random searches, controlled visits, nets over and around exercise 
yards, monetary control, seizure analysis, and voluntary drug testing as well as mandatory drug testing (IPS, 2006). 
To reduce the demand for drugs in prison the IPS has outlined three core tasks to support drug treatment and 
rehabilitation: identifying and engaging with drug users, providing treatment options, and ensuring continuity of 
treatment and care following release. In terms of treatment options, these include opiate replacement therapies 
(methadone maintenance), methadone detoxification and reduction programmes, information, education and 
awareness programmes, and mental health care (Connolly et al., 2006).
While the IPS drug treatment and harm reduction programme has grown substantially over the last two decades 
there is still a lack of information that would assist public authorities in evidence-based decision-making in the 
provision of these services. As Jürgens (2006) points out, although numerous studies have examined various 
policies and interventions on drug use in the general community, few have focused on drug treatment and services 
in prisons. What follows below is a discussion of findings from those international studies that have focused on the 
same type of harm reduction strategies that the IPS has introduced.
2.5.1 Substitution Treatment
Substitution treatment, mainly provided in the form of methadone maintenance, is offered to opiate-dependent 
drug users as a harm reduction measure, i.e. to reduce or eliminate opiate use, to control and reduce the risk of 
blood-borne viruses in relation to injecting drug use (hepatitis and HIV/AIDS), and to reduce mortality and decrease 
criminal behaviour (recidivism) after release (Stöver et al., 2006). Despite the widespread use of methadone in 
maintenance treatment for opioid dependence in many countries, it is a controversial treatment whose effectiveness 
has been disputed.
In a study in Australia, prisoners on a methadone maintenance treatment with a dose of more than 60 mg provided 
during the whole prison sentence were least likely to inject heroin, to share needles or to engage in HIV risk-taking 
behaviour (Dolan et al., 1998). Johnson et al. (2001) found that Canadian prisoners on a 12-month methadone 
maintenance treatment whilst incarcerated had lower levels of recidivism than heroin-using prisoners with no 
treatment. Similar to the above findings, in an extensive literature review of prison based substitution treatment 
Stallwitz and Stöver (2007) reported that substitution treatment can reduce drug use and injection within prisons. 
Moreover, substitution treatment can reduce injecting risk behaviours as well as drug charges and recidivism rates.
In a study of practices and policies for the provision of substitution treatment in prisons across 18 European 
countries Stöver et al. (2006) found that although psychosocial care was seen as a valuable and necessary part of 
the treatment to support the medical part of the substitution treatment in prison, it was found that such support 
was rarely provided. Similar comments were made about Irish prisons more recently by the CPT (European 
Committee for the Prevention of Torture and Inhuman or Degrading Treatment of Punishment (CPT), 2011).
In contrast, findings in other studies are not as positive. In a review of randomised controlled clinical trials of 
methadone maintenance therapy compared with either placebo maintenance or other non-pharmacological therapy 
for the treatment of opioid dependence, Mattick et al. (2009) found methadone maintenance appeared statistically 
significantly more effective than non-pharmacological approaches in retaining patients in treatment and in the 
suppression of heroin use as measured by self report and urine/hair analysis (6 RCTs, RR = 0.66 95% CI 0.56–
0.78), but not statistically different in criminal activity (3 RCTs, RR=0.39; 95% CI: 0.12–1.25) or mortality (4 RCTs, 
RR=0.48; 95% CI: 0.10–2.39). Dolan et al. (2002) in a randomised control trial in Australia, found that methadone 
maintenance in a prison healthcare setting can be effective in significantly reducing heroin use (27% vs 42%), drug 
injection and syringe sharing, however, no group difference was measured regarding seroconversions to hepatitis C.
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2.5.2 Detoxification
Detoxification is the management of withdrawal symptoms associated with the cessation of a drug of dependence. 
It can be managed in a number of ways, depending on the drug or drugs of dependence. Medical intervention 
may assist the detoxification process, particularly in the case of opiate or severe alcohol dependence. Alternatively, 
detoxification can be managed non-medically, through the provision of psychological support and care.
Detoxification is the most common intervention provided to drug dependent offenders who are received into 
custody in the UK (Department of Health et al., 2006). However, in the whole prison service in Ireland, there are 
only 9 detoxification beds available (in the Medical Unit in Mountjoy Prison) for those who wish to come off drugs 
(Irish Prison Chaplains Report, 2010; O’Keefe, 2011). According to the Irish Prison Chaplains’ Annual Report (2010) 
this is wholly inadequate.
There is a paucity of information regarding detoxification in prison, the majority of evidence is gathered from the 
community setting (Dolan et al., 2007). This suggests that detoxification services should lead to other forms of 
support, otherwise there is a danger that prisoners who have been detoxified, and therefore have a reduced level 
of tolerance, may experience overdose if they return to previous doses of illicit drugs (Strang et al., 2003). Because 
of the narrow and short-term focus of detoxification programmes and the high frequency of relapse, the committee 
for the Council of Europe (2002) report on drug misusing offenders in prison and after release concluded that 
detoxification should not be viewed as a method of treatment alone. It is, however, an important gateway to 
treatment.
2.5.3 Drug-Free Wings and Units
Voluntary drug-free units or drug-free wings are a form of residential correctional treatment programme with the 
primary objective of rehabilitating offenders with histories of illicit drug use. Inmates residing in drug-free wings are 
segregated from the general prison population and pledge to abstain from drug use, usually in return for increased 
privileges such as recreational facilities or improved accommodation (Dolan et al., 2007).
In the Netherlands, a study by Van den Hurk (1995, cited in the Council of Europe report, 2002) drug-free units 
were evaluated in comparison to other forms of treatment. Findings include the fact that drugs were used less 
(enforced due to regular urine testing and punishment for positive urinanalysis). More interestingly, drug-free units 
were effective in providing continuity of care on release, with 42% of those released from such units continuing 
with treatment, whereas only 8% from conventional prison-based services did so.
2.5.4 Prison Needle and Syringe Exchange Programme
Switzerland was the first country to start a prison Needle and Syringe exchange Programme (NSP) in 1992. Since 
then, NSPs have been introduced to 12 countries in Western and Eastern Europe and in central Asia (Jürgens et 
al., 2009). Several models for the distribution of sterile injecting equipment have been used, including automatic 
dispensing machines, hand-to-hand distribution by prison healthcare staff, drug counsellors, or external community 
health workers, and distribution by prisoners trained as peer outreach workers.
Systematic assessments of the effects of NSPs on HIV and HCV related risk behaviours and their overall 
effectiveness have been undertaken in a number of studies (Jürgens et al., 2009; Stöver and Nelles, 2003; Stark 
et al., 2006; Dolan et al., 2003; Jacob and Stöver, 2000). Jürgens et al. (2009) note that with the exception of 
one prison in which sharing continued because of insufficient supply of needles and syringes, all available reports 
have shown that sharing of injecting equipment either ceased or substantially declined after the implementation of 
the NSP. Furthermore Jürgens et al. (2009) found that no new cases of HIV were reported in any of the studies 
reviewed. In five of the six prisons in which blood tests were done for HIV or hepatitis, no sero-conversions were 
observed. There were no reports of syringes being used as weapons, nor did the availability of sterile injecting 
equipment result in an increase in drug use (Jürgens et al., 2009).
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In an assessment of prison needle-exchange for Ireland, based on international evidence of prison needle-exchange, 
Forde et al. (2009) argued that prison needle-exchange constitutes a viable, effective means of addressing 
the drug problem and associated health risks within Irish prisons. However, Forde et al. (2009) acknowledged 
that data measuring drug use among the prison population is either dated or a proxy approach. Therefore, they 
recommended that a study be commissioned to measure the extent of drug use and the prevalence of blood-borne 
viruses among the prisoner population.
2.5.5 Mandatory Drug Testing
Since 2007 the IPS have had the power to take mandatory drug tests (MDT) from a random sample of between 5 
and 10% of Irish prisoners each month in order to monitor and deter drug-misuse. A positive test result or refusal 
to take the test results in sanctions being applied to that individual (IPS, 2006).
In a study of five prisons in England, Edgar and O’Donnell (1998) found that the increased risk of detection and 
sanctioning through MDT had a substantial positive impact on the prevalence of drug-misuse amongst prisoners. 
Fifty two percent of those interviewed (n=58/111) said they had desisted, reduced or altered their drug use 
because of the consequences that could follow if they were to test positive under MDT. However, two-thirds of the 
prisoners interviewed did not consider MDT to be fair and three quarters of prisoners believed MDT had increased 
staff prisoner tensions. Furthermore, when asked what impact MDT had had on the prison, not one prisoner, out of 
the one hundred and forty eight interviewed, mentioned an improvement in drug treatment.
An often-stated claim is that implementation of MDT will result in prisoners changing their use of drugs by switching 
from cannabis, which has a relatively long detection time in urine, to heroin which is cleared more rapidly and is far 
more difficult to detect (Robinson and Mirabelli, 1996; MacDonald, 1997; Edgar and O’Donnell, 1998; Hucklesby 
and Wilkinson, 2001). However, a major survey of prisoners carried out in England and Wales in 2001–2002 
concluded that MDT testing, along with other drugs treatment strategies, had substantially reduced cannabis use in 
prisons, but had little effect on the use of heroin (Singleton et al., 2005). This is consistent with findings of a study 
on MDT of prisoners in England and Wales which reported that there was no evidence for switching from cannabis 
to opiate use based on an analysis of the trends in positive test results (Farrell et al., 1998).
2.6 Conclusion
In conclusion, while IPS has adopted a number of strategies to address the problem of drug abuse amongst the 
Irish prisoner population, this is not without challenges. As acknowledged in the IPS 2010 Annual Report (2011) the 
delivery of drug treatment services and ensuring continuity of care for prisoners with addiction problems continues 
to be a significant challenge for health-care services in prisons. Yet, as noted above, the most recent study assessing 
the prevalence of blood-borne viruses along with self-report drug use within Irish prisons (Allwright et al., 1999) 
was carried out over a decade ago. Reliable up-to-date data on the extent of drug use and the prevalence of blood-
borne viruses among the prisoner population is necessary in order to ensure evidence-based decision-making when 
determining the need for drug treatment and harm reduction services in Irish prisons.
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3.1 Study Aim and Objectives
The aim of the study is to estimate the prevalence of drug use, including intravenous drug use, among the prisoner 
population in Ireland in order to determine the need for drug treatment and harm reduction (including needle 
exchange) services for Irish prisoners.
The project objectives are:
1. To describe the nature, extent and pattern of consumption for different drugs among the prisoner population;
2. To describe methods of drug use, including intravenous drug use, among the prisoner population;
3. To estimate the prevalence of blood-borne viruses among the prisoner population and to identify associated risk 
behaviours;
4. To measure the uptake of individual drug treatment and harm reduction interventions (including hepatitis B 
vaccination) in prison.
3.2 Study Design
In order to achieve the objectives, a cross-sectional study targeting a random sample of prisoners was devised, that 
would allow conclusions to be drawn about drug use, blood-borne virus status and the uptake of drug treatment 
and harm reduction interventions across the full prison population in all prisons. The study instruments comprised 
a self-administered questionnaire in addition to separate oral fluid sampling for a) five drugs (cannabinoids, opiates, 
methadone, cocaine and benzodiazepines) and b) blood-borne viruses (hepatitis B, hepatitis C and HIV).
3.2.1 Sample Size Calculations
Calculation of the sample size for accurate estimation of a proportion (in this instance a prevalence rate) was  
based on:
• The size of the population from which the sample was to be drawn, based on Irish Prison Service population 
statistics;
• The estimated prevalence of the condition of interest, based on prevalence of drug use and any Blood-
Borne Virus (BBV) status reported in a previous study of the Irish Prison population (Allwright et al., 1999);
• An acceptable margin of error for the prevalence estimate – a sample size which permits an interval of 6% 
(i.e. margin of +3%) was chosen; and
• The level of confidence with which the prevalence will be estimated, which was set at 95%.
3.2.2 Sampling Strategy
In the absence of any advance data that allowed the prisons to be categorised definitively as high, medium or low 
drug use, all prisons were included in the study. The sampling strategy was therefore to survey a random sample 
of the prison population proportionate to the population in each prison, to achieve a sample size of approximately 
840, in order to estimate prevalence of drug use and blood-borne virus prevalence with a confidence level of 95% 
and a ± 3% margin of error.
The sampling frame was all inmates (sentenced and remand) currently in prison in the Republic of Ireland (2009 
bed capacity 4,106: daily average occupancy 3,881). In this context, ‘currently’ implied current to the period in 
which the study was administered. Based on previous estimates of participation among prisoners, and anticipating 
an 80% response rate, it was calculated that 1,050 prisoners would need to be selected from the sampling 
frame for approach. The likely response rate took into account the response rates to similar studies among prison 
inmates, which vary from 62% in Northern Ireland (Danis et al., 2007) to 80% in the UK (Weild et al., 2000) to 
85% in Ireland (Allwright et al., 1999). A likely response rate of 80% among inmates was used. If in the event 
that participation was substantially lower than 80% in the first prisons, for whatever reason, it was planned that the 
sample size to be chosen in subsequent prisons would be increased to ensure an adequate number for estimation 
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of prevalence. During fieldwork, the response rate was lower than anticipated in the first few prisons visited and the 
sample size was increased accordingly; this process is described below. The exception was Limerick Female Prison, 
which at the time of strategy development had an operational capacity of 22. For logistical reasons and in the 
interest of both enhancing participation and confidentiality, all inmates in this prison were surveyed. Prisoners aged 
< 18 years and ≥ 65 years old, hospitalised prisoners or those deemed unfit to consent or participate and prisoners 
deemed by the IPS to be too high a security risk were excluded. Prisoners not present on the day of the study were 
also excluded from random selection where this was known in advance. Following exclusions, sampling was random 
within prisons, proportionate to occupancy, and without replacement.
3.3 Sampling Procedure
Sampling was based on a live list of PRIS numbers (prisoners’ IPS identity number), for all prisoners in custody 
aged 18 to 64 inclusive for each prison, provided by the IPS IT department to the Governor of each prison, on 
a date shortly before each visit (the sampling frame (SF) for all prisons comprised 4,474 prisoners). Because 
fieldwork was carried out over seven weeks, the list for each prison was generated on a rolling basis as near to the 
date of the visit as feasible for prison logistics purposes.
Governors excluded from the list prisoners who they deemed could not be included using the criteria provided. 
Political prisoners, having been notified about the study in advance by the relevant Governor, declined as a group to 
participate and were also excluded in advance of random sampling. In total, 485 prisoners (11%) were excluded by 
the Governors in advance of random sampling. Governors provided a list of non-excluded prisoners’ PRIS numbers 
to the team. These combined lists, the adjusted sampling frame (ASF), comprised 3,989 prisoners.
A random sample was generated by the research team for each prison and the list of PRIS numbers returned 
to the Governor. The proportion selected by random sampling was decided on a prison by prison basis, based 
on the target sample number in each prison (proportionate to population size) but mediated by locally provided 
information about prisoner turnover, Governors’ views on how likely prisoners would be to participate, and the 
response rate in previously visited prisons or prisons with a similar prisoner profile. The sample requested in each 
prison was based on the formula provided in the technical report. In six prisons it was necessary to increase the 
initially requested proportion in the field, and additional time or a follow-up visit to the prison was arranged if 
necessary. These prisons were all visited early during fieldwork: Mountjoy (increased requested sample from 27% 
to 41%), Wheatfield (from 34% to 52%), Portlaoise (from 47% to 60%), Cloverhill (from 42% to 50%), Dóchas 
(from 55% to 70%), and St. Patrick’s Institution (from 53% to 71%).
The final proportion of requested randomly selected prisoners ranged from 28% to 71% of the population in 
individual prisons, with the exception of Limerick female prison, where all prisoners aged 18 to 64 were included in 
the sample because of the very small population involved. The total sample requested from all prisons was 1,989.
During fieldwork, 323 prisoners (8% of ASF) were not available to participate in the study on the day(s) of the 
team’s visit, because of unanticipated transfer, release, temporary release, court, hospital visit, 23-hour lock up or 
being placed in isolation, or not being available for unspecified reasons. This included a small number of selected 
prisoners (10) deemed not to have sufficient English to understand what they were being asked to attend. Towards 
the end of fieldwork, a small number of the selected prisoners (6) who identified themselves as having previously 
participated in another prison were also considered unavailable for participation.
The final eligible available sample was 1,666 prisoners.
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Table 3.1 Sampling frame, exclusions and final sample by prison
Prison Sampling 
frame (SF) 
 
 
n
Excluded 
in advance 
by 
Governor 
n
Adjusted 
sampling 
frame 
(ASF) 
n
Random 
sample 
(no.) 
requested 
n
Requested 
sample as 
% of ASF 
 
%
Excluded/
not 
available 
on the day 
n
Final 
(eligible 
available) 
sample 
n
Final 
sample 
as % of 
ASF 
%
Arbour Hill 143 12 131 52 39.7 3 49 37.4
Castlerea 384 33 351 166 47.3 10 156 44.4
Cloverhill 414 10 404 202 50.0 49 153 37.9
Cork 309 28 281 141 50.2 22 119 42.3
Dóchas Centre 140 8 132 93 70.5 19 74 56.1
Limerick (Female) 38 – 38 38 100 14 24 63.2
Limerick (Male) 319 – 319 160 50.2 23 137 42.9
Loughan House 149 – 149 74 49.7 28 46 30.9
Midlands 548 37 511 256 50.1 58 198 38.7
Mountjoy 691 106 585 237 40.5 34 203 34.7
Portlaoise 269 54 215 130 60.5 13 117 54.4
Shelton Abbey 106 20 86 34 39.5 2 32 37.2
St. Patricks 184 71 113 80 70.8 20 60 53.1
Training Unit 113 21 92 26 28.3 – 26 28.3
Wheatfield 667 85 582 300 51.5 28 272 46.7
Total 4,474 485 3,989 1,989 49.9 323 1,666 41.8
3.4 Design and Piloting of Study Documentation and Survey Instrument
The design process comprised development and piloting of advance documentation, i.e. staff and participant 
information and questionnaire, and piloting of the process.
3.4.1 Documentation
Advance documentation consisted of a staff information leaflet, a prisoner letter, a prisoner leaflet and a prison 
poster. The staff information sheet was designed for a professional reader. The content of the staff information sheet 
was reviewed within the study team, before being reviewed at piloting stage by staff in Cloverhill prison, at which 
stage no amendments were suggested.
The draft prisoner letter and draft prisoner leaflet, prepared with the intention of being provided to all prisons and 
delivered to every prisoner by cell drop, were designed for a low literacy audience. The format was designed in a 
manner known to facilitate ease of reading for participants with reading difficulties. Comments on early drafts were 
invited from the NACD Research Advisory Group, the UCD study team, and then from the wider academic team 
within UCD. The letter and leaflet were piloted for literacy and ease of reading with three separate prisoner groups: 
a group of 7–10 male prisoners, facilitated by the school in Mountjoy prison; a group of ex-offenders, facilitated by 
the community based voluntary agency PACE (http://www.paceorganisation.ie/); and among volunteers in Cloverhill 
prison in advance of piloting the process. The post-pilot documentation was edited by the National Adult Literacy 
Agency (NALA).
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3.4.2 Questionnaire
The questionnaire instrument took account of European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
requirements, with appropriate modifications for both the Irish context and the prison context. Self-administered 
questionnaires, in combination with saliva sample collection, had previously been successfully used with prisoner 
populations in Ireland (Allwright et al., 2000), England and Wales (Weild et al., 2000) and Northern Ireland (Danis 
et al., 2007).
Questionnaire content was developed taking account of the most up-to-date EMCDDA questions, relevant questions 
and wording successfully used in the most recent NACD 2006/Drug Prevalence Survey (2008), and in the 
most recent relevant Irish prisoner surveys (Allwright et al., 1999, Centre for Health Promotion Services, 2000). 
Consultation took place with the NACD Research Advisory Group. Nurse managers and addiction nurses from the 
Irish Prison Service provided advice on drug treatment and harm reduction options within the prison setting and the 
terminology in use in Irish prisons around drug use. New questions included questions that aided determination 
of whether participants were in prison at the time of drug use, particularly for questions on drug use in the last 12 
months. A series of questions were developed on drug treatment and harm reduction services in the prison setting. 
The questionnaire and supporting documentation were developed in the English language. It was agreed that any 
selected prisoner who had a language difficulty but wanted to participate would be dealt with on a case-by-case 
basis.
In designing the layout and format of the questionnaire account was taken of the literacy and learning difficulty 
levels that might be expected among the Irish prisoner population and the advice of NALA, plain English guides and 
following discussion with prison teachers. The questionnaire comprised mostly closed dichotomous (mostly yes/no) 
and multiple choice questions, with the exception of questions such as what country participants were born in and 
ethnicity, or questions where participants were asked to report a number, e.g. age, number of times needles shared, 
etc.
Comments on early drafts were initially invited from the Research Advisory Group, the UCD study team, and 
then from the wider academic team within UCD, including many who had experience working with literacy-
challenged populations and marginalised groups, including prisoners. Following revisions recommended by 
peers, the questionnaire was piloted for content as well as for literacy and ease of reading with three separate 
prisoner groups: a group of 7–10 male prisoners facilitated by the school in Mountjoy prison; a mixed-gender 
group of ex-offenders facilitated by the community based voluntary agency PACE (http://www.paceorganisation.
ie/); and among volunteers in Cloverhill prison. The latter two groups provided page by page feedback. Finally, the 
questionnaire was piloted in real-time, along with the full process of information session, consenting, administration 
of the questionnaire and collection of saliva samples, in Cloverhill prison, with a group of 20 prisoners, simulating 
the proposed process for actual fieldwork conditions.
Questionnaire development, consultation and piloting incorporated minor revisions to language and terminology, 
sequence and format.
The final questionnaire collected data on:
• Demographic information;
• Drug use;
• Injecting drug use;
• Risk behaviours for BBVs;
• General health.
The final questionnaire was approved by the NACD Research Advisory Group and is provided in the Technical 
Report.
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3.5 Piloting of Process and Information Session Documentation
Draft Standard Operating Procedures (SOPs) for labelling of samples, data collection and individual fieldworker roles 
were developed in advance of the pilot of the information session and data collection process. The entire data 
collection process was piloted in Cloverhill prison and included piloting of the process from preparation and packing 
of the equipment required for daily visits, to arrival at prison entrance and progression through security, through 
providing the information session to prisoners, consenting process, questionnaire completion, sample collection, to 
management of linking the questionnaires to the samples, all the way through to deconstructing the survey from 
samples collected, returning to UCD, secure filing of the questionnaires and dispatch of samples to the laboratory 
for analysis. The pilot group included participants who reported drug use and injecting drug use and who required 
assistance with completion of the survey due to reading difficulties.
Following the pilot process, minor amendments were made to the contents of equipment transportation cases, 
and to the information presentation. The SOP for data collection was amended to remove in-the-field labelling of 
samples, and a SOP for labelling in advance was developed. It was also decided to complete deconstruction of 
the survey and oral sample packs in the prison setting. One question was amended in the field and subsequently 
clarified for all participants.
3.6 Fieldwork
In advance of fieldwork a member of the team met individually with the Governor and/or Deputy Governor and 
key personnel in each prison and proposed dates and locations were agreed. A primary prison liaison person 
was appointed in each prison. During fieldwork the planned schedule was amended as required to take account 
of additional days and/or second visits required to individual prisons. The Irish Prison Service (IPS) required that 
fieldwork take place primarily in February and March 2011. Fieldwork commenced on 18 February 2011, and took 
place on a daily basis on all working weekdays up to and including 08 April 2011. Thirty seven fieldwork days were 
completed over 35 consecutive working days. It was necessary to have two teams in the field on three days over 
the 35 working day period.
The fieldwork team comprised two UCD Principal Investigators (PIs), two UCD researchers, and a panel of 10 
fieldworkers recruited and trained specifically for the fieldwork phase of the project. The team included health 
professionals who could answer questions relating to BBVs and risk status. To facilitate entry to prisons, an 
application for Garda security clearance was submitted via the IPS for all fieldworkers.
In advance of each prison visit, Governors and relevant IPS staff were provided with details of proposed 
arrangements, in addition to staff information sheets and prisoner packs containing a brochure and letter to be 
delivered by cell drop, and posters to promote the study among both staff and prisoners. In one prison prisoners 
(Red Cross Volunteers) promoted the study among peers. Information sessions for large groups of prison staff were 
held where possible. Security clearance for the fieldwork team was arranged by the Governor in all prisons. Staff 
information was disseminated in advance of the study being notified to prisoners through a cell drop of letter and 
information sheet, and display of the posters in prominent places.
3.6.1 Fieldwork: Data Collection Process
On arrival in each prison the team met and briefed key IPS personnel. Each day, the senior member of the 
fieldwork team briefed the IPS staff assigned to go to the landings/cell areas to collect prisoners. In a small number 
of prisons individual prisoners were notified in advance that they had been selected to participate in the study, 
but in the majority of prisons selected prisoners only found out that they had been selected when approached on 
the day by the designated officer(s). In eight prisons, where the response rate was less than expected, the senior 
member of the team sought permission from prison Governors and senior staff to accompany designated IPS staff 
when they went to collect selected prisoners – this was permitted in three prisons.
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In order to collect attendees, the randomly selected list of PRIS numbers in prison officers’ possession now 
contained names and cell locations and prison-related information, and was collated into an attendance schedule 
by the IPS liaison taking into account the time available (number of days), landing locations, security, prisoner 
movement patterns and other logistical issues. These lists with prisoner names were not provided to the fieldwork 
team.
Briefing of the officers escorting prisoners included asking them:
• To inform the prisoners they had been randomly selected to participate in the voluntary and confidential 
study on drugs and health in prisons, about which they had received a letter and leaflet within the past  
few days;
• To encourage selected prisoners to attend the information session before making up their minds regarding 
participation;
• To encourage prisoners who had visits, school, gym, work, court, or individual appointments scheduled for 
that morning or afternoon to attend a later session (this was mostly possible in prisons where the schedule 
was greater than one day) – officers were encouraged to note these prisoners names and to return to them 
to ask again; and
• To note prisoners who declined to attend, but to let them know that if they changed their minds they  
could attend a later session.
The IPS Liaison who was overseeing the visit provided participation information at the end of the prison visit, 
specifically: the number of selected prisoners approached; the number of selected prisoners who declined; and 
the number of selected prisoners who were not available to attend (no longer in custody [released or transferred], 
on temporary release, in court, in hospital, unavailable for security reasons), or, late in the schedule, who had 
completed the study previously in a different prison. During data collection an officer, or officers, normally remained 
just outside the door of, or adjacent to, the room. Only one prison deemed it necessary to have officers present in 
the room for the information sessions, and in that case the officers sat outside the room during data collection.
Selected prisoners who came to the information session were provided with a participant information sheet and 
an information presentation about the process of collecting data through a) the self-administered questionnaire 
and b) the oral fluid samples, following which a discussion took place and questions were answered. Issues 
of confidentiality and anonymity were addressed and attendees were notified that because of anonymity, no 
individual’s results would be available or identifiable to any other party. This also meant that individuals would not 
receive their sample results but participants were informed that blood-borne virus testing could be requested and 
would be facilitated through the IPS Medical Centres.
Consent forms were read out loud, explained to the group of attendees and questions were addressed. Consent 
form signatures or marks were witnessed and co-signed by a fieldworker, and the groups’ original consent forms 
were placed together in a sealed envelope. Duplicate consent forms were given to prisoners to keep. The overall 
number of attendees who did not wish to participate was noted, however, no data was collected from them. This 
study did not have ethical approval to, nor would it have been appropriate, to collect any information on non-
responders.
Part 2 of the information session comprised orientation to the questionnaire document. Each consenting participant 
was then provided with a questionnaire. Discreet assistance was provided to those who required it. It appeared that 
assistance was mostly required for literacy reasons or due to poor English language reading skills. All of the allocated 
rooms were large enough to allow privacy during this process. The average time taken to complete a questionnaire 
was 20 minutes.
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3.6.2 Oral Fluid Sample Collection
Depending on the circumstances, sometimes during but normally immediately following completion of the 
questionnaire, a fieldworker approached each participant with a sample tray and a transparent A4 sized sample 
folder containing two oral fluid sampling kits. Each kit and associated forms were pre-coded with the same study 
identification number, which would become the unique ‘study ID’ for that participant. The fieldworker checked the 
participant’s duplicate consent form and proceeded to collect the samples for which consent had been provided. 
Oral fluid samples were collected separately, using propriety drug testing kits for blood-borne viruses (BBVs) and 
Drugs of Abuse (DOA). The Oral Fluid Collection Devices consist of a treated, absorbent cotton fibre pad affixed to a 
plastic shaft (Oral Specimen Collection Pad) and a preservative solution in a plastic container (Oral Specimen Vial). 
The Oral Specimen Collection Pad, impregnated with a mixture of common salts and gelatin, creates a hypertonic 
environment that produces an osmotic gradient across the buccal and gingival mucosae. The pad was placed in 
contact with the gingival mucosa (between the gum and cheek) which enhances the flow of mucosal transudate 
onto the absorptive cotton fibres of the pad, which is left in situ for three minutes. Following collection of the oral 
specimen, the Oral Specimen Collection Pad was removed from the mouth and placed into the Oral Specimen Vial. 
The Oral Specimen Vial contains a preservative solution that inhibits the growth of oral microorganisms recovered 
on the Oral Specimen Collection Pad. The vial was sealed with a plastic cap and placed in the tube provided. 
Collected specimens can be stored at between 4° C and 37° C for 21 days.
The sample folder contained an additional study ID label, which was placed on the front page of the questionnaire 
following completion, making it possible to link the BBV sample, the DOA sample and the questionnaire (for 
those who participated in all three components) to one another without allowing the ID to be traced back to any 
individual participant. Once the oral fluid sample(s) were taken, the fieldworker asked permission of the participant 
to look through the questionnaire in case any sections had been omitted in error. This provided an opportunity 
for the fieldworker to clarify any areas of obvious ambiguity and to amend if necessary. In a minority of cases/
sessions this step was not possible because of time and logistical constraints. Participant names or PRIS numbers 
were not provided to or collected by the fieldwork team and were not recorded on any data collection instrument 
(questionnaire or oral fluid samples) or on fieldwork logs.
At the end of each morning and afternoon session, the sample folder contents were deconstructed by at least three 
team members. Questionnaires, BBV and DOA samples were separated and counted and recorded in the fieldwork 
log. Labelling was checked for consistency and to ensure that it was in place on all components. DOA and BBV 
samples were sealed into the (provided) individual plastic postal envelopes, placed into appropriately labelled larger 
opaque plastic bags (which were labelled either DOA or BBV, and whether from the morning or afternoon session, 
along with the date). Questionnaires were packed in bundles by dated morning or afternoon session. Materials 
were transported in this manner to UCD, at the end of each day for prisons in or near to Dublin, and at the end of 
the fieldwork trip for prisons at a distance from Dublin. Questionnaires were securely stored in date order in UCD. 
BBV and DOA samples were boxed and subsequently collected on a pre-booked basis on the next working day by 
the laboratory’s couriers. BBV samples were transported to the West of Scotland Virology Laboratory at Gartnavel 
General Hospital, which is part of the Scottish National Blood-Borne Virus Specialist Testing Service. DOA samples 
were transported to Concateno’s Laboratory in Abingdon, UK.
3.6.3 Flexibility Required in Different Prisons
While the aim was to address up to 20 participants in the designated room during each morning or afternoon 
session, due to individual prison schedules availability of prisoners was normally limited to 10.30 to 12.00 in 
the mornings and 14.30 to 16.00 in the afternoons. In addition, while the allocated room(s) in all prisons could 
physically accommodate 20 prisoners, and in most cases a gathering of 20 was permitted by the prison, prisoners 
did not always arrive at the same time and often arrived sporadically in small groups. It was therefore frequently 
necessary to provide an information session for less than 20 attendees, and at times to have two or three 
information/data collection sessions within a single morning or afternoon. In a number of prisons, movement 
of prisoners was also restricted in order to accommodate the security arrangements needed to segregate gang 
members and associates. In addition, some sessions, in order to include randomly selected participants who 
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were segregated or on protection, were held with very small groups, and occasionally on a one-to-one basis, in 
locations such as segregation units, recreation areas, corridors, and staff offices. The largest number of participants 
from whom data was collected during a single morning or afternoon was 32; the lowest number was 0. These 
arrangements contributed to the need for additional days to be added to the original prison visit schedule.
3.6.4 Non-Participation
Table 3.2 Prisoners who declined to attend and declined to participate by prison
Final 
eligible 
available 
sample
Declined 
to attend
Attended Attendees who 
declined to 
participate
Declined Total
n n % n n % n %
Arbour Hill 49 13 26.5 36 1 2.8 14 28.6
Castlerea 156 65 41.7 91 9 9.9 74 47.4
Cloverhill 153 98 64.1 55 4 7.3 102 66.7
Cork 119 64 53.8 55 2 3.6 66 55.5
Dóchas Centre 74 41 55.4 33 – – 41 55.4
Limerick (Female) 24 12 50.0 12 – – 12 50.0
Limerick (Male) 137 89 65.0 48 2 4.2 91 66.4
Loughan House 46 7 15.2 39 11 28.2 18 39.1
Midlands 198 96 48.5 102 11 10.8 107 54.0
Mountjoy 203 62 30.5 141 13 9.2 75 36.9
Portlaoise 117 91 77.8 26 4 15.4 95 81.2
Shelton Abbey 32 – – 32 1 3.1 1 3.1
St. Patricks 60 20 33.3 40 – – 20 33.3
Training Unit 26 – – 26 – – – –
Wheatfield 272 122 44.9 150 4 2.7 126 46.3
Total 1,666 780 46.8 886 62 7.0 842 50.5
Of the 1,666 in the final eligible available sample, 780 (47%) declined to attend the information session. Of the 
886 prisoners who attended the information session, 62 (7%) declined to participate.
Stated reasons for declining to attend the information session reported by collecting officers, sometimes witnessed 
on landings by fieldworkers, and suggested by prisoners who did attend, included: being busy; attending the gym, 
school, workshop or work; mistrust, suspicion, cynicism; apathy; “Don’t do drugs”; concerns re MDT (increased in 
prisons where MDT was taking place during the visit); and concerns re DNA.
In summary, the final effective sample was 824 (49.5%) of those selected to participate.
3.7 Oral Fluid Sample Analysis
A commercial laboratory company in the UK (Concateno) was selected to carry out analysis of oral fluid samples 
because they provide a full service from specimen collection devices, through logistics, to laboratory analysis for 
oral fluid specimen analysis for both drug metabolite testing and blood-borne virus testing. Concateno undertake 
drug metabolite testing in its own laboratory in England and blood-borne virus testing is carried out in the West of 
Scotland Virology Laboratory.
Two proprietary devices, manufactured by Orasure, were used for sample collection: Intercept Oral Fluid Collection 
device for DOA testing, and Orasure Oral Fluid Collection Device for BBV testing. The devices differ in product 
labelling and the buffer fluid solution used.
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3.7.1 Oral Fluid Sample Testing for Drugs of Abuse
There are limitations to testing biological samples for drug metabolites because the actual time a particular drug will 
remain detectable in any biological sample from different individuals will change significantly based on a wide range 
of variables, including: the amount of actual drug consumed, the pharmacological properties of the drug, the amount 
of fluids consumed after ingestion of the drug, the amount of exercise taken after ingestion of the drug, the health 
of the individual, the genetic makeup of the individual, and the tolerance of the individual to the drug. Oral fluid 
drug testing reliability is affected by contributory factors such as the administration method of the drug (for example, 
when smoked or taken orally, deposits can be left in the mouth) and the variability of pH levels within oral fluid.
For drug screening purposes oral fluid testing using enzyme-linked immunosorbent assays (ELISA), also known as 
enzyme immunoassays (EIA), is appropriate. The tests works by means of a colour reaction which is produced in 
the presence or absence of compounds of similar physical structure to the target compound of the given assay. 
The intensity of the colour reaction for a given sample is compared to the intensity of the colour reaction for a 
calibration sample of known concentration of the target analyte. As the reaction is triggered by a structurally similar 
compound it is susceptible to interference (of cross-reactivity) with compounds which are structurally similar to the 
target compound, but not the compound itself or of the same group (e.g. opiates), therefore the result produced by 
this method are indicative and do not unequivocally identify the drug as present, however, the test is appropriate for 
screening use and the sensitivity and specificity rates for the tests completed are shown below. There is a small risk 
of false positives, however for non-legal and screening purposes immunoassay is very reliable. For legal purposes, 
positive or non-negative screening results may require a more detailed confirmation test, but screening tests are 
appropriate in an anonymous study, where follow-up testing of individuals is not possible. The table below shows 
the sensitivity and specificity for each test.
Table 3.3 Sensitivity and specificity of oral fluid drug of abuse testing
Test Sensitivity (%) Specificity (%)
Benzodiazepines 86 92
Cannabis 96 89
Cocaine 96 87
Opiates 93 90
Methadone 100 94
The OraSure Technologies Intercept® MICRO-PLATE assays can accurately and reliably detect drugs of abuse in 
samples collected with the Intercept Oral Specimen Collection Device. Studies have shown that there is good 
agreement between assay results and confirmation testing by gas chromatography/mass spectrometry (GC/MS or 
GC/MS/MS) (Manufacturer’s information).
Individual results by Study ID were provided to UCD, individually or in small batches, by email on an intermittent 
basis during and after fieldwork. Collated results were provided to UCD in an Excel spread-sheet following 
completion of the study.
During fieldwork 70 DOA samples were misdirected within the laboratory system and did not reach the laboratory 
for testing. Samples were tracked to a final destination and confirmed as having been put beyond use, most likely 
through incineration. As the samples were completely anonymous they were not traceable to the study or to any 
individual who participated and no data protection issues arose. The NACD and Research Advisory Group were 
informed and consulted in addition to the Prison-Based Research Ethics Committee. Ultimately, following the 
laboratory evaluating the compatibility of the assay with the collector, and using the anonymous study ID system, 
it was possible to test for DOA 68 of those samples that had been provided for BBV analysis.
The laboratory have confirmed that analysis of control BBV samples matching previously tested DOA samples 
for drugs of abuse demonstrated that analysis of BBV samples for drugs of abuse using the DOA ELISA is a valid 
approach within the same limitation as the DOA immunoassay. The elapsed time and different buffer did not appear 
to make any difference to the analysis except for the cannabinoids (THC) assay, which was backed up by LC-MS-MS 
analysis to identify any false positives. As the ELISA test was not designed to be used for BBV samples there are not 
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equivalent sensitivity and specificity data for the BBV samples tested for DOA, although the control testing done at 
Abingdon only demonstrated discrepancies on the cannabinoids assay. This proved to be a scientifically valid route 
for analysis of 68 of the 70 BBV samples, thus minimising the loss to the study to 2 (of 782) DOA results (0.3%). 
In summary, the laboratory is satisfied that the DOA results on the BBV samples are valid for all of the tests.
3.7.2 Oral Fluid Sample Testing for Blood-Borne Viruses
Blood-borne virus analyses were carried out in the West of Scotland Virology Laboratory at Gartnavel General 
Hospital, which is part of the Scottish National Blood-Borne Virus Specialist Testing Service. It holds Clinical Pathology 
Association (CPA) accreditation incorporating Standards of the Medical Laboratory ISO 15189:2003. Diagnosis of 
hepatitis B, hepatitis C and HIV is made by taking blood from subjects and carrying out serological tests. In recent 
years oral fluid analysis techniques have been developed and they have been used in previous prison population 
studies to estimate prevalence of hepatitis B, hepatitis C and HIV. This is a more convenient and safer body fluid on 
which to carry out virological tests and results obtained are comparable to those obtained with blood tests.
The assays (or tests) used in this study were specific to each blood-borne virus:
• Hepatitis B: hepatitis B surface antigen test (Murex HBsAg Version 3, Murex Biotech Limited); Sensitivity 
90.7%, Specificity 100%.
• Hepatitis C: Anti-HCV antibody test (modified Ortho HCV 3.0 Elisa Test System, Ortho Clinical Diagnostics); 
Sensitivity 83%, Specificity 93%.
• HIV: Vironostika HIV (Uni-Form II plus O, Biomerieux); Sensitivity 97.2%, Specificity 100%.
The sensitivity rate indicates the proportion of positive cases which are correctly identified by the test as positive, so 
for example, for HIV above, with a sensitivity rate of 97.2%, we will know that 97.2% of those that test positive for 
HIV are actually positive. The specificity rate indicates the proportion of negative cases which are correctly identified 
by the test as negative. So, for example, for hepatitis B and HIV above, with a specificity rate of 100%, we will know 
that 100% of those that test negative are actually negative.
In previous prison studies testing carried out for estimating prevalence of hepatitis B has used different tests. For 
example Kazi et al. (2010) and Saiz de la Hoya et al. (2011) tested for hepatitis B using HB surface antigen (HBs 
Ag). Long et al. (2000) and Butler et al. (2007) used anti-HBc (antibodies to the hepatitis B core antigen) testing. 
However Guimarães et al. (2001), Butler et al. (1997) and Mahfoud et al. (2010) used both anti-HBsAg and 
anti-HBc to estimate the prevalence. The test deemed appropriate to use in this study to establish the prevalence 
of current (recent or chronic) infection with hepatitis B was the anti-HBsAg test. The question of whether it was 
necessary to also carry out the anti-HBc (anti-core antigen) test was considered. It was possible that a small 
proportion of participants who are anti-HBsAg negative may be anti-HBc positive, indicating past infection. However, 
since these persons are unlikely to be viraemic, neither currently nor chronically infected with hepatitis B (and 
therefore will not be counted as prevalent cases), nor do they pose a risk of transmission, therefore, it was deemed 
not necessary to carry out the anti-HBc test on those who are anti-HBsAg negative in this study.
Individual results by Study ID were provided to UCD, individually or in small batches, by email on an intermittent 
basis during and after fieldwork. Collated results were provided to UCD in an Excel spread-sheet following 
completion of the study. Interpretation of BBV results was reviewed by the National Virus Reference Laboratory.
3.8 Data Entry
A data dictionary was compiled and a set of data entry rules was agreed. The data dictionary contained abbreviated 
variable names, full name of variables, definitions of variables, source(s) and coding options.
In order to facilitate accurate and speedy data entry of questionnaire data, the questionnaire form was reproduced 
as a web page form. The user entered data on the web form exactly as it was entered by the participant in 
the original questionnaire form. The output file was capable of being opened in Microsoft Excel or any other 
spreadsheet program. At the end of each day of data entry the set of files was removed from the desktop of the 
user’s machine and moved to a secure (Trucrypt encrypted) location.
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Double data entry of 100% of questionnaire data was carried out. In order to reduce possible errors due to data 
entry, each survey was captured twice using the web form, each time by a different person. This resulted in two 
sets of individual-output files. One of these was arbitrarily denoted as the master set and the other the copy set. 
Following consistency checking the corrected master set was then collated into a single spread-sheet containing 
all the individual survey entries for the study. An automated procedure was developed for correcting logical blanks 
using data processing scripts written in the PHP scripting language. This procedure for removing the logical blanks 
removed the bulk of the inconsistencies due to data entry. In addition, ‘backfilling’ of questions where prisoners had 
answered ‘yes’ to a question which implied that a previous question should have been answered ‘yes’ was carried 
out. When discrepancies due to typographical errors and logical blanks were removed the overall rate of data entry 
errors was 0.8% (based on all sections except for demographic data, which was analysed prior to the discrepancy 
checking process being automated). This means there was a rate of 99.2% consistency between the double-
entered data (master and copy datasets). The outstanding errors were resolved by referring to the original data 
source and two researchers making joint decisions on a case-by-case basis.
3.8.1 Surveys, BBV samples and DOA Samples Included in the Study
Figure 3.1 Surveys completed and oral fluid samples collected in the study
* Survey and samples could  
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Following preliminary analysis two of the 824 study participants were excluded as they reported that they were aged 
over 64 years; subsequent descriptions exclude these two cases. Figure 3.1 shows the remaining 822 eligible study 
participants and the study components in which they participated (survey and or BBV sample and or DOA sample).
There were 818 surveys completed. One survey was excluded (due to entirely nonsensical responses throughout 
the questionnaire) leaving 817 valid surveys. It is not unusual in surveys for respondents to fail to respond to 
individual questions – this may be an error on their part, or it may be because they do not want to answer the 
question. When estimating prevalence on self-reported questions the denominator for every question can be the 
total number of respondents to the survey, irrespective of missed items, or it can be the number of respondents 
to each individual item, thus having a different denominator for each item. In order to comply with EMCDDA 
guidelines, the NACD requested that the latter method of estimating prevalence be used in this study.
There were 780 eligible DOA oral fluid samples collected. Three samples were excluded (1 with insufficient oral 
fluid for testing and 2 unavailable samples) leaving 777 DOA screening results available for statistical analysis. 
This number (n = 777) was used for all analyses based on DOA oral fluid results and was the denominator used 
for estimating prevalence based on oral fluid samples. It should be noted, however, that two DOA samples had 
insufficient specimen to carry out the cannabis test, therefore the denominator for analysis of cannabinoids from 
oral fluid was 775.
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There were 779 BBV eligible BBV oral fluid samples collected. Two samples were excluded (rejected by the 
laboratory due to a labelling inconsistency) leaving 777 BBV sample results available for statistical analysis. This 
number (n=777) was the basis for all analyses of prevalence estimates based on BBV oral fluid sample test results.
There were 6 participants for whom survey and biological sampling data could not be linked, including one 
participant who completed a survey during a morning and provided samples in the afternoon; it was not possible 
to link the survey data with the biological samples because two different study IDs were used for the survey and for 
the DOA/BBV samples.
Concordance analysis of BBV samples with self-reported blood-borne virus status was based on the 771 participants 
for whom both survey results and BBV sample results are available and linkable.
Figure 3.2 shows the surveys and oral fluid samples that were available for statistical analysis.
Figure 3.2 Surveys and oral fluid samples available for statistical analysis
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3.9 Data Analysis
Statistical analysis was carried out using PASW version 18, SAS version 9.1 and WinPepi 11.15. For discrete/
categorical variables data were described and summarised using frequency counts and percentages. For continuous 
variables data were described and summarised using means, standard deviations, medians, quartiles and ranges as 
appropriate.
Self-reported prevalence was estimated using all those who reported drug use (i.e. responded ‘Yes’ to the 
prevalence questions) as the numerator and all those who responded to relevant survey questions as the 
denominator; missing values for prevalence questions were excluded from the denominator. Prevalence of BBV and 
DOA screening was estimated based on all those who tested positive to the relevant test as the numerator and all 
those who provided usable samples (n = 777) as the denominator. As described in section 3.8 the denominator 
for cannabis was 775 and there were no other missing values.
Confidence intervals (95%) were calculated for prevalence proportions using the Wilson Score Method without 
continuity correction (Wilson, 1927; Newcombe, 1998; Agresti and Coull, 1998) for drug use, injecting drug use, 
and blood-borne virus status (self-reported and results of oral fluid sampling). Correction of confidence intervals for 
finite populations was carried out (Burstein, 1975).
For comparisons between groups (e.g. male versus female) the appropriate statistical techniques were used: paired 
or independent t-tests or Wilcoxon Rank Sum test for comparison of means and medians/distributions respectively. 
For comparisons between proportions the Pearson Chi square test or Fisher’s Exact Test were used as appropriate. 
Differences with a p value <0.05 were regarded as statistically significant.
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Analysis of factors potentially predictive of blood-borne virus status was carried out using multivariate analysis for a 
dichotomous dependent variable, i.e. logistic regression. Odds Ratios and 95% confidence intervals are reported for 
variables found to be significant in multivariate analysis. These are generated from the Logistic Regression process.
Prison Drug Use Categories
A cluster analysis was performed to see if any obvious drug use classification for the prisons was naturally apparent 
in the data. Cluster analysis is a useful and widely used technique to probe a dataset to see if core objects in the 
dataset (e.g. the prisons) are naturally grouped based on some set of observations for each of these objects (e.g. 
the drug use level in each prison) (Kaufmann, 1990).
In this analysis we were interested in looking at the prisons according to the drugs associated with the EMCDDA 
definition of recent problematic drug use (EMCDDA, 2006). Recent problematic drug users are defined as those 
who have injected or regularly used opiates, cocaine, amphetamines in the last 12 months. This definition includes 
legal opiates such methadone. In this study data were not collected on 12 month frequency of use, however we 
used reported use of the key drugs (from this definition) in the last 12 months in individual prisons in an attempt 
to identify prisons which group together according to drug use of resident prisoners. Hence, from the survey data 
we determined the use levels in the last 12 months for prisoners in each prison for each of Heroin, Methadone, 
Other Opiates, Crack Cocaine, Cocaine Powder (survey Section B, questions 4 d to h inclusive) and injected 
Amphetamines (Section D, question 5 b) – the use level is the percentage of prisoners who answered ‘yes’ to the 
question, and excluding those who refused to answer the question. Note that this is the use level in the last 12 
months regardless of whether that use was inside or outside prison.
Cluster analysis looks at how ‘close’ objects are to each other based on the observations. This requires a ‘distance’ 
between objects. Using a Euclidean measure, the distance between two objects A and B is defined as:
DAB = √∑i (xiA – xiB)2
where xiA, xiB are the values for the ith observation for A and B respectively. In this analysis there are six 
observations for each prison, and the squared ‘distance’ between two prisons is the sum of the squares of the 
differences between the two prisons for each of these six observations. Other measures of ‘distance’ are also 
possible, but there is no compelling reason not to use the standard Euclidean measure in this analysis. Normally 
the xi are observations taken at different scales or units, and the data needs to be standardised to remove this 
scale dependence. In this analysis all the six observations are use levels valued between 0 and 1 so no such 
standardisation is necessary.
One of the primary methods for performing cluster analysis is Hierarchical (also called Agglomerative) clustering 
(Kaufmann et al., 1990). This is a bottom up approach: the algorithm starts by joining the ‘closest’ two objects 
to form a cluster, and successively joins the next closest objects/clusters to form the new greater cluster until the 
data are finally described by a single cluster. The results from hierarchical clustering are best illustrated using a 
dendrogram (tree diagram). The resulting dendrogram for this present analysis is shown in figure 3.3. Reading 
from the bottom up, each horizontal line in the tree represents an agglomeration step in the algorithm. The items 
grouped below this horizontal line give the cluster formed at that step of the algorithm. The data objects (i.e. 
prisons) are on the horizontal axis, and the distance between the clusters joined at each step on the vertical axis. 
A large change in vertical height in forming a cluster signifies that the cluster formed at this step is ‘loose’ and 
probably not a valid cluster. Conversely, a short vertical span for a given cluster signifies a compact cluster likely 
to be a true grouping in the data. Note there is no scale on the horizontal axis: this is merely an ordering of the 
objects to correctly display the tree structure.
The number and membership of any clusters in the data are determined by inspection of this dendrogram. The 
dendrogram in figure 3.3 strongly shows a four cluster solution in the data. These clusters are outlined by the 
different coloured rectangles overlayed on the dendrogram.
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An important point to note is that the only input to this Hierarchical clustering algorithm is the distance matrix, DAB, 
as defined above. This only gives the distance between objects (prisons), not between clusters of objects. Hence a 
further choice is required of how to determine this distance between clusters as they are formed, based solely on 
the distance between objects. Amongst the several standard methods are:
• Complete Linkage: The distance between two clusters is measured by the largest possible distance between 
observations in the two clusters. Usually clusters with similar diameters are obtained.
• Average Linkage: The distance between two clusters is given by the average of the distances between all 
the possible pairs of observations. Usually clusters with similar variances are obtained.
• Ward’s Method: This method is based upon the concept of within sum of squares. The two clusters with  
the smallest between sum of squares are joined. This method is regarded as very efficient and usually finds 
the most compact clusters in the data.
Each of these methods generally produces slightly different dendrograms and cluster memberships. Ward’s method 
was used to generate the dendrogram in figure 3.3. The other methods produced slightly different dendrograms but 
similar cluster memberships.
It is also possible to use a top-down approach to cluster analysis, so-called Partitional Clustering. Unlike Hierarchical 
clustering, in Partitional clustering the number of clusters is not inferred from the results but is an input to the 
algorithm. The number of clusters expected, k, must first be chosen, and then the output of the Partitional 
techniques is the membership of these k clusters. There is no dendrogram in this approach. The different Partitional 
algorithms all work similarly: the objects are initially randomly partitioned into k clusters, and then the membership 
of these clusters is iteratively changed to maximise some objective measure of ‘distance’ between clusters. The 
most commonly used Partitional technique is the k-means algorithm (Kaufmann et al., 1990). As a further check on 
the results of our Hierarchical clustering we also applied k-means clustering with an input number of clusters k=4. 
This produced an identical cluster membership as given in the dendrogram in figure 3.3.
It is important to note that there is no best method to use in cluster analysis. The type of data in the analysis is 
irrelevant to the method used. What is relevant is the “shape” of the clusters, but of course this is not a-priori 
known. Where there are clearly distinct clusters, regardless of shape, all the cluster methods will give the same 
number of clusters and identical cluster membership. Where there is some overlap between clusters, the different 
methods will favour different cluster shapes, and so it is possible that the different cluster methods will give different 
numbers of clusters and cluster membership. Hence, in a cluster analysis, it is important to try different methods 
and see if there is consensus across the methods – this is true in this study. Partitional k-means and Hierarchical 
clustering are methods that reveal the most compact clusters in the data, so the results from these methods are 
generally trusted most.
When this study commenced, no model existed for categorising prison according to the drug use history of its 
residents. This post-hoc clustering model provides a means of categorising prisons based on prisoners’ self-reported 
use in the previous 12 months of the six drugs included in the EMCDDA ‘problem drug use’ definition. This 
provides a way of describing drug use within the prison service at an aggregate level including all prisons, without 
compromising confidentiality or anonymity by naming individual prisons. It must be emphasised that this is based 
on self-reported drug use among those who participated in the study.
Cluster analysis is only a descriptive technique, not a statistical testing methodology. Results are very much a matter 
of interpretation. However, the hierarchical clustering method employed in this study strongly shows a four cluster 
description of the data, and the summary statistics for each cluster as reported elsewhere in this report also strongly 
support this four group structure in the data.
As might be expected the trend for overall percentage use of each drug increases across the levels of prison 
defined. The ranges are provided to assess discrimination between categories. While some overlap occurs between 
prisons in some drugs, the ranges demonstrate that the technique used is robust in describing prisons by level of 
use.
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In table 3.4 the combined numbers who reported 12 month drug use in each prison in the cluster forms the 
numerator for the overall percent. The denominators are the combined number of participants from each prison. 
The range is compiled from the percent use in each individual prison in the cluster.
Table 3.4 Overall percent self-reported drug use in the last 12 months by cluster
Low Use Medium Use High Use Very High Use
n Overall 
%*
Range 
%**
n Overall 
%*
Range 
%**
n Overall 
%*
Range 
%**
n Overall 
%*
Range 
%**
Heroin 9 10.1 7–12 68 24.5 8–31 119 36.0 33–46 37 39.8 33–67
Methadone 1 1.1 1–3 28 10.0 3–15 93 27.8 20–30 45 47.9 41–67
Other Opiates 5 5.7 4–7 38 13.5 6–36 45 13.5 5–16 15 16.7 12–42
Crack Cocaine 1 1.1 0–4 22 7.9 7–11 44 13.2 5–17 25 27.5 23–28
Cocaine Powder 10 11.2 6–20 85 30.1 17–40 95 28.7 19–32 36 40.4 34–64
IV Amphetamines 0 0.0 0–0 2 0.7 0–2 7 2.1 0–4 3 3.3 0–10
* Overall % = Total numbers using drug in question/Total number of prisoners in prisons in the category. 
** Range = Based on the percentage of prisoners in each prison in the category using the drug in question.
Figure 3.3 Dendrogram resulting from hierarchical clustering of prisons based on recent (12 month) 
‘problematic’ drug use of prisoners
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Dendrogram resulting from hierarchical clustering (Ward’s method) of prisons based on recent (12 month) problematic drug use of  
prisoners, inside or outside of prison. This dendrogram strongly suggests four clusters of prisons. We label these clusters Low, Medium,  
High and Very High based on summary statistics for these clusters reported elsewhere in the report. These cluster memberships are:
Low 
(n = 91) 
SA: Shelton Abbey 
AH: Arbour Hill 
LH: Loughan House 
 
Medium 
(n = 289) 
CK: Cork 
SP: St Patrick’s Institution 
CR: Castlerea 
ML: Midlands 
TU: Training Unit
High 
(n = 341) 
PL: Portlaoise 
LM: Limerick Male 
MJ: Mountjoy 
WF: Wheatfiled 
Very High 
(n = 96) 
F: Female 
CH: Cloverhill 
 
Note that both female prisons were pre-grouped as one: they showed similar statistics and are clearly distinct from the other prisons  
in the study. This is borne out by this cluster analysis and other descriptive statistics in this report.
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Dendrogram resulting from hierarchical clustering (Ward’s method) of prisons based on recent (12 month) 
problematic drug use of prisoners, inside or outside of prison. This dendrogram strongly suggests four clusters of 
prisons. We label these clusters Low, Medium, High and Very High based on summary statistics for these clusters 
reported elsewhere in the report. These cluster memberships are:
Low Medium High Very High
(n = 91) (n = 289) (n = 341) (n = 96)
SA: Shelton Abbey
AH: Arbour Hill
LH: Loughan House
CK: Cork
SP: St Patrick’s Institution
CR: Castlerea
ML: Midlands
TU: Training Unit
PL: Portlaoise
LM: Limerick Male
MJ: Mountjoy
WF: Wheatfiled
F: Female
CH: Cloverhill
Note that both female prisons were pre-grouped as one: they showed similar statistics and are clearly distinct from the other prisons in the study. 
This is borne out by this cluster analysis and other descriptive statistics in this report.
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4.1 Response Rates
Eight hundred and twenty four (824) prisoners took part in the study, giving an overall response rate of 49.5%. 
The range of response rates was from 33.3% to 100%. A detailed breakdown by prison is provided in table 4.1. 
Most of the prisons provided a majority response rate. Only three, Cloverhill, Limerick male and Portlaoise, had poor 
response rates.
Table 4.1 Response rate by prison
Prison Final eligible 
available sample
Declined total Participants Response rate
n n % n %
Arbour Hill 49 14 28.6 35 71.4
Castlerea 156 74 47.4 82 52.6
Cloverhill 153 102 66.7 51 33.3
Cork 119 66 55.5 53 44.5
Dóchas Centre 74 41 55.4 33 44.6
Limerick (Female) 24 12 50.0 12 50.0
Limerick (Male) 137 91 66.4 46 33.6
Loughan House 46 18 39.1 28 60.9
Midlands 198 107 54.0 91 46.0
Mountjoy 203 75 36.9 128 63.1
Portlaoise 117 95 81.2 22 18.8
Shelton Abbey 32 1 3.1 31 96.9
St. Patricks 60 20 33.3 40 66.7
Training Unit 26 – – 26 100.0
Wheatfield 272 126 46.3 146 53.7
Total 1,666 842 50.5 824 49.5
The overwhelming majority of participants took part in all three components of the study (the questionnaire, 
biological sample for DOAs and biological sample for BBVs). A small number of participants did not take part in one 
or other components of the study. Participation rates for each component are provided in table 4.2. This may be 
interpreted as random rather than systematic error for the purposes of data interpretation.
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Table 4.2 Participation in study components by prison
Prison Attended Declined 
all 
components
Participated in 
at least one 
component
Component Participation
Survey BBV DOA
n n n n n n
Arbour Hill 36 1 35 35 33 33
Castlerea 91 9 82 82 78 78
Cloverhill 55 4 51 51 45 45
Cork 55 2 53 53 51 51
Dóchas Centre 33 – 33 33 33 33
Limerick (Female) 12 – 12 12 12 12
Limerick (Male) 48 2 46 46 44 44
Loughan House 39 11 28 25 27 28
Midlands 102 11 91 91 87 89
Mountjoy 141 13 128 128 121 122
Portlaoise 26 4 22 22 16 15
Shelton Abbey 32 1 31 31 31 31
St. Patricks 40 – 40 40 38 38
Training Unit 26 – 26 26 26 26
Wheatfield 150 4 146 145 139 137
Total 886 62 824 820 781 782
Component participation rate 99.5% 94.8% 94.9%
Within Ireland the two previous inmate studies (Allwright et al., 1999 and Centre for Health Promotion Studies, 
2000) achieved an 85% and 88% response rate respectively. However, while these studies asked some questions 
about drug use the questions were not as detailed as in the current study, and neither included a biological test 
for drugs and this may have been an important factor. Furthermore, both studies were carried out over a decade 
ago. A number of developments have taken place in the last decade in the Irish prison system that could have 
reduced the response rate in the present study. These include improvements in the work, school and gym facilities, 
the introduction of in-cell televisions (IPS, 2002, 2003 and 2004) and the introduction of continuous drug supply 
elimination measures (IPS, 2006). It is also possible that IPS staffing levels in 1999 facilitated a higher response 
rate by facilitating research team members to visit landings, explain the purpose of the study and carry out the 
survey in individual cells for those prisoners that initially did not wish to participate. Though a crude measure, the 
number of IPS staff in 1999 exceeded the number of prisoners. There was 3,073 staff for a daily average of 2,871 
prisoners and 10,834 committals (IPS, 2002). In contrast in 2009/10, the number of prisoners exceeded the 
number of staff. There were 3,385 staff for a population of around 4,100 (CPT, 2011) and 15,425 committals (IPS, 
2010). In this study, with very few exceptions, the research team could not approach selected individuals to solicit 
participation. While every possible resource was provided to facilitate this study it was generally not possible to visit 
landings or to directly recruit selected participants.
As the prevalence of lifetime, last year and last month self-reported drug use (including IV drug use), and of 
biologically proven drug use and blood-borne viruses are reported by prison category as well as overall, it was 
considered relevant to examine the response rates by prison category.
Participation was considerably lower in the ‘very high’ drug use prison category (38%) compared with that in the 
other categories (74%, 52% and 47% in the ‘low’, ‘medium’ and ‘high’ use prisons).
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Table 4.3 Response rate by prison drug use category
Final eligible 
available sample
Declined total Participants Response rate
n n % n %
Low Use 127 33 26.0 94 74.0
Medium Use 559 267 47.8 292 52.2
High Use 729 387 53.1 342 46.9
Very High Use 251 155 61.8 96 38.2
Total 1,666 842 50.5 824 49.5
It could be suggested that this may reflect reluctance on the part of prisoners in the ‘very high’ use prisons to 
participate in a study which could reveal their drug use habits. While there is no way of ruling out that possibility, it 
cannot be assumed to have a ‘cause and effect’ relationship on study participation. There are several other potential 
reasons for reduced participation in these particular prisons, including:
• a higher proportion of prisoners in the ‘very high’ drug use prisons are likely to be in short term and  
pre-sentence custody (committals, remand prisoners, etc). It is known, for example, that 68% of those in 
the ‘very high’ use prisons are remand prisoners, compared with 4.9%, 8.7% and 0.25% of those in the 
‘high’, ‘medium’ and ‘low’ use prison respectively (IPS, 2011). The three prisons in the ‘very high’ drug use 
category are the prisons with the highest proportion of remand/trial prisoners in the system (Dóchas 23%; 
Limerick female 19%; and Cloverhill 84%). In contrast the prisons in the ‘low’ drug use category comprise 
Arbour Hill, where the population is largely made up of long term sentenced prisoners with no remand/trial 
prisoners, and the open prisons Shelton Abbey and Loughan House, with virtually no remand prisoners  
(IPS, 2011);
• a significantly higher proportion of the prison population in the ‘very high’ use prisons (49.5%) had been 
in prison for less than three months compared with the other prison categories (10.3%, 21.3% and 17.3% 
in low, medium and high use prisons respectively). While prisoners in custody < 3 months also comprised 
a higher proportion of the sample from the ‘very high’ use prisons compared with the same proportion 
from the other categories of prison, the relative proportion was lower (12.3% vs 18.9%, 14.3% and 17.7% 
respectively). This substantiates the relative lack of availability of prisoners in the very high use prisons due 
to court appearances, solicitors’ visits and interaction with other professionals compared with this group of 
prisoners in the other prison categories; and
• the two female prisons in Ireland are included in the ‘very high’ drug use category. It is known that the 
committal rate among female prisoners (12.4% of committals are females; 3.8% of the prison population 
are female) is higher than that among male prisoners (87.6% of committals are male; 96.2% of the prison 
population are male) (IPS, 2011). It has also been noted in the previous studies that women prisoners 
less likely to participate in studies than male prisoners (Allwright et al, 1999; Centre for Health Promotion 
Studies, 2000).
Notwithstanding the reasons for lower participation rates in the ‘very high’ use prisons, the potential impact of 
varying rates of participation on the overall prevalence rates of drug use and blood-borne viruses were considered. 
Overall (crude) prevalence rates for all drugs and BBVs were adjusted for participation rate by prison category. The 
‘weighted’ prevalence rates derived were compared with the crude rates. Results of these analyses are provided 
in the Technical Report. It will be noted that the impact of participation rate by prison category on the overall 
prevalence of lifetime, 12 month and 30 day drug use is negligible. The impact of varying participation by prison 
category on the overall prevalence of the blood-borne viruses is also negligible.
Therefore, in the interest of ease of interpretation and comparability with previous studies, it was decided to present 
overall crude prevalence rates rather than weighted prevalence rates for both drugs and BBVs in this report. To our 
knowledge this is the first study in Ireland or the UK in which prison category has been defined as described and 
has been used to report use of drugs and BBVs by category.
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4.2 Description of the Sample
Respondents were predominantly male (94.5%) reflecting the gender breakdown of the prisoner population. The 
mean age was 31 years (male 31 and female 30) and the median age was 28 years for men and women. The 
majority of respondents were Irish (92%), and 87% were born in Ireland.
Table 4.4 Demographics: Gender and age distribution
All 
n = 817 
%
Male 
n = 772 
%
Female 
n = 45 
%
18–24 years 
n = 254 
%
25–34 years 
n = 321 
%
35–64 years 
n = 232 
%
All 100.0 94.5 5.5 31.5 39.8 28.7
Male – – – 31.5 39.1 29.4
Female – – – 31.1 51.1 17.8
Table 4.5 Demographics: Ethnic or cultural background
All 
n = 812 
%
Male 
n = 767 
%
Female 
n = 45 
%
18–24 years 
n = 254 
%
25–34 years 
n = 318 
%
35–64 years 
n = 231 
%
White Irish 80.4 80.4 80.0 76.8 80.8 84.8
White Irish Traveller 11.1 11.2 8.9 18.5 10.1 3.9
Any other white background 3.8 3.8 4.4 2.4 3.8 5.2
Black, Asian or other, 
including mixed background
4.6 4.6 6.6 2.4 5.3 6.0
There was a relatively high proportion of Travellers, especially males in the 18–24 year age-group, also moderately 
so relative to the prevalence of Travellers in the general population, which is 1% (All Ireland Traveller Health Study 
team, 2010).
Table 4.6 Demographics: Educational background
All
n = 807
%
Male
n = 764
%
Female
n = 43
%
18–24 years
n = 252
%
25–34 years
n = 317
%
35–64 years
n = 229
%
No schooling 3.8 4.1 0.0 2.8 3.2 6.1
Primary school education 
only
19.3 19.8 11.6 17.5 18.9 20.1
Some secondary education 47.3 47.8 39.5 61.1 45.4 35.8
Complete secondary 
education
16.6 16.2 23.3 13.9 18.0 17.9
Some third level education  
at college, university, IT
8.2 7.3 23.3 4.4 10.7 9.2
Complete third level 
education at college, 
university, IT
4.7 4.8 2.3 0.4 3.8 10.9
Educational background results revealed a group with much lower educational attainments than the general 
population, as reported in the 2006 census (CSO, 2007), with 23% of prisoners having received no schooling 
or primary education only (vs 19% for the general population), 47% with some secondary (vs 21% with lower 
secondary), 17% with completed secondary education (vs 30% with upper secondary), and 13% with some third 
level or completed third level (vs 31%). This educational profile is broadly consistent with results from the 1999 
General Healthcare Study of the Irish Prisoner Population (Centre for Health Promotion Studies, 2000).
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Table 4.7 Demographics: Length of time in prison on this occasion
All
n = 805
%
Male
n = 761
%
Female
n = 44
%
18–24 years
n = 249
%
25–34 years
n = 316
%
35–64 years
n = 231
%
< 1 month 4.6 4.1 13.6 5.2 3.8 5.2
1–3 months 11.8 11.3 20.5 17.3 10.1 8.7
3–12 months 22.7 22.5 27.3 29.7 25.0 12.6
1–3 years 34.4 34.3 36.4 32.9 35.1 33.8
> 3 years 26.1 27.5 2.3 14.5 25.6 39.4
Don’t know 0.4 0.4 0.0 0.4 0.3 0.4
The majority of prisoners (60%) had been in custody for more than one year and a majority had spent more than 
three of the past 10 years in prison (52%).
Table 4.8 Demographics: Length of time in prison in the last 10 years
All
n = 753
%
Male
n = 714
%
Female
n = 39
%
18–24 years
n = 232
%
25–34 years
n = 300
%
35–64 years
n = 213
%
< 1 month 1.2 0.8 7.7 1.3 0.7 1.9
1–3 months 4.8 4.6 7.7 7.3 3.7 3.8
3–12 months 13.1 12.7 20.5 18.1 11.7 10.3
1–3 years 26.7 26.1 38.5 28.9 26.7 24.4
> 3 years 51.8 53.4 23.1 40.9 55.0 58.2
Don’t know 2.4 2.4 2.6 3.4 2.3 1.4
More than one in ten of those surveyed had experienced homelessness for more than seven days in the year 
before the study. A significantly higher proportion of women did so than men (29% vs 11%, p<0.01). When 
analysis was confined to those who had been in prison for 12 months or less, 23% responded that they had 
lived on the street in the previous 12 months; in this analysis women were also significantly more likely to have 
experienced homelessness in the previous 12 months than men (46% vs 22%, p<0.05), however there was no 
difference by age-group.
Table 4.9 Demographics: Homelessness in the previous 12 months
All Male Female 18–24 years 25–34 years 35–64 years
n % n % n % n % n % n %
Lived on the street for more 
than 7 days in previous 12 
months
85 12.4 74 11.4 11 28.9 29 13.6 29 10.6 27 14.1
Lived on the street for more 
than 7 days in previous 12 
months (among those who 
had been in prison for 12 
months or less)
63 23.4 53 21.5 10 45.5 24 21.4 23 22.1 16 30.8
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4.3 Representativeness of the Sample
Representativeness of the sample was assessed on demographic information provided by participants, and on 
comparable anonymous population demographic data provided by the IT department of the IPS. The IPS provided 
demographic data for all prisoners in custody in each prison, on the date that the list was sent to Governors for the 
random selection exercise, for the following variables: age, nationality (country of origin), ethnic origin and number 
of days in custody. Separate data was provided for male and female prisoners in Limerick prison, otherwise gender 
was assumed based on the prison.
It should be noted that a) prisoner movement over the time frame of the study may have resulted in some 
unidentifiable double-counting in the IPS population data, and that b) the total number for whom IPS demographic 
data were provided (4,569) exceeds the number in the sampling frame (4,474) by 2%. The latter is due to the 
time of day that the IPS data generated each list, i.e. lists for Governors during fieldwork were generated from live 
reports, reflecting the population at the exact time the report was generated, and population demographic reports 
for comparison purposes were generated from recorded daily statistical summaries.
The sample is strongly representative of the prison population on most demographic characteristics.
Figure 4.1 Population and sample: Gender distribution
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Women are slightly over-represented. Full sample, male and female mean and median ages were all within 1 year 
of the corresponding population results, although women were over-represented in the 25 to 34 age-group.
There were no significant differences in age distribution across the age categories for the full population or for the 
male and female sub-groups, using t-tests for equality of means and Pearson chi-square test to detect significant 
differences in proportions.
Figure 4.2 Population and sample: Age distribution
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Figure 4.3 Population and sample: Male age distribution
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Figure 4.4 Population and sample: Female age distribution
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The overall sample, and both male and female groups sampled are representative of the population in relation to 
region of birth (Pearson chi-square test not significant) being Ireland or other place of birth. While non-EU females 
are under-represented (4.4% in the sample vs 11.5% in the population), this is likely to be due to the small 
numbers involved or to language difficulties.
Figure 4.5 Population and sample: Region of birth
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Prisoners in custody for less than one month are under-represented in the sample as previously discussed. This is 
not unexpected, as prisoners deemed ineligible for inclusion in the study by the Governors, or who were unavailable 
when escorting officers went to collect them, were more likely to have included a) people who had been in prison 
on remand or on very short sentences and had been released by the time data was collected, b) prisoners who 
were committed near to the date of the study and were either released, transferred or in court when data collection 
was carried out, and c) prisoners who were committed in the short timeframe between generation of the random 
sample and commencement of data collection. The proportions in each sentence grouping are broadly similar and 
the maximum difference between groups in any category is 7%.
Figure 4.6 Population and sample: Length of time in prison
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Figure 4.7 Male population and sample: Length of time in prison on this occasion
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Figure 4.8 Female population and sample: Length of time in prison
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The proportion of the sample that self-reported methadone use and the proportion that tested positive for 
methadone were consistent with the proportion of prisoners on methadone treatment reported by the Drug 
Treatment Centre Board (DTCB) in December 2009. In figure 4.9 the numerator for the DTCB methadone treatment 
proportion is the number in IPS DTCB methadone treatment at the ‘end of period’ January to December 2009 
(496) (information provided by IPS). The denominator is the IPS ‘snapshot’ prison population of 4,040 in custody 
on 04 December 2009 (IPS 2009 Annual Report, 2010).
Figure 4.9 Methadone use
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A concern in any study of this type is the potential impact of non-response on the validity of the results obtained. 
Non-responders may differ from responders in respects which are relevant to the outcomes of the study. In this 
instance the concern would be that non-responders may differ in relation to their drug use habits or BBV status. 
While every effort was made to ensure as high a response rate as possible (prior notification, information sessions 
with prison staff and prisoners, assurances of confidentiality, etc.) it must be acknowledged that this is a particularly 
challenging group from which to illicit co-operation. There are many reasons for this, including:
a) lack of availability due to court appearances, visitations, school, gym or work activities;
b) apathy and disillusionment with anything to do with establishment;
c) suspicion of the motivation for the study;
d) confusion with Mandatory Drug Testing in the prison; and
e) concerns about confidentiality of the data and possible repercussions and sanctions.
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It is not clear, however, that these factors were unique to those who are more or less likely to be drug users or 
BBV positive. Therefore, it is not possible to say what impact, if any, a higher response rate would have had on the 
prevalence rates derived. Suffice it to say that the final sample achieved was representative of the total population 
of prisoners in custody at the time on all major demographic variables and on prison-related variables of length of 
time in custody and methadone use, and is therefore acceptable for data interpretation purposes. The demographic 
characteristics of the prisoner sample are also similar to that found in previous surveys (Hannon et al., 2007) and in 
keeping with the international scientific literature – prisoners are much more likely to be male, in their thirties, with 
very poor levels of education.
4.4 General Health
Table 4.10 General health: Self-reported health
All
n = 749
%
Males
n = 706
%
Females
n = 43
%
18–24 Years
n = 235
%
25–34 Years
n = 294
%
35–64 Years
n = 212
%
Excellent 12.3 12.7 4.7 14.5 10.9 12.3
Very Good 27.2 27.1 30.2 30.6 26.9 24.1
Good 40.9 40.9 39.5 40.9 45.2 34.9
Fair 15.9 15.4 23.3 11.5 15.0 21.7
Poor 3.7 3.8 2.3 2.6 2.0 7.1
Male prisoners’ self-rated health status had improved since the general healthcare study of the prisoner population 
(Centre for Health Promotion Studies, 2000), when only 28% reported excellent or very good health (vs 40% in 
this study) and 4% as poor (no change). For women, self-rated health had also improved; in 1999 15% of women 
prisoners reported excellent or very good health (vs 35% in this study) and 7% as poor (vs 2%). Despite the 
improvement, this is a lot lower than in SLAN 2007, where 58% rated their health as excellent or very good and 
3% as poor (Morgan et al., 2009), but somewhat less positive than in the All Ireland Traveller Health Study (AITHS, 
2010) where adults indicated that their health was excellent (23%) or very good (28%). There was no significant 
gender difference in self-rated health, however, there was an age-related difference, with older prisoners significantly 
more likely to rate their health as fair or poor than the other age-groups (p<0.01).
4.5 Extent of Consumption for Different Drugs among the Prisoner Population
Summary results are presented here for self-reported lifetime, last year and last month drug use. Full prevalence 
tables with confidence intervals are presented in the appendices.
4.5.1 Tobacco (Cigarettes)
Table 4.11 General health: Smoking prevalence
All Males Females 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Ever smoked cigarettes 725 89.7 684 89.6 41 91.1 232 91.7 288 90.6 196 86.0
Smoke cigarettes now 622 86.0 586 85.8 36 90.0 206 88.8 251 87.2 158 81.4
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The vast majority (90%) of prisoners had smoked cigarettes during their lifetime and 86% were current smokers. 
There was no significant difference between men and women but there was a difference for age with the older 
age-group significantly less likely to smoke (p<0.05 for ever smoking and p<0.01 for current smoking). Smoking 
prevalence rates are high among Irish prisoners compared to 76% of Scottish prisoners (Scottish Prison Service, 
2009), and to the general Irish population, with 48% of SLAN 2007 respondents having smoked cigarettes at 
some stage in their lives and 29% reporting being current smokers (Ward et al., 2009). This finding is a modest 
improvement on, but broadly consistent with, previous findings of the 1999 prisoner General Healthcare Study 
(Centre for Health Promotion Studies, 2000), which found that over 90% of prisoners had ever smoked and that 
over 90% were current smokers; that result compared to 31% regular smokers in the 1999 SLAN survey.
The median age for commencing smoking was 13 years (range 4–48) and among current smokers 84% smoked 
hand-rolled cigarettes (median per day was 20) and 24% smoked branded cigarettes (median per day was 15); 
17% of current smokers smoked a combination of branded and hand-rolled.
Table 4.12 Smoking habits
n Median Range Interquartile 
range
Age commenced smoking 715 13 4–48 11–15
Branded cigarettes smoked per day (among current smokers) 151 20 1–60 10–20
Hand-rolled cigarettes smoked per day 
(among current smokers)
522 15 1–80 10–20
4.5.2 Alcohol
The vast majority (96.4%) reported that they had drunk alcohol at some stage in their life, with men significantly 
more likely to have done so than women (97% vs 87%, p<0.01).
In the year before coming into prison nearly nine out ten 10 (87.7%) of those who had ever drunk alcohol reported 
usually drinking alcohol in a typical week, with men significantly more likely to do so than women (88% vs 74%, 
p<0.05). This shows a moderate increase since the 1999 prisoner General Healthcare Study (men 82% and 
women 60%) (Centre for Health Promotion Studies, 2000).
Among those who ever drank, the median number of days that alcohol was taken in a typical week (in the year 
before coming into prison) was three days, and the median number of drinks taken on the days that alcohol was 
drunk was 12 drinks. The type of alcohol most frequently used was beer for men (80%, down from 91% in the 
1999 General Prisoner Healthcare study) followed by spirits (42%, up from 31% in 1999). The type of alcohol 
most frequently used by women was spirits (64%, up from 44% in 1999) followed by beer (33%, down from 
56% in 1999) (Centre for Health Promotion Studies, 2000).
Table 4.13 Frequency of alcohol use (among those who ever drank)
Regarding 12 months before coming into prison n Median Range Interquartile 
range
No. of days in a typical week alcohol was drunk 690 3 0–7 2–5
Number of drinks taken on average, on days that alcohol was 
taken
641 12 0–101 8–20
Patterns of drinking, in the 12 months prior to coming into prison, showed that the majority (about 70%) drink 
more than once a week, and that about a third drink more often than 2–3 times a week.
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Table 4.14 Alcohol: Patterns of alcohol consumption
Daily 4–5 times 
a week
2–3 times 
a week
Once a 
week
2–3 times 
a month
Once a 
month
< once a 
month
Never
n % n % n % n % n % n % n % n %
How often alcohol 
was drunk
147 19.2 120 15.7 292 38.2 88 11.5 33 4.3 24 3.1 37 4.8 24 31.1
How often a specified 
amount of alcohol* 
was drunk
121 17.0 107 15.0 265 37.3 90 12.7 34 4.8 28 3.9 36 5.1 30 4.2
* equivalent of 4 pints of beer/cider or more, or 7 pub measures of spirits or one bottle of wine on one drinking occasion.
4.5.3 Drug Use: Lifetime Prevalence
Prevalence of drug use was high among prisoners for all drugs. Lifetime prevalence refers to the proportion of the 
sample that reported ever having used the named drug at the time they were surveyed. A person who records 
lifetime prevalence may – or may not – be currently using the drug. Lifetime prevalence should not be interpreted 
as meaning that people have necessarily used a drug over a long period of time or that they will use the drug in the 
future (NACD, 2011).
Lifetime prevalence for individual drugs among prisoners is shown in table 4.15. Lifetime cannabis use (87%) 
just falls short of lifetime smoking prevalence (90%), and was the illegal drug reported by the largest proportion, 
followed by cocaine powder (74%). In 1999, lifetime cannabis prevalence of 78% for male prisoners and 75% 
for women prisoners was reported (Centre for Health Promotion Studies, 2000). Lifetime prevalence for cannabis 
among the general population in 2011 was 25% (NACD, 2011). In this study, none of the individual drugs 
surveyed had a reported lifetime prevalence of less than 33%.
Table 4.15 Self-reported drug use: Lifetime prevalence by gender and age-group
Drug All Male Female 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Cannabis 708 86.9 670 87.0 38 84.4 241 94.9 297 92.5 162 70.4
Benzodiazepines 547 67.8 516 67.7 31 68.9 203 80.2 229 71.8 109 48.4
Other Sedatives or 
Tranquillisers
466 58.2 435 57.5 31 68.9 166 66.4 196 61.6 100 44.8
Heroin 348 43.3 319 42.1 29 64.4 94 37.8 159 50.2 90 39.7
Methadone 262 32.6 235 31.0 27 60.0 60 24.1 128 40.4 69 30.4
Other Opiates 260 32.5 241 31.9 19 42.2 54 22.0 131 41.3 72 31.7
Crack Cocaine 284 35.6 258 34.3 26 59.1 74 29.8 134 42.8 72 31.9
Cocaine Powder 600 74.2 571 74.6 29 65.9 210 83.7 262 81.9 121 53.1
Even given the small numbers, women were significantly more likely than men to have used heroin (64% vs 42%; 
p<0.01), methadone (60% vs 31%, p<0.001) and crack cocaine (59% vs 34%, p<0.01). There was no significant 
gender difference for any of the other drugs surveyed.
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Figure 4.10 Self-reported drug use: Lifetime prevalence by gender
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A pattern of lower use among older prisoners emerged for a number of drugs, with the older age-group of 35 years 
and above significantly less likely than age-groups 18 to 24 and 25 to 34 years respectively to have used cannabis 
(70% vs 95% and 93%, p<0.001), benzodiazepines (48% vs 80% and 72%, p<0.001), other sedatives or 
tranquillisers (45% vs 66% and 62%, p<0.001), or cocaine powder (53% vs 84% and 82%, p<0.001).
The age-group of 25–34 year olds was significantly more likely than the older or younger age-groups respectively to 
have used heroin (50% vs 40% and 38%, p<0.01), methadone (40% vs 30% and 24%, p<0.001), other opiates 
(41% vs 32% and 22%, p<0.001) and crack cocaine (43% vs 32% and 30%, p<0.01).
Table 4.16 recalls the prison drug use categories devised using cluster analysis previously described in Chapter 3. 
Table 4.17 then shows lifetime drug use by prison drug use category.
Table 4.16 Prison drug use categories
Low use (n = 91) Medium use (n = 289) High use (n = 341) Very high use (n = 96)
Arbour Hill Castlerea Limerick Male Cloverhill
Loughan House Cork Mountjoy Dóchas
Shelton Abbey Midlands Portlaoise Limerick Female
St. Patrick’s Institution Wheatfield
Training Unit
Note: within categories prisons are presented in alphabetical order, not in order of severity of drug use
In general, the lifetime prevalence rates across the prison drug use categories show an upwards usage history 
trend, among those currently resident, from low use prisons to the very high use prisons. Levels of significance for 
differences between the prison categories are shown in the table below.
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Table 4.17 Self-reported drug use: Lifetime prevalence by prison drug use category
Low use Medium use High use Very High use
n % n % n % n %
Cannabis* 71 78.9 247 85.5 307 90.0 83 87.4
Benzodiazepines*** 34 38.2 195 68.7 254 74.9 64 67.4
Other Sedatives or 
Tranquillisers***
35 39.3 161 56.9 212 63.5 58 61.1
Heroin*** 20 22.2 100 35.5 171 50.7 57 60.6
Methadone*** 9 10.1 61 21.7 138 40.7 54 57.4
Other Opiates* 14 15.9 89 31.4 123 36.6 34 36.6
Crack Cocaine*** 13 14.9 86 30.6 139 41.1 46 50.5
Cocaine Powder** 55 61.1 206 72.3 271 79.7 68 72.3
Chi2 test * p<0.05, ** p<0.01, *** p<0.001
4.5.4 Drug Use: Last Year Prevalence
Last year prevalence refers to the proportion of the sample that reported using a named drug in the year prior to 
the survey, and is often referred to as recent use (NACD, 2011).
Table 4.18 Self-reported drug use: Last year prevalence by gender and age-group
Drug All Male Female 18–24 Years 25–34 Years 35–64 Years
n % n % N % n % n % n %
Cannabis 554 68.6 523 68.6 31 68.9 210 84.0 231 72.6 105 45.7
Benzodiazepines 434 54.6 406 54.1 28 62.2 174 69.3 188 59.9 68 30.9
Other Sedatives or 
Tranquillisers
367 46.3 337 45.0 30 68.2 136 55.5 158 50.0 69 31.1
Heroin 233 29.5 212 28.4 21 46.7 74 29.7 112 36.0 45 20.4
Methadone 167 20.9 142 18.8 25 55.6 36 14.5 83 26.4 44 19.5
Other Opiates 103 13.0 94 12.6 9 20.0 29 11.8 52 16.6 21 9.4
Crack Cocaine 92 11.7 78 10.5 14 31.8 26 10.5 47 15.2 18 8.0
Cocaine Powder 226 28.6 208 27.8 18 41.9 96 38.9 101 32.3 26 11.8
Figure 4.11 Self-reported drug use: Last year prevalence by gender
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Cannabis remains the drug used by the largest proportion (69%) for last year use, followed by benzodiazepines 
(55%) with no significant difference in rates of use between men and women for either of these drugs. In 1999 
last year prevalence of cannabis among prisoners was approximately 63% for men and approximately 78% for 
women (Centre for Health Promotion Studies, 2000). Self-reported cannabis use in the last year among the general 
population was 6% (NACD, 2011).
There were some gender differences and in the last year women were significantly more likely than men to have 
used other sedatives and tranquillisers (68% vs 45%, p<0.01), heroin (47% vs 28%, p=0.01), methadone (56% 
vs 19%, p<0.001), and crack cocaine (32% vs 11%, p<0.001). In the previous prison study (Allwright et al., 1999) 
women were also found to be significantly more likely to report smoking heroin (in the last year) than men but the 
proportions were greater (45% for men vs 28% in this study and 60% for women vs 47% in this study). In the 
1999 General Healthcare study of prisoners (Centre for Health Promotion Studies, 2000), 38% of male prisoners 
and 68% of female prisoners reported smoking heroin in the previous year. In that study 37% of men and 51% of 
women used cocaine (type not specified) in the previous year compared to 30% and 52% respectively reporting 
total cocaine use in this study
From an age perspective, a similar pattern to lifetime use emerged. A pattern of decreasing use as the age-group 
increased was shown for some drugs. Lower proportions of the older age-group of 35 years and above reported 
use than age-group 25 to 34 years, who in turn reported less use than 18 to 24 years for cannabis (46% vs 73% 
vs 84%, p<0.001), benzodiazepines (31% vs 60% vs 69%, p<0.001), other sedatives or tranquillisers (31% vs 
50% vs 56%, p<0.001), and cocaine powder (12% vs 32% vs 39%, p<0.001). The age-group of 25–34 year olds 
was significantly more likely than the older or younger age-groups respectively to have used heroin (36% vs 20% 
vs 30%, p<0.001), methadone (26% vs 20% and 15%, p<0.01), other opiates (17% vs 9% vs 12%, p<0.05) 
and crack cocaine (15% vs 8% and 11%, p <0.05).
An overall trend of increasing drug use among residents across the prison drug use categories is again visible for 
last year use. This is to be expected, as a number of drugs from this table and the 12 month timeframe (heroin, 
methadone, other opiates, crack cocaine and cocaine powder) were used in the prison cluster model, which also 
included injecting amphetamines.
Table 4.19 Self-reported drug use: Last year prevalence by prison drug use category
Low use Medium use High use Very High use
n % n % n % n %
Cannabis* 50 55.6 198 68.5 236 70.7 70 73.7
Benzodiazepines*** 19 21.6 152 54.3 207 62.2 56 59.6
Other Sedatives or 
Tranquillisers***
25 28.4 117 41.8 173 52.1 52 55.9
Heroin*** 9 10.1 68 24.5 119 36.0 37 39.8
Methadone*** 1 1.1 28 10.0 93 27.8 45 47.9
Other Opiates 5 5.7 38 13.5 45 13.5 15 16.7
Crack Cocaine*** 1 1.2 22 7.9 44 13.2 25 27.5
Cocaine Powder*** 10 11.2 85 30.1 95 28.7 36 40.5
Chi2 test * p<0.05, ** p<0.01, *** p<0.001
4.5.5 Drug Use: Last Month Prevalence
The NACD definition of last month prevalence refers to the proportion of the sample that reported using a named 
drug in the 30 day period prior to the survey, and is often referred to as current use. The NACD caution that a 
proportion of those reporting current use may be occasional (or first-time) users who happen to have used in the 
period leading up to the survey and that it should be appreciated that current use is not synonymous with regular 
use (NACD, 2011).
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Table 4.20 Self-reported drug use: Last month prevalence by gender and age-group
Drug All Male Female 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Cannabis 349 43.4 332 43.7 17 38.6 128 51.2 148 46.8 67 29.4
Benzodiazepines 229 29.0 211 28.3 18 40.0 79 31.5 106 34.0 43 19.7
Other Sedatives or 
Tranquillisers
195 24.8 173 23.3 22 50.0 65 26.6 82 26.1 44 20.0
Heroin 87 11.1 81 11.0 6 13.3 27 10.9 40 12.9 19 8.8
Methadone 106 13.3 90 12.0 16 35.6 13 5.2 57 18.2 34 15.1
Other Opiates 35 4.4 35 4.7 0 0.0 6 2.5 17 5.4 12 5.4
Crack Cocaine 15 1.9 13 1.8 2 4.6 2 0.8 7 2.3 6 2.7
Cocaine Powder 41 5.3 40 5.4 1 2.4 11 4.6 19 6.1 10 4.6
Figure 4.12 Self-reported drug use: Last month prevalence by gender
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Cannabis remains the drug used by the largest proportion (43%) for last month use, followed by benzodiazepines 
(29%), and other sedatives or tranquillisers (25%). Last month use of cannabis among prisoners in 1999 was 
approximately 43% for men and approximately 34% for women (Centre for Health Promotion Studies, 2000), and 
3% of the general population report last month cannabis use (NACD, 2011). Self-reported methadone use, at 13%, 
is consistent with the proportion of prisoners on methadone treatment with the Drug Treatment Centre Board at the 
end of 2009 (12.3%, information supplied by the IPS). Thirteen percent also stated that they were on methadone 
maintenance within the last 30 days.
Women were significantly more likely than men to use other sedatives and tranquillisers (50% vs 23%, p<0.001) 
and methadone (36% vs 12%, p<0.001) but there was no gender association with any other drug.
From an age perspective, a slightly different pattern to lifetime and last year use emerged. A pattern of decreasing 
use as the age-group increased was shown for cannabis (29% vs 47% vs 51%, p<0.001), with lower proportions 
of the older age-group of 35 years and above reporting use than age-group 25 to 34 years, who in turn reported 
less use than 18 to 24 years. The age-group of 25–34 year olds was significantly more likely than the older or 
younger age-groups respectively to have used benzodiazepines (34% vs 20% vs 31%, p=0.001) and methadone 
(18% vs 15% and 5%, p<0.001). There were no significant age associations for other sedatives and tranquillisers, 
heroin, other opiates, crack cocaine or cocaine powder. Frequency of drug use in the last 30 days was highest for 
methadone, as one would expect with a daily dose, but otherwise the median frequency for individual drugs ranged 
from two to five times in the last month, suggesting that drug use is not a daily occurrence for the majority.
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Table 4.21 Frequency of drug use in the last 30 days
Drug n Median Range Interquartile range
Cannabis 313 5 1–1000 3–10
Benzodiazepines 211 3 1–300 2–10
Sedatives or Tranquillisers 175 5 1–450 2–12
Heroin 82 2 1–60 1–5
Methadone 99 30 1–50 30–30
Other Opiates 32 4 1–90 1–10
Crack Cocaine 12 3.5 1–30 1–9
Cocaine Powder 36 2 1–30 1–4
The pattern of increasing drug use across the prison drug use categories is generally maintained for last month use, 
although residents in the very high drug use category prisons show lower proportions using some illegal drugs in 
the last 30 days than residents in the medium and or high drug use prisons. In some cases this may be a factor of 
small numbers.
Table 4.22 Self-reported drug use: Last month use by prison drug use category
Drug Low use Medium use High use Very High use
n % n % n % n %
Cannabis* 33 36.7 121 42.2 162 48.7 33 35.1
Benzodiazepines*** 11 12.5 73 26.4 113 34.0 32 34.0
Other Sedatives or 
Tranquillisers***
8 9.1 59 21.2 99 30.2 29 31.2
Heroin** 3 3.4 26 9.5 50 15.2 8 8.6
Methadone*** 0 0.0 10 3.6 66 19.8 30 31.9
Other Opiates 3 3.4 12 4.3 18 5.4 2 2.2
Crack Cocaine* 0 0.0 1 0.4 11 3.3 3 3.3
Cocaine Powder 3 3.4 11 4.0 23 7.1 4 4.6
Chi2 test * p<0.05, ** p<0.01, *** p<0.001
4.5.6 Drug Use: Previous 24–72 Hours (Oral Fluid Sample Testing)
Oral fluid samples were taken for drug screening. These results show evidence of drug use in the 24 to 72 hours 
before the sample was taken. Because random sampling lists were generated more than 72 hours before data were 
collected, it is unlikely that anyone randomly selected to participate was not in custody in the 72 hours prior to data 
collection, however, some participants may have been on temporary release or out of prison, e.g. in court, during 
that time period.
Table 4.23 Drug Use: Previous 24–72 hours based on positive oral fluid sample tests
Drug All Men Women 18–24 years 25–34 years 35–64 years
n = 775 n = 730 n = 45 n = 240 n = 308 n = 212
n % n % n % n % n % n %
Cannabis 31 4.0 31 4.2 0 0.0 9 3.8 14 4.5 8 3.8
n = 777 n = 732 n = 45 n = 241 n = 309 n = 212
n % n % n % n % n % n %
Benzodiazepines 83 10.7 74 10.1 9 20.0 25 10.4 40 12.9 18 8.5
Methadone 103 13.3 88 12.0 15 33.3 11 4.6 55 17.8 35 16.5
Opiates 2 0.3 2 0.3 0 0.0 0 0.0 1 0.3 0 0.0
Cocaine 1 0.1 1 0.1 0 0.0 0 0.0 1 0.3 0 0.0
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The test with the largest proportion of positive results was methadone (13%). This proportion is consistent with self-
reported methadone use among prisoners and with the proportion expected to be on methadone treatment within 
the prison system. Women were significantly more likely to test positive than men for methadone (33% vs 12%, 
p<0.001), and 18 to 24 year olds significantly less likely to be positive for methadone than the other age-groups 
(5% vs 18% and 17%, p<0.001). The prevalence of benzodiazepines was 11%, with women again significantly 
more likely to test positive than men (20% vs 10%, p<0.05). No women tested positive for cannabis, opiates or 
cocaine and there was no discernable age pattern. Prevalence rates for men for these drugs were very low (4% for 
cannabis and < 1% for opiates and cocaine). There were no differences by age-group for any of the other drugs.
When analysed by prison category, the distribution of positive cannabis results shows a reverse trend, with the 
highest use in the lower drug use prison categories. The distribution of methadone results, which is most likely to 
be on prescription, reflected the prison drug use categories. In addition to the known limitations of drug screening 
tests (results are affected by the amount of drug consumed, the amount of fluids consumed and exercise taken 
since ingestion of the drug, etc. outlined in section 3.7.1), it is likely that these results are mediated by whether or 
not the drug was on prescription (e.g. benzodiazepines and opiates) and local availability in the days preceding the 
research team’s visit to each prison.
Table 4.24 Drug use: Positive Oral fluid test results by prison drug use category
Drug Medium use Low use High use Very High use
n % n % n % n %
Cannabis 14 15.2 9 3.2 7 2.2 1 1.1
Benzodiazepines 10 10.9 24 8.6 36 11.4 13 14.4
Cocaine 0 0.0 0 0.0 1 0.3 0 0.0
Methadone 1 1.1 10 3.6 63 20.0 29 32.2
Opiates 1 1.1 0 0.0 1 0.3 0 0.0
4.6 Extent of Consumption for Injected Drugs
Summary results are presented here for self-reported lifetime, last year and last month injecting drug use. Full 
prevalence tables with confidence intervals are presented in the appendices.
4.6.1 Injecting Drug Use: Lifetime Prevalence
Prisoners were asked about their lifetime history of injecting drug use (for non-medical reasons). Recall that 
a person who records lifetime prevalence may, or may not, be currently using the drug. Just over a quarter of 
prisoners reported that they had ever injected drugs (26%). Overall lifetime prevalence of injecting drugs among 
prisoners in the Allwright et al. (1999) study was 43%. However, it must be noted that prisons that were regarded 
as low risk for BBVs were not included in the Allwright study (prevalence in medium risk prisons was 21% and in 
high risk prisons was 58%). This is a significant difference between that study and the current study and almost 
certainly accounts for the overall lower prevalence rate of 26% in this study.
Women were significantly more likely to have a lifetime history of injecting drugs than men (44% vs 24%, 
p<0.01); this is consistent with findings in the previous inmates’ study in 1999 (Allwright et al., 1999), although 
the proportions in that study were much higher (60% for women and 42% for men). The 25 to 34 year age-group 
were significantly more likely to have ever injected than the younger or older age-groups respectively (34% vs 18% 
and 22%, p<0.001).
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Table 4.25 Self-reported injecting drug use: Lifetime prevalence by gender and age-group
Drug All Male Female 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Any drug ever 207 25.5 187 24.4 20 44.4 46 18.2 109 34.1 51 22.2
Benzodiazepines 71 8.8 64 8.4 7 15.9 9 3.6 36 11.4 25 10.9
Amphetamines 47 5.9 43 5.7 4 9.3 7 2.8 21 6.7 18 7.9
Heroin 154 19.1 135 17.7 19 43.2 26 10.4 83 26.4 44 19.2
Methadone 22 2.8 21 2.8 1 2.3 3 1.2 9 2.9 10 4.4
Other Opiates 54 6.8 48 6.4 6 14.3 7 2.8 24 7.7 22 9.8
Cocaine Powder 104 13.0 90 11.9 14 31.8 13 5.2 56 17.8 34 14.9
Mephedrone 34 4.3 27 3.6 7 15.6 11 4.4 16 5.1 6 2.7
Methylone 20 2.5 15 2.0 5 11.1 7 2.8 9 2.9 4 1.8
Crystal Meth 13 1.6 12 1.6 1 2.2 2 0.8 5 1.6 5 2.2
Steroids 69 8.6 68 9.9 1 2.2 22 8.7 33 10.4 13 5.7
Any other drug 35 4.5 29 3.9 6 14.3 3 1.2 20 6.6 11 5.0
The injected drug reported by the largest proportion was heroin (19%) followed by cocaine powder (13%). On 
an individual drug basis, women were significantly more likely than men to have injected heroin (43% vs 18%, 
p<0.001), cocaine powder (32% vs 12%, p<0.001), mephedrone (16% vs 4%, p<0.01), methylone (11% vs 
2%, p<0.01) and any other drug (14% vs 4%, p<0.01).
Figure 4.13 Injecting drug use: Lifetime injecting prevalence by gender
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There was no significant age pattern for lifetime injecting of methadone, methylone, mephedrone, crystal meth or 
steroids, however, an age pattern emerged for injecting drug use for the remaining drugs surveyed. The younger 
age-group was significantly less likely to have injected these drugs than the older age-groups, and the group 
aged 25 to 34 years was more likely to have injected. Proportions for the younger, middle and older age-groups 
respectively and p values were: benzodiazepines (4%, 11% and 11%, p<0.01), amphetamines (3% vs 7% vs 8%, 
p<0.05), heroin (10%, 26% and 19%, p<0.001), other opiates (3%, 8% and 10%, p<0.01) and cocaine powder 
(5%, 18% and 15%, p<0.001) and any other drug (1% vs 7% vs 5%, p<0.01).
There is an increasing pattern of use by prison drug use category. While numbers are low, lifetime injecting rates  
are very high in the high drug use category, and for heroin reach 36%.
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Table 4.26 Self-reported injecting drug use: Lifetime prevalence by prison drug use category
Drug Low use Medium use High use Very High use
n % n % n % n %
Any Drug (ever injected)*** 11 12.4 42 14.6 115 33.7 39 41.1
Benzodiazepines*** 3 3.4 13 4.6 41 12.2 14 15.1
Amphetamines** 3 3.4 8 2.8 25 7.5 11 12.0
Heroin*** 7 8.0 29 10.1 85 25.2 33 35.5
Methadone* 0 0.0 4 1.4 14 4.2 4 4.4
Other Opiates** 3 3.4 11 3.9 28 8.5 12 13.2
Cocaine Powder*** 6 6.8 14 4.9 58 17.2 26 28.0
Mephedrone*** 1 1.2 2 0.7 20 6.0 11 11.7
Methylone* 1 1.2 2 0.7 11 3.3 6 6.5
Crystal Meth 1 1.2 2 0.7 7 2.1 3 3.2
Steroids* 4 4.5 17 5.9 39 11.5 9 10.0
Any Other Drug*** 1 1.2 4 1.4 19 5.9 11 12.1
Chi2 test * p<0.05, ** p<0.01, *** p<0.001
4.6.2 Injecting Drug Use: Last Year Prevalence
In the last year, the drug reported as injected by the largest proportion was heroin (7%) followed by cocaine 
powder (3%) benzodiazepines (3%) and steroids (2%). In total, 82 prisoners had injected at least one of the 
drugs surveyed in the last year (10.1%, 95% CI 8.4%–12.2%).
Table 4.27 Self-reported injecting drug use: Last year prevalence by gender and age-group
Drug All Male Female 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Benzodiazepines 23 2.9 18 2.4 5 11.4 7 2.8 13 4.1 3 1.3
Amphetamines 12 1.5 9 1.2 3 7.0 4 1.6 6 1.9 2 0.9
Heroin 55 6.9 46 6.1 9 20.9 20 8.0 27 8.7 8 3.6
Methadone 6 0.8 5 0.7 1 2.3 2 0.8 3 1.0 1 0.4
Other Opiates 8 1.0 7 0.9 1 2.4 2 0.8 5 1.6 1 0.5
Cocaine Powder 25 3.1 19 2.5 6 14.0 7 2.8 13 4.2 5 2.2
Mephedrone 18 2.3 12 1.6 6 13.3 7 2.8 9 2.9 2 0.9
Methylone 9 1.1 6 0.8 3 6.7 3 1.2 5 1.6 1 0.5
Crystal Meth 3 0.4 3 0.4 0 0.0 0 0.0 2 0.6 1 0.5
Steroids 19 2.4 19 2.5 0 0.0 5 2.0 12 3.8 2 0.9
Any other drug 11 1.4 9 1.2 2 4.8 2 0.8 5 1.7 4 1.8
Women were significantly more likely to have injected a number of drugs than men in the last year: most notably 
heroin (21% vs 6%, p<0.001), cocaine powder (14% vs 3%, p=0.001), mephedrone (13% vs 2%, p<0.001), 
methylone (7% vs 1%, p<0.05), amphetamines (7% vs 1%, p<0.05) and benzodiazepines (11% vs 2%, 
p<0.01). There were no significant differences across the age-groups.
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Figure 4.14 Self-reported Injecting drug use: Last year injecting prevalence by gender
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While the numbers are low in most categories, the increasing trend of drug use among respondents from low use 
to very high use prison categories continues for last year injecting. Once more a steep gradient is seen rising notably 
in the case of heroin use, however, because of low numbers and empty cells significant differences are not seen 
between prison categories in many cases.
Table 4.28 Self-reported injecting drug use: Last year prevalence by prison drug use category
Drug Low use Medium use High use Very High use
n % n % n % n %
Benzodiazepines*** 1 1.1 1 0.4 12 3.6 9 9.7
Amphetamines 0 0.0 2 0.7 7 2.1 3 3.3
Heroin*** 1 1.2 10 3.5 27 8.1 17 18.7
Methadone 0 0.0 1 0.4 4 1.2 1 1.1
Other Opiates 0 0.0 0 0.0 3 0.9 5 5.6
Cocaine Powder*** 0 0.0 3 1.1 13 3.9 9 10.0
Mephedrone*** 0 0.0 1 0.4 8 2.4 9 9.6
Methylone 0 0.0 1 0.4 4 1.2 4 4.3
Crystal Meth 0 0.0 1 0.4 2 0.6 0 0.0
Steroids 1 1.1 5 1.8 9 2.7 4 4.3
Any Other Drug 0 0.0 0 0.0 7 2.2 4 4.4
Chi2 test * p<0.05, ** p<0.01, *** p<0.001
4.6.3 Injecting Drug Use: Last Month Prevalence
Recall that the NACD point out that when reviewing last month prevalence, some of those reporting current use 
may be occasional or first-time users who happen to have used in the period leading up to the survey, therefore 
current use is not necessarily synonymous with regular use (NACD, 2011).
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Table 4.29 Self-reported injecting drug use: Last month prevalence by gender and age-group
Drug All Male Female 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Benzodiazepines 4 0.5 3 0.4 1 2.3 1 0.4 2 0.6 1 0.4
Amphetamines 2 0.3 1 0.1 1 2.3 1 0.4 1 0.3 0 0.0
Heroin 7 0.9 5 0.7 2 4.6 2 0.8 3 1.0 2 0.9
Methadone 3 0.4 2 0.3 1 2.3 1 0.4 2 0.6 0 0.0
Other Opiates 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Cocaine Powder 8 1.0 7 0.9 1 2.3 1 0.4 6 1.9 1 0.4
Mephedrone 2 0.3 1 0.1 1 2.2 1 0.4 1 0.3 0 0.0
Methylone 1 0.1 1 0.1 0 0.0 0 0.0 1 0.3 0 0.0
Crystal Meth 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Steroids 4 0.5 4 0.5 0 0.0 0 0.0 3 1.0 1 0.4
Any other drug 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Figure 4.15 Injecting drug use: Last month injecting prevalence by gender
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Numbers injecting individual drugs in the last month were very low and ranged from 0 to 7 (≤ 1% of the prison 
population). In total, 16 prisoners had injected at least one of the drugs surveyed in the last month (2.0%, 95% 
CI 1.3%-3.1%). Individual drugs injected by the largest proportions were cocaine powder (1%) and heroin (0.9%) 
followed by benzodiazepines (0.5%) and steroids (0.5%). There were no significant differences between men and 
women, or across the age-groups. This was primarily because of the very small numbers involved.
Table 4.30 Drug use: Frequency of injecting drugs in last 30 days
Drug n Median Range Interquartile range
Benzodiazepines 4 25 3–40 7–38
Amphetamines 2 15 10–20 N/A
Heroin 6 22 3–60 15–38
Methadone 3 25 3–30 N/A
Other Opiates 0 – – –
Cocaine Powder 7 4 1–15 3–8
Mephedrone 2 8.5 2–15 N/A
Methylone 1 20 N/A N/A
Crystal Meth 0 – – –
Steroids 4 8 1–50 2–41
Any Other Drug 0 – – –
N/A indicates that there were insufficient respondents to calculate an interquartile range
64
Study on the prevalence of drug use, including intravenous drug use,  
and blood-borne viruses among the Irish prisoner population
Chapter 4 Results
Numbers reporting use in the last 30 days were very low, but seven respondents in the high and very high drug use 
categories reported injecting heroin. Because of the low numbers and empty cells, significant differences are not 
seen between prison categories for any drug.
Table 4.31 Self-reported injecting drug use: Last month use by prison drug use category
Drug Low use Medium use High use Very High use
n % n % n % n %
Benzodiazepines 0 0.0 0 0.0 2 0.6 2 2.2
Amphetamines 0 0.0 0 0.0 1 0.3 1 1.1
Heroin 0 0.0 0 0.0 3 0.9 4 4.4
Methadone 0 0.0 0 0.0 2 0.6 1 1.1
Other Opiates 0 0.0 0 0.0 0 0.0 0 0.0
Cocaine Powder 0 0.0 2 0.7 5 1.5 1 1.1
Mephedrone 0 0.0 0 0.0 1 0.3 1 1.1
Methylone 0 0.0 0 0.0 1 0.3 0 0.0
Crystal Meth 0 0.0 0 0.0 0 0.0 0 0.0
Steroids 0 0.0 2 0.7 2 0.6 0 0.0
Any Other Drug 0 0.0 0 0.0 0 0.0 0 0.0
Chi2 test * p<0.05, ** p<0.01, *** p<0.001
4.7 Nature and Patterns of Consumption for Different Drugs
4.7.1 Age of First Use
The median age of first drug use ranged from 14 to 21 years, with use of cannabis commencing earliest, at a 
median age of 14 years, followed by benzodiazepines (median 17 years), other sedatives or tranquillisers (median 
17 years) and cocaine powder with a median age of 18 years. The median age for first use of heroin or other 
opiates was 19 and for methadone and crack cocaine use the median commencement age was 21 years. A pattern 
of movement from softer drugs to harder drugs with increasing age is apparent. The range and interquartile range 
for age of commencement of use of each drug are provided in the table below.
Table 4.32 Age first used drugs presented in ascending order of median age
n Median Range Interquartile range
Cannabis 700 14 7–51 12–16
Benzodiazepines 524 17 9–43 15–20
Other sedatives and 
tranquillisers
441 17 10–50 15–21
Cocaine Powder 577 18 11–45 16–20
Heroin 328 19 11–44 16–23
Other opiates 243 19 11–40 16–22
Methadone 258 21 13–45 18–26
Crack Cocaine 275 21 12–44 19–26
The lowest median age (18 years) for initiating injecting drug use was for opiates other than heroin or methadone. 
Twenty years was the median age for commencing injecting the majority of drugs surveyed: benzodiazepines, 
amphetamines, heroin, methadone and crystal meth, followed by cocaine powder for which injecting commenced 
at a median age of 21 years. The median age for commencing injecting ‘head shop’ drugs methylone and 
mephedrone was 24 years. The median age for commencing steroid injection was 22 years. The range and 
interquartile range for age of commencement of injecting each drug are provided in the table below.
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Table 4.33 Age first injected drugs presented in ascending order of median age
n Median Range Interquartile range
Other opiates 48 18 13–42 16–23
Benzodiazepines 68 20 11–31 17–23
Amphetamines 43 20 13–34 18–25
Heroin 150 20 11–42 17–24
Methadone 19 20 14–44 17–24
Crystal Meth 12 20 15–42 16–25
Any other drug 31 20 11–42 17–24
Cocaine powder 100 20.5 13–42 18–25
Steroids 65 22 16–52 19–26
Mephedrone 31 24 16–42 20–29
Methylone 20 24 13–42 19–30
Among heroin injectors, the mean age for first use of heroin was 18.2 years and the mean age for first injecting 
heroin was 21 years, with the mean duration of moving from smoking to injecting at 2.8 years. This is consistent 
with previous findings. In an Irish study of addiction service users in the community, Gervin et al. (2001), found that 
the mean duration of moving from smoking to injecting heroin was 2.9 years, and cited findings of a study in the 
London area (Griffith et al., 1994) which found the mean duration of smoking prior to first injecting to be 2.4 years. 
Moving to injecting heroin has been linked to earlier illicit drug use, an earlier commencement age of heroin use, 
and a previous history of ecstasy use (Gervin et al., 2001). The increase of injecting in prison amongst those who 
did not previously inject, and those who held a preference to smoke, has been reported to be due to the necessity 
to be more efficient with the drug (Dillon, 2001). Efficient in this context means the requirement of the greatest 
number of prisoners, to use the limited quantity of heroin, to the maximum effect (Dillon, 2001). Prisoners felt 
compelled to partake in this method even in situations where they did not wish to inject (Dillon, 2001). Long et al. 
(2004) found that while prisoners were not forced to partake in injecting, scarcity of the drug would determine the 
method of administration, the desire to reach a certain ‘buzz’ being a strong determining factor.
The mean duration of using prior to first injecting for other drugs was 4.8 years for benzodiazepines (mean ages 
15.4 and 20.2, p<0.001), 2.2 years for other opiates (mean ages 20.2 and 18.0, p=0.01), and 2.9 years for 
cocaine powder (mean ages 19.0 and 21.9, p<0.001). For methadone injectors there was no difference in the 
mean ages for use or injecting. For each of the other drugs, the mean age at which injecting commenced was 
significantly higher than the mean age of first use.
4.7.2 Overdosing on Drugs
Table 4.34 Self-reported drug use: Overdose history
Total Male Female 18–24 years 25–34 years 35–64 years
n % n % n % n % n % n %
Ever overdosed on 
any drug (of all)
217 26.7 197 25.7 20 44.4 66 26.1 95 29.7 55 23.9
Ever overdosed on 
any drug (of IDUs)
119 57.8 103 55.4 16 80.0 22 47.8 64 59.3 32 62.7
More than a quarter (27%) of all prisoners and a majority of Injecting Drug Users (IDUs) (58%) had overdosed on 
drugs at some stage in their life. Women were significantly more likely than men to have overdosed (44% vs 26%, 
p<0.01) and female IDUs were significantly more likely than male IDUs to have an overdose history (80% vs 55%, 
p<0.05). A trend of increasing overdose history is visible across the prison categories in which prisoners who had 
ever overdosed were currently resident. No significant age associations were found.
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Table 4.35 Self-reported drug use: Overdose history by prison drug use category
Low use Medium use High use Very High use
n % n % n % n %
Ever overdosed 16 17.8 68 23.5 97 28.7 36 37.5
4.7.3 Drug Use in Prison
While a primary concern is addressing the health needs of prisoners who use drugs irrespective of whether they 
are taking them within or outside of prison, the extent to which drug use takes place in prison is also relevant for 
health planning purposes, because it shows the extent to which the problems are directly associated with the prison 
setting. Participants answered specific questions about drug use in prison, addressing whether their first use of a 
drug was in prison and whether drug use in the previous year included use in prison.
4.7.3.1 First Use and First Injecting Use in Prison
Taking a particular drug for the first time in prison is likely to be associated with the age at which the drug was 
first taken (as evidenced by cannabis), and with the point in an individual’s drug taking experience that they have 
reached when they are ready to progress to another drug. For example, for those who reported first use of a drug 
in prison, it is not known on how many occasions they had been in prison before that time, or whether they just 
happened to be in custody when they reached the point where they were ready to take the step and this should be 
noted when interpreting the following results.
More than two fifths (43%) of those who had ever used heroin reported that they had taken it for the first time in 
prison. More than a third (38%) of those who had ever received methadone reported their first use being while in 
prison. Other drugs that were reported as being taken for the first time in prison, among those who had ever taken 
the drug, were: benzodiazepines (20%) and other sedatives or tranquillisers (28%). Less than one in 10 users 
reported first taking cannabis (6%), cocaine powder (5%) or crack cocaine (9%) in prison and this is likely to be 
associated with the age of first use for cannabis and possibly availability of cocaine in prison. Men were significantly 
more likely than women to report first using heroin in prison (46% vs 17%, p<0.01). There were no other 
significant gender differences, and no significant age patterns.
Table 4.36 Self-reported drug use: (Of those who have ever used) In prison when first used by gender 
and age-group
Drug All Males Females 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Cannabis 40 5.7 39 5.9 1 2.7 10 4.2 15 5.1 14 8.8
Benzodiazepines 105 19.6 101 20.0 4 12.9 32 16.0 48 21.2 24 23.1
Other Sedatives or 
Tranquillisers
129 28.4 123 28.9 6 20.0 42 25.9 57 29.5 29 30.2
Heroin 146 43.2 141 45.6 5 17.2 48 51.1 67 43.2 30 35.7
Methadone 99 38.4 90 39.0 9 33.3 27 45.0 48 38.7 21 30.4
Other opiates 54 21.2 53 22.5 1 5.3 7 13.0 34 26.8 13 18.3
Crack cocaine 25 8.8 23 9.0 2 7.7 7 9.5 11 8.3 7 9.7
Cocaine powder 28 4.8 28 5.0 0 0.0 5 2.4 15 5.8 8 6.8
In the previous Irish study of inmates (Allwright et al., 1999) 21% of injectors first injected in prison. In the current 
study, the drug injected for the first time in prison by the largest proportion of those who had ever injected it 
was steroids (24%, 16/69). Mephedrone and methylone were the next highest proportions (13% and 14% 
respectively). In all other cases 10% or less of ever injectors of the drug reported having injected it for the first time 
in prison. More than a fifth of women (21%) who had ever injected heroin injected it for the first time in prison; 
this was significantly different to men (6%, p=0.05). There were no other significant gender or age patterns for first 
use in prison among injectors.
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Table 4.37 Self-reported injecting drug use: (Of those who have ever injected) In prison when first 
injected
Drug All Males Females 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % % n %
Benzodiazepines 7 10.1 5 8.1 2 28.6 0 0.0 5 14.3 2 8.3
Amphetamines 3 6.7 3 7.5 0 0.0 0 0.0 3 15.8 0 0.0
Heroin 12 8.1 8 6.2 4 21.1 1 3.9 8 10.0 3 7.1
Methadone 2 10.0 2 10.5 0 0.0 0 0.0 2 25.0 0 0.0
Other opiates 2 4.0 1 2.2 1 20.0 0 0.0 1 4.6 1 5.0
Cocaine powder 8 8.1 8 9.3 0 0.0 1 7.7 6 11.1 1 3.2
Mephedrone 4 12.5 3 12.0 1 14.3 1 9.1 2 14.3 1 16.7
Methylone 3 14.3 2 12.5 1 20.0 0 0.0 2 22.2 1 20.0
Crystal meth 1 7.1 1 7.7 0 0.0 0 0.0 1 20.0 0 0.0
Steroids 16 23.5 16 23.9 0 0.0 4 19.1 8 24.2 4 30.8
Any other drug 2 5.9 1 3.5 1 20.0 0 0.0 2 10.5 0 0.0
It should be noted that 8% of prisoners who ever injected heroin, did so for the first time in prison, therefore 
92% of injectors made the move from using to injecting heroin outside of prison. This is in contrast to 43% 
who first used heroin (by any means) in prison. In the UK, Strang et al. (2006) found (for heroin, cocaine 
and amphetamines) that recency of drug use before entering prison and dependence were two key factors in 
persistence of drug use during imprisonment, and that persistence of heroin use in prison occurred more often than 
use of the other two drugs.
4.7.3.2 In-prison Drug Use: Last Year
Among those who reported that they had used drugs within the past year, for most drugs the majority reported 
that they had used in prison during that time period: cannabis (88%), benzodiazepines (85%), other sedatives or 
tranquillisers (87%), heroin (84%), methadone (87%), other opiates, (66%) and crack cocaine (52%). Men were 
significantly more likely than women to have used cannabis (88% vs 74%, p<0.05) and heroin (86% vs 62%, 
p=0.01) in this context.
Table 4.38 Self-reported drug use: (Of those who used within the last year) Did that include times 
when you were in prison?
Drug All Males Females 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Cannabis 481 87.5 458 88.3 23 74.2 176 83.8 204 89.5 93 89.4
Benzodiazepines 369 85.4 346 85.6 23 82.1 142 81.6 168 90.3 58 85.3
Other Sedatives or 
Tranquillisers
319 87.4 293 87.5 26 89.7 113 83.1 141 90.4 61 89.7
Heroin 192 83.8 179 86.1 13 61.9 58 78.4 96 88.1 36 81.8
Methadone 142 87.1 120 87.0 22 88.0 23 63.9 75 93.8 40 93.0
Other opiates 67 65.7 63 67.7 4 44.4 17 58.6 36 70.6 14 66.7
Crack cocaine 48 52.7 39 50.7 9 64.3 9 34.6 28 60.9 11 61.1
Cocaine powder 98 43.8 92 44.7 6 33.3 32 33.7 52 52.0 13 50.0
The numbers reporting using each drug in prison during the last year are presented below, by prison drug use 
category, as a proportion of all prisoners (who had answered the ever use question for the relevant drug) (table 
4.39). Usage of all of the drugs shows a trend of an increase in use from low use to high use categories, but there 
is a decrease for in-prison use between the high use and very high use category for most drugs (the exceptions are 
methadone and crack cocaine).
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Table 4.39 Self-reported in-prison drug use: Last year use by prison drug use category  
(among all prisoners)
Drug Low use Medium use High use Very High use
n % n % n % n %
Cannabis* 47 68.1 168 70.6 212 78.8 54 66.7
Benzodiazepines*** 18 24.3 124 51.9 182 62.3 45 51.7
Other Sedatives or Tranquillisers** 22 27.9 101 42.1 153 52.2 43 48.9
Heroin*** 8 10.1 54 21.9 108 37.9 22 30.1
Methadone*** 1 1.2 16 6.5 87 29.8 38 44.7
Other Opiates 4 5.1 21 9.1 35 13.6 7 9.5
Crack Cocaine*** 0 0.0 10 4.6 25 10.3 13 18.6
Cocaine Powder 6 13.3 38 23.2 45 27.6 9 14.5
Chi2 test * p<0.05, ** p<0.01, *** p<0.001
In the next table (4.40) the numbers reporting using each drug in prison are presented as a proportion of those 
who reported use of the drug within the last year. The pattern here is very different and may reflect availability of 
drugs in particular prison categories.
Thus for cannabis, for example, between 68% and 79% (depending on the prison category) of all prisoners in 
these categories reported that they had used cannabis in prison in the last year (table 4.39), but between 78% 
and 94% (depending on the prison category) of those who used cannabis in the last year did so in prison (table 
4.40). Likewise for heroin, between 10% and 38% (depending on the prison category) of all prisoners in these 
categories reported that they had used heroin in prison in the past year, and between 61% and 91% (depending 
on the prison category) of all prisoners who used heroin in the last year reported that they had done so in prison. 
As previously cautioned, prevalence estimates do not provide any information about the number of times a person 
used in a time period, and use for some may have been a once-off event.
Table 4.40 Self-reported in-prison drug use: Last year use by prison drug use category  
(among those who used in the last year)
Drug Low use Medium use High use Very High use
n % n % n % n %
Cannabis* 47 94.0 168 85.7 212 90.2 54 78.3
Benzodiazepines 18 94.7 124 82.7 182 87.9 45 80.4
Other Sedatives or Tranquillisers 22 88.0 101 86.3 153 89.5 43 84.3
Heroin*** 8 88.9 54 83.1 108 90.8 22 61.1
Methadone 1 100.0 16 61.5 87 95.6 38 84.4
Other Opiates 4 80.0 21 56.8 35 77.8 7 46.7
Crack Cocaine 0 0.0 10 47.6 25 56.8 13 52.0
Cocaine Powder 6 60.0 38 45.2 45 47.9 9 25.0
Chi2 test * p<0.05, *** p<0.001
Finally, the reported use of each drug was reviewed from the perspective of those who must have been in prison 
during the time period by virtue of their self-reported length of time in prison.
Thirty nine percent of all prisoners had been in prison for 12 months or less. Among the 61% whose length of time 
in prison exceeded 12 months, two thirds had taken cannabis during the past year, more than a quarter had taken 
heroin and one fifth had taken cocaine powder in that time period.
Five percent of all prisoners had been in prison for less than 1 month. Among the 95% whose length of time in 
prison exceeded a month, a similar pattern is evident.
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Table 4.41 Self-reported drug use: Last year and last month use for all prisoners and for those  
in prison longer than a year or a month
Drug All In prison > 1 
year
All In prison > 1 
month
Last year use Last year use Last month use Last month use
n % n % n % n %
Cannabis 554 68.6 322 66.7 349 43.4 325 43.2
Benzodiazepines 434 54.6 242 50.1 229 29.0 211 28.5
Other Sedatives or Tranquillisers 367 46.3 217 46.0 195 24.8 181 24.5
Heroin 233 29.5 136 28.8 87 11.1 80 10.9
Methadone 167 20.9 82 17.2 106 13.3 97 13.0
Other Opiates 103 13.0 49 10.4 35 4.4 34 4.6
Crack Cocaine 92 11.7 33 7.0 15 1.9 12 1.6
Cocaine Powder 226 28.6 95 20.3 41 5.3 35 4.8
The 2009 Scottish prison survey found that the proportion of all prisoners who reported ever taking illegal drugs in 
prison reduced from 58% to 45% over the period 2004–2009 (Scottish Prison Service, 2009). A fifth of Scottish 
prisoners (22%) reported that they had used drugs in prison in the month prior to the 2009 survey; in this study 
the proportion of those who were in prison during the previous month, and that reported using drugs in that period, 
ranged from 2% to 43% for individual drugs.
4.7.3.3 In-prison Injecting Drug Use
Of the small numbers of injectors who had injected individual drugs in prison over the past year (ranging from one 
to 13 for different drugs) the largest proportion was for steroids (68%, 13/19). Only nine of 56 last year heroin 
injectors, seven of 23 last year benzodiazepine injectors, and seven of 25 who had injected cocaine had injected 
in prison in the last year. Any further sub-analysis of the distribution of in-prison injecting among last year users (for 
example by prison category) is meaningless with such small numbers.
4.42 Self-reported injecting drug use: (Of those who injected the drug in the last year) Did that include 
injecting while in prison?
Drug All Males Females 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Benzodiazepines 7 30.4 5 27.8 2 40.0 1 14.3 5 38.5 1 33.3
Amphetamines 1 10.0 1 14.3 0 0.0 0 0.0 1 20.0 0 0.0
Heroin 9 16.7 8 17.8 1 11.1 1 5.0 6 23.1 2 25.0
Methadone 2 33.3 2 40.0 0 0.0 0 0.0 2 66.7 0 0.0
Other opiates 1 12.5 1 14.3 0 0.0 0 0.0 0 0.0 1 100
Cocaine powder 7 29.1 7 38.9 0 0.0 0 0.0 5 41.7 2 40.0
Mephedrone 4 22.2 3 25.0 1 16.7 0 0.0 4 44.4 0 0.0
Methylone 2 22.2 1 16.7 1 33.3 0 0.0 2 40.0 0 0.0
Crystal meth 1 33.3 1 33.3 0 0.0 0 0.0 1 50.0 0 0.0
Steroids 13 68.4 13 68.4 0 0.0 4 80.0 7 58.3 2 100
Any other drug 1 9.1 1 11.1 0 0.0 0 0.0 1 20.0 0 0.0
Finally, the reported use of injecting each drug was reviewed from the perspective of those who must have been 
in prison during the time period by virtue of their self-reported length of time in prison. Among those whose length 
of time in prison exceeded 12 months, very small proportions had injected individual drugs in the past year – the 
highest proportions were for steroids (2.5%), heroin (1.9%) and cocaine powder (1.1%). The proportion reporting 
injection of any of the drugs surveyed in the last year among those definitely known to be in prison for greater than 
or equal to one year was 4.9% (n = 24, 95% CI 3.5%-7.0%).
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Five percent of all prisoners had been in prison less than one month. Among those whose length of time in prison 
exceeded a month, less than 1% had injected any of the individual drugs surveyed (0.8% for cocaine powder). The 
proportion reporting injection of any of the drugs surveyed in the last month among those definitely known to be in 
prison for greater than or equal to one month was 1.3% (n = 10, 95% CI 0.8%-2.3%).
Table 4.43 Self-reported drug use: Last year and last month injecting use for all and for those in prison 
longer than that period
Drug All In prison > 1 year All In prison > 1 month
Last year IDU Last year IDU Last month IDU Last month IDU
n % n % n % n %
Benzodiazepines 23 2.9 3 0.6 4 0.5 1 0.1
Amphetamines 12 1.5 2 0.4 2 0.3 1 0.1
Heroin 55 6.9 9 1.9 7 0.9 1 0.1
Methadone 6 0.8 2 0.4 3 0.4 2 0.3
Other Opiates 8 1.0 0 0.0 0 0.0 0 0.0
Cocaine Powder 25 3.1 5 1.1 8 1.0 6 0.8
Mephedrone 18 2.3 4 0.9 2 0.3 1 0.1
Methylone 9 1.1 2 0.4 1 0.1 1 0.1
Crystal Meth 3 0.4 0 0.0 0 0.0 0 0.0
Steroids 19 2.4 12 2.5 4 0.5 4 0.5
Other drug 11 1.4 2 0.4 0 0.0 0 0.0
In the 2009 Scottish prison survey 3% of prisoners reported that they had injected in prison within the previous 
month. In this study the proportion was 1.3%.
These results provide evidence that current injecting drug use in prison is not a common activity. This may reflect 
the relatively recent increase in measures to reduce supply getting into prisons and, in the case of heroin, the recent 
heroin drought (Concateno, 2011; Daily Mail, 2011).
4.7.4 Prescription Drug Use in Prison
The use of prescription drugs (benzodiazepines and other sedatives and tranquillisers, methadone and other opiates 
– not including methadone) was highly prevalent among prisoners as shown in previous sections, and prisoners 
were asked where they got prescription drugs the last time they took them in prison.
The majority (56%) of those who had ever taken methadone had taken it on prescription the last time they 
took it in prison. In relation to benzodiazepines, other sedatives and tranquillisers and prescription opiates (other 
than methadone) a minority of prisoners were taking such drugs under medical supervision (10%, 15% and 9% 
respectively); the majority had received them from someone they knew (67%, 51% and 51% respectively) or from 
another source (4%, 3% and 4% respectively).
Table 4.44 Self-reported drug use: Source of drug last time they were taken in prison (among those 
who had ever taken the drug)
Drug Never took them 
in prison
On prescription From someone 
I know
Other Source
n % n % n % n %
Benzodiazepines 105 19.2 57 10.4 366 66.9 23 4.2
Other Sedatives or tranquillisers 110 23.6 68 14.6 239 51.3 12 2.6
Opiates (other than heroin or methadone) 69 26.5 24 9.2 133 51.2 10 3.8
Methadone 56 21.4 146 55.7 42 16.0 8 3.1
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The majority (85%) of those who had taken methadone in the past month had taken it on prescription the last 
time they took it in prison. In relation to benzodiazepines, other sedatives and tranquillisers and prescription opiates 
(other than methadone) a minority of prisoners who took it within the last month had done so in prison under 
medical supervision (14%, 22% and 11% respectively); the majority (76%, 58% and 74% respectively) had 
received it from someone they knew the last time they took it in prison.
Table 4.45 Self-reported drug use: Source of drug last time they were taken in prison (among those 
who had taken the drug in the last 30 days)
Drug Never took them 
in prison
On prescription From someone 
I know
Other Source
n % n % n % n %
Benzodiazepines 18 7.9 31 13.5 175 76.4 15 6.6
Other Sedatives or tranquillisers 19 9.7 42 21.5 113 57.9 6 3.1
Opiates (other than heroin or 
methadone)
5 14.3 4 11.4 26 74.3 2 5.7
Methadone 10 9.5 89 84.8 9 8.6 3 2.9
Figure 4.16 Self-reported drug use: Source of drug last time they were taken in prison  
(among those who had taken the drug in the last 30 days)
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4.8 Methods of Drug Use, including Intravenous Drug Use
4.8.1 Methods of Drug Use
The questionnaire first asked questions about drug use without specifying the method of use, and subsequently 
asked specifically about injecting drug use. Six drugs were included in both sections: benzodiazepines, heroin, 
methadone, other opiates and cocaine powder.
Table 4.46 Self-reported drug use: Methods of drug use based on ever use
Drug Total 
Taking Drug
IV Only Both IV & 
Other Method
IV Total Other Method
n % n % n % n % n %
Benzodiazepines 547 100.0 4 0.7 67 12.2 71 13.0 476 87.0
Heroin 348 100.0 6 1.7 148 42.5 154 44.3 194 55.7
Methadone 262 100.0 – – 22 8.4 22 8.4 240 91.6
Other Opiates 260 100.0 4 1.5 50 19.2 54 20.8 206 79.2
Cocaine Powder 600 100.0 3 0.5 101 16.8 104 17.3 496 82.7
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Based on ever use, methods other than injecting were used by the majority of users for all drugs. Less than 2% 
used injection as their only method of using any of the five drugs, however 44% had injected heroin, 21% other 
opiates and 17% cocaine powder.
Figure 4.17 Relationship between methods of benzodiazepine use
Total taking benzodiazepines n = 547
476 (87.0%)
67 (12.2%)
4 (0.7%)
Other method 543 (99.3%)
Inject 71 (13%)
Not to scale
Figure 4.18 Relationship between methods of heroin use
Total ever taking heroin n = 348
194 (55.7%)
148 (42.5%)
6 (1.7%)
Other method 342 (98.3%)
Inject 154 (44.3%)
Not to scale
Figure 4.19 Relationship between methods of methadone use
Total ever taking methadone n = 262
240 (91.6%)
22 (8.4%)
0 (0%)
Other method 240 (100%)
Inject 22 (8.4%)
Not to scale
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Figure 4.20 Relationship between methods of other opiates use
Total ever taking other opiates n = 260
265 (79.2%)
50 (19.2%)
Other method 256 (98.5%)
Inject 54 (20.8%)
4 (1.5%)
Not to scale
Figure 4.21 Relationship between methods of cocaine powder use
Total ever taking cocaine powder n = 600
496 (82.7%)
101 (16.8%)
Other method 597 (99.5%)
Inject 104 (17.3%)
3 (0.5%)
Not to scale
Respondents who ‘do heroin now’ were asked what method they used. Of the 226 prisoners who answered the 
question, the majority (75%) currently used smoking or ‘chasing the dragon’ as their only method of choice, while 
13% used injecting as their only method; less than 1% snorted only. Only a very small proportion currently used all 
three methods of administration (1.3%), or smoked and snorted (1.3%); 9% both smoked and injected.
Figure 4.22 Methods of use for heroin among prisoners who currently do heroin
Those who 'do heroin now' n = 226
169 (74.8%)
Smoke/Chase the dragon 195 (86%)Inject heroin 52 (23%)
Snort heroin 8 (3.5%)
2 (0.9%)
3 (1.3%)
3 (1.3%)
0
29 (12.8%) 20 (8.9%)
Not to scale
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4.8.2 Sharing Works
About 13% of all prisoners reported ever sharing any works.
Table 4.47 Sharing injecting equipment
All Male Female 18–24 25–34 35–64
n % n % n % n % n % n %
Ever shared needles 84 10.8 70 9.5 14 32.6 11 4.6 43 14.4 29 12.7
Ever shared syringes 81 10.5 67 9.2 14 32.6 10 4.2 42 14.3 28 12.3
Ever shared other works 84 10.9 68 9.4 16 38.1 12 5.0 44 15.1 27 11.9
Ever shared needles or 
syringes or other injecting 
equipment
102 13.0 83 11.2 19 43.2 14 5.8 56 18.5 31 13.5
A significantly greater proportion of women shared injecting equipment than men (for needles 33% vs 10%, 
p<0.001; for syringes 33% vs 9%, p<0.001; and for other injecting equipment 38% vs 9%, p<0.001). The 
youngest age group (18–24 year olds) were significantly less likely to have shared needles, syringes or other works 
(p<0.05).
About half of those who reported ever injecting drugs had ever shared needles, syringes or other injecting 
equipment. Again a significantly greater proportion of women shared than men (for needles and syringes 78% vs 
46%, p<0.05; for other injecting equipment 94% vs 47%, p<0.001, and for any of needles or syringes or other 
injecting equipment 53% vs 100%, p<0.001).
Table 4.48 Sharing injecting equipment: Sharing among injecting drug users
All Males Females 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Ever shared needles 84 48.8 70 45.5 14 77.8 11 33.3 43 48.9 29 58.0
Ever shared syringes 81 49.1 67 45.6 14 77.8 10 30.3 42 51.2 28 57.1
Ever shared other injecting 
equipment
84 51.9 68 46.9 16 94.1 12 36.4 44 55.0 27 56.3
Ever shared needles or 
syringes or other injecting 
equipment
102 58.0 83 52.9 19 100.0 14 42.4 56 61.5 31 60.8
Figure 4.23 Sharing injecting equipment: Sharing among injecting drug users
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When viewed by prison drug use category, the pattern of current prison residence for IDUs who had ever shared 
was consistent with the low use to high use prison categories.
Table 4.49 Sharing injecting equipment: Ever shared by prison drug use category (among IDUs)
Low use Medium use High use Very High use
n % n % n % n %
Shared Needles 4 36.4 13 40.6 47 49.0 20 60.6
Shared Syringes 3 30.0 15 45.5 41 45.6 22 68.8
Shared Other Works* 3 30.0 14 43.8 44 49.4 23 74.2
Shared needles or syringes or other works** 4 36.4 17 48.6 53 55.2 28 82.4
Chi2 test * p<0.05, ** p<0.01
A series of questions about sharing in the previous 30 days were asked. Among those who had ever shared 
needles, 9% (7/76) had used a new needle and syringe for their last injection in the last 30 days. The median 
number of times that injecting had taken place, among IDUs in the last 30 days was 4 (range 0–70).
Table 4.50 Injecting Drug Use: Sharing frequency among IDUs in last 30 days
n Median Range Interquartile 
range
Times injected in last 30 days 16 4 0–70 1–12
Sterile needles received in the last 30 days 15 2 0–300 0–20
Sterile syringes received in the last 30 days 15 1 0–300 0–10
Times re-used the last needle and syringe used in the last 
30 days
18 1 0–6 0–2
No. of people from whom a used needle and syringe was 
received
17 0 0–4 0–0
Those who had ever shared were asked about their sharing habits in the previous month both in and out of prison. 
Regarding sharing needles outside of prison, 84% (42/50) of the ever sharers who responded considered the 
question not applicable, suggesting they had not been outside of prison in that time or that they were not current 
IDUs. Of the remaining eight, half shared either always or sometimes, and the other half shared rarely or never. For 
syringes and other works, 60% of the 10 who had shared rarely or never shared.
Table 4.51 Sharing works: Last month frequency of sharing works outside prison  
(among those who had ever shared)
Always Sometimes Rarely Never Total
n % n % n % n % n %
Needles 1 12.5 3 37.5 2 25.0 2 25.0 8 100.0
Syringes 1 10.0 3 30.0 2 20.0 4 40.0 10 100.0
Other Works 2 20.0 2 20.0 2 20.0 4 40.0 10 100.0
Regarding sharing in prison, more than half never shared needles or syringes in the previous month, and just under 
half never shared works, with between a fifth and a quarter sharing rarely. A greater proportion sometimes or always 
shared other works than shared needles and syringes, but the numbers concerned in all cases are very low.
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Table 4.52 Sharing works: Last month frequency of sharing works in prison  
(among those who had ever shared)
Always Sometimes Rarely Never Total
n % n % n % n % n %
Needles 1 5.3 4 21.1 4 21.1 10 52.6 19 100.0
Syringes 1 5.0 3 15.0 5 25.0 11 55.0 20 100.0
Other Works 3 14.3 4 19.0 4 19.0 10 47.6 21 100.0
4.9 Prevalence of Blood-Borne Viruses among the Prisoner Population
4.9.1 Prevalence of Blood-Borne Viruses (BBVs)
Prevalence tables with confidence intervals for proportions for a) self-reported hepatitis B, hepatitis C and HIV status 
and b) status based on the results of the serological analysis of oral fluid samples are presented in the appendices.
Table 4.53 Blood-borne viruses: Hepatitis B, hepatitis C and HIV self-report and oral fluid sample test 
results
All Males Females 18–24 Years 25–34 Years 35–64 Years
Positive n % n % n % n % n % n %
Self-reported HBV status 9 1.1 9 1.2 0 0.0 2 0.8 3 1.0 3 1.4
Hepatitis B Test (HBsAg) 
result
2 0.3 2 0.3 0 0.0 0 0.0 1 0.3 1 0.5
Self-reported HCV status 67 8.6 60 8.1 7 15.9 2 0.8 37 12.0 27 12.4
Hepatitis C Test (Anti-HCV) 
result
100 12.9 90 12.3 10 22.2 7 2.9 51 16.6 41 19.0
Self-reported HIV status 11 1.4 9 1.2 2 4.6 0 0.0 5 1.6 5 2.3
HIV Test (Anti-HIV) result 15 1.9 11 1.5 4 8.9 1 0.4 6 2.0 7 3.2
Table 4.53 shows both the self-reported prevalence (based on a positive self-report for either first or last test result) 
and the results from oral fluid testing. Among those who reported, there was a significant difference by age-group 
for self-reported hepatitis C with the youngest age-group least likely to report being infected (0.8% vs 12.0% vs 
12.4%, p<0.001). The prevalence (from oral fluid sample test results) of hepatitis B was 0.3%, hepatitis C was 
12.9% and HIV 1.9%.
Figure 4.24 Blood-borne viruses: Prevalence of hepatitis B, hepatitis C and HIV  
(oral fluid sample test results)
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Prevalence rates for hepatitis B and C in this study (0.3% and 12.9% respectively) were a lot lower than rates 
in the previous Irish prison study (Allwright et al., 1999), which were 9% and 37% respectively, with the rates 
in medium risk (for BBV) prisons at 4% and 17% respectively. Again, it should be noted that the three prisons 
perceived to be low risk for BBVs were excluded from that study.
The test for hepatitis B carried out in the 1999 study was hepatitis B core-antibody test, a measure of any  
exposure, whereas the current study investigated current infection (using hepatitis B surface antigen testing 
[HBsAg]), therefore the results are not directly comparable. Furthermore, one of the developments since the 
1999 study was development of IPS healthcare standards for blood-borne virus testing and hepatitis B vaccination 
services (IPS, 2009) and it is not unexpected that these interventions would impact on prevalence. Other published 
estimates for prevalence of hepatitis B in prison studies using HBsAg included 3% in Australia (Butler et al., 2007), 
2.5% in Germany (Radun et al., 2008) and 2.4% in the Lebanon (Mahfoud et al., 2010). Blood screening results 
also indicate a low prevalence in the general population. Serological surveillance screening was carried out in 2003 
as part of the European Sero-Epidemiology Network project and a HBsAg prevalence of 0.1% was found in the 
Irish sample tested (ESEN unpublished data, cited in Murphy and Thornton, 2008a:2). The Irish Blood Transfusion 
Service (IBTS) tested 207,015 first time blood donors between 1997 and 2006 and found a HBsAg prevalence of 
0.014% (cited in Murphy and Thornton, 2008a:2). Among IDUs prevalence of hepatitis B (using HBsAg) has been 
estimated at 1% (Smyth et al., 1998) and among drug users at 2% (Grogan et al., 2005).
Prevalence of hepatitis C in the previous Irish prison inmates’ study (Allwright et al., 1999) was 37%. Hepatitis C 
prevalence (using Anti-HCV testing) in other prison studies ranged from 7% in a study of prisons in England and 
Wales (Weild et al., 2000) to 82% in a German study (Stark et al., 2006). In the Scottish Prison Survey (2009) 
13% thought that they were positive for hepatitis C but no serological testing was carried out. A recently published 
estimate of prevalence of hepatitis C in the Irish population is 0.5–1.2% (Thornton et al., 2011). In Ireland 
prevalence of hepatitis C among injecting drug users has previously been estimated at 61.8% (Smyth et al., 1998) 
and among drug users at 66% (Grogan et al., 2005).
Prevalence of HIV in the previous prison study (Allwright et al.,1999) was 2% (0.8% in medium BBV-risk prisons). 
The prevalence rate for HIV therefore appears to have not changed, however recall that the Allwright study excluded 
prisons considered to be low risk for BBVs, which could inflate the estimate. Prevalence studies in other prisons 
have shown results ranging from 0.2% in the Lebanon (Mahfoud et al., 2010) and 0.4% in England and Wales 
(Weild, 2000) to 18% (Stark et al., 2006) in Germany. The Irish population prevalence is estimated to be 0.2% 
(UNAIDS, 2010). In previous Irish studies, prevalence of HIV among injecting drug users has been estimated at 
1.2% (Smyth et al., 1998) and among drug users at 11% (Grogan et al., 2005).
Women were significantly more likely than men to be infected with HIV (8.9% vs 1.5%, p<0.001), and the younger 
age-group was significantly less likely to be infected with hepatitis C than the age-groups 25–34 and 35–64 
respectively (2.9% vs 17% and 19%, p<0.001).
4.9.2 Concordance of Oral Fluid BBV Sample Results with Self-Reported Results
Table 4.54 Concordance between hepatitis B self-report status and hepatitis B oral fluid sample test 
result
Self-reported status from first and last hepatitis B test Hepatitis B Virus 
Positive
antibody test 
(HBsAg) Negative
result Total
n (%) n (%) n (%)
Self-reported positive 1 (11.1) 8 (88.9) 9 (100)
Self-reported negative 1 (0.4) 276 (99.6) 277 (100)
Did not know status 0 (0) 43 (100) 43 (100)
Not answered 0 (0) 442 (100) 442 (100)
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Two participants (0.3%) tested positive for hepatitis B. Concordance of hepatitis B self-report status with HBsAg 
test results revealed that eight (89%) of the nine prisoners who thought that they were positive had a negative test 
result, and one person (0.4%) who thought they were negative had a positive test result. In this study 99.6% of 
those who thought they were negative actually tested negative.
Table 4.55 Concordance between hepatitis C self-report status and hepatitis C oral fluid sample test 
result
Self-reported status from first and last hepatitis C test Hepatitis C Virus antibody test (Anti-HCV) result
Positive Negative Total
n (%) n (%) n (%)
Self-reported positive 59 (95.2) 3 (4.8) 62 (100)
Self-reported negative 21 (8.9) 214 (91.1) 235 (100)
Did not know status 2 (6.1) 31 (93.9) 33 (100)
Not answered 18 (4.1) 423 (95.9) 441 (100)
One hundred participants tested positive for hepatitis C (13%), and 59 (95%) of those who self-reported that they 
were positive were in fact positive. Likewise, 91% of those who thought that they were negative tested negative.
Biological hepatitis C test results revealed that three (5%) of those who thought that they were positive had a 
negative test result, and 21 (9%) of those who thought they were negative had a positive test result.
Two (6%) of those who did not know their status tested positive for hepatitis C, and 18 (4%), of those who had 
not reported on their status had a positive result.
Table 4.56 Concordance between HIV self-report status and HIV oral fluid sample test result
Anti-HIV result
Self-reported status from first and last HIV test Positive Negative Total
n (%) n (%) n (%)
Self-reported positive 10 (90.9) 1 (9.1) 11 (100)
Self-reported negative 3 (1.0) 290 (99.0) 293 (100)
Did not know status 0 (0) 31 (100) 31 (100)
Not answered 2 (0.5) 434 (99.5) 436 (100)
Fifteen participants tested positive for HIV (1.9%). Concordance of HIV self-report status with HIV test results 
revealed that one (9%) of those who thought that they were positive had a negative test result, and three (1%) 
who thought that they were negative had a positive test result; none of those who did not know their status tested 
positive, although two (0.5%) of those who had not reported on their status had a positive result.
There are a number of reasons why self-reported results may not match test results, such as incorrect completion 
of the questionnaire, which may be due to unwillingness to report status, or be simply an oversight or a reflection 
of poor understanding of the question. For hepatitis B, this may reflect inclusion in the ‘self-reporting’ group of 
previous HBV infection (anti-HBc positive), which was not determined during this study. Alternatively, a number may 
have been acutely infected and had HBsAg detected previously, but have subsequently resolved infection and are 
now HBsAg negative. It is also possible for hepatitis C, that seroconversion has occurred since they received their 
previous test result.
When viewed by prison drug use category, a pattern of increased infectivity with increased drug use prison category 
is evident for hepatitis C and HIV. There is a highly significant difference in the prevalence of biologically tested HIV 
and hepatitis C between prison drug use categories, with increasing prevalence matching higher last year drug use. 
Differences in hepatitis B cannot be assessed because of the small numbers.
79
Study on the prevalence of drug use, including intravenous drug use, 
and blood-borne viruses among the Irish prisoner population
Chapter 4 Results
Table 4.57 Blood-borne virus oral fluid sample test results by prison drug use category
Low use 
n = 89
Medium 
n = 278
High use 
n = 320
Very High use 
n = 90
n % n % n % n %
HIV Test (Anti-HIV)*** 0 0.0 1 0.4 8 2.5 6 6.7
Hepatitis B Test (HBsAg) 1 1.1 0 0.0 1 0.3 0 0.0
Hepatitis C Test (Anti-HCV)*** 2 2.3 20 7.2 52 16.3 26 28.9
Chi2 test *** p<0.001
4.9.3 Co-infection
Fourteen percent (106/777) of prisoners had serological evidence for blood-borne virus infection. No prisoners 
tested positive for all three viruses, and there was no co-infection between hepatitis B and HIV. However, 
co-infection with hepatitis C and HIV was detected in 1.3% (10/777) of prisoners and co-infection with hepatitis B 
and HIV was detected in 1 participant (0.1%).
Figure 4.25 Relationship between blood-borne viruses
BBV samples (n+777)
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4.9.4 Factors Associated with Blood-Borne Viruses
4.9.4.1 Tattoos
The majority of prisoners had tattoos or borstal marks (68%; men 68%, women 78%). While the majority of those 
with tattoos had some done by a tattoo artist (71%, 393/556), many had them done by a friend or relative (24%, 
132/556) or another prisoner (18%, 99/556); a fifth did the tattoo themselves (20%, 111/256). Over a third of 
those with tattoos or borstal marks had a tattoo done in prison at some stage (35%, 190/538). In the Scottish 
prison survey 2008, 54% reported having a tattoo, with 18% reporting receipt of a tattoo in prison (Scottish Prison 
Service, 2008).
Table 4.58 Tattoos/Borstal marks
Total Male Female 18–24 25–34 35–64
n % n % n % n % n % n %
Tattoos 556 68.4 521 67.8 35 77.8 167 65.7 242 75.9 142 61.7
Tattooing involves piercing of the skin and it is likely that receiving a tattoo from a non-professional and/or having 
tattoos done in prison involves sharing of tattoo equipment, which may or may not be clean. When exploring 
behaviours associated with BBVs using logistic regression, having a tattoo and having a tattoo carried out in prison 
were included in the analysis, which is described below.
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4.9.4.2 Sexual behaviour
High risk sexual behaviour for BBVs includes men having sex with men and unsafe sex (i.e. having sex without a 
condom). The majority of those who had ever had sex in prison or ever had sex outside of prison did not use a 
condom the last time they had sex (73% in prison, 79% outside of prison). The majority rarely or never used a 
condom (62% in prison, 51% outside of prison).
Table 4.59 Safe sex: Condom use (among those who had ever had sex in or out of prison)
Not 
applicable
Always Sometimes Rarely Never Total
n % n % n % n % n % n %
In prison 8 11.8 8 11.8 10 14.7 15 22.1 27 39.7 68 100.0
Outside prison 38 5.3 92 12.9 218 30.5 148 20.7 218 30.5 714 100.0
Less than 2% of men reported that they had ever had sex with other men (1.5% outside of prison, 11/714, 
and 0.9%, 6/701 in prison). When exploring behaviours associated with BBVs using logistic regression, which is 
described below, the following variables were included in the analysis: type of sexual partner, sex in prison, whether 
safe sex was usually practiced and the number of sexual partners in the previous 12 months.
4.9.4.3  Socio-demographic, behavioural and drug-related factors associated with Blood-Borne Viruses in the prisoner 
population in Ireland
A stated objective of this study was to assess the relationship of a number of socio-demographic, behavioural and 
drug-related factors elicited as part of the survey to the presence of biologically-confirmed blood-borne viruses 
among prisoners in Ireland. To that end the statistical relationship between several factors and the presence of 
hepatitis B, hepatitis C, HIV and co-infection with any combination of these viruses was assessed.
The socio-demographic factors examined included:
• age categorised into predefined age-groups;
• gender;
• educational level; and
• length of time in prison in last 10 years.
Behavioural factors included:
• the presence of tattoos, whether done in prison or elsewhere; and
• sexual practices, such as sexual orientation, number of sexual partners in the last year, sexual activity in 
prison and the frequency of practicing safe sex.
Drug-related factors included:
• prison category;
• history of IV drug use;
• the sharing of IV equipment such as needles, syringes or other works; and
• the IV drugs used and number of years using drugs IV.
It was not possible to analyse the frequency of drug use (number of times injected in the last 30 days) as only 14 
respondents provided an answer to that question.
The relationship of each of these factors to the presence or absence of each of the BBVs and to the presence 
or absence of co-infection was analysed separately, using appropriate statistical techniques. These included the 
Pearson’s Chi-square test or Fisher’s Exact Test for categorical variables and the two-sample t-test or Wilcoxon Rank 
Sum (Mann Whitney U) Tests as appropriate for numerical variables, depending on their level of measurement and/
or distribution.
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While univariate statistical analyses as described above are valuable for suggesting relationships between dependent 
and independent variables individually, they are limited by the failure to take account of more than one variable 
at a time. Thus, multivariate analytical techniques are required to examine the potential interrelationships between 
dependent variables and their independent relationship(s) with the dependent variable. In this study the multivariate 
technique used was logistic regression, which allows for simultaneous assessment of multiple variables, both 
categorical and numerical, with the dependent variable. For logistic regression, categorical variables with more 
than two categories require particular attention. It is necessary to assign a reference category and create ‘dummy’ 
variables of the remaining categories, each of which is then assessed against the reference category for significance 
with the dependent variable. The variables in this dataset to which this applies were: age-group (three levels), time 
in prison in the past 10 years (collapsed into three levels from the data recorded) and prison category (collapsed 
into three levels by combining ‘low’ and ‘medium’ use prisons into one category). In each case the referent category 
is the lowest category. Educational level attained was collapsed into two categories: none, primary and some 
secondary education vs completed secondary or any higher education. Results of logistic regression are presented 
as p values, odds ratios (OR) and adjusted 95% confidence intervals (CI) for the estimate of ‘risk’/‘benefit’, i.e. the 
OR. By definition the OR associated with the reference category of any variable is 1.0.
The relationship of the use of individual drugs intravenously with each blood-borne virus and co-infection was 
assessed using univariate analyses only. They were not included as independent variables in the multivariate 
modelling. This is because it is highly likely that the real relationship of a BBV with a drug used intravenously accrues 
to the IV use rather than to the drug per se.
Descriptive data for each variable and the results of univariate (p values) and multivariate analyses (p values, 
adjusted ORs and 95% CIs) of the socio-demographic, behavioural and drug-related factors outlined above are 
provided in tables 4.60, 4.61 and 4.62 for hepatitis C, HIV and BBV co-infection respectively. It was not possible to 
carry out meaningful statistical analyses for hepatitis B alone as there were only two participants who tested positive 
for hepatitis B and statistical testing returned invalid results.
Factors associated with Hepatitis C 
There were 100 participants who tested positive for hepatitis C in this study. The comparisons were made between 
these and the 677 participants who tested negative. The following variables were significantly associated with 
hepatitis C in univariate analyses: older age (p<0.001), longer time (>3 years) in prison in the past 10 years 
(p<0.001), greater likelihood of being in a high or very high use prison (p<0.001), a history of IV drug use ever 
(p<0.001), the sharing of IV drug equipment (p<0.001), IV use of all of the drugs enquired about (p<0.05 to 
p<0.001), number of years using drugs IV (p<0.001) and the presence of tattoos (p<0.001), especially if acquired 
while in prison (p<0.001). Of note was that neither sexual orientation nor sexual practices appeared to relate to 
presence of hepatitis C. The median number of sexual partners in the past year was similar for those with and 
without hepatitis C.
The more interesting and important information, however, comes from the multivariate analysis. Each of the 
variables significant in univariate analysis (except the individual IV drugs used) was entered into the logistic 
model. In addition, gender, educational level attained and sexual orientation were added to the initial model as 
potentially important variables even though not significant in univariate analysis. Examination of the model identified 
several variables clearly not associated with hepatitis C. These included educational level attained, time spent in 
prison in last 10 years, years using drugs, existence of a tattoo and sexual orientation. The final logistic model 
included complete data on all remaining variables for 643 participants and identified the following variables as 
being independently and significantly associated with hepatitis C in this study population: older age, specifically 
age-group 25–34 [p<0.05, OR=3.6(1.3–9.7)] and age-group 35–64 [p<0.001, OR=7.8(2.7–22.5)], female 
gender [p<0.05, OR=4.5(1.04–20.0)], being in a very high drug use prison [p<0.01, OR=9.8(3.1–31.1)], 
ever having used drugs intravenously [p<0.001, OR=8.3(3.5–20.0)], ever having shared IV drug equipment 
[p<0.001,OR=4.5(2.0–10.4)] and having had a tattoo done in prison [p<0.001, OR=2.6(1.4–5.10]. It is 
especially noteworthy that both ‘ever having used drugs IV’ and ‘ever having shared IV drug equipment’ were 
independently significantly associated with hepatitis C.
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Table 4.60 Socio-demographic, behavioural and drug-related factors associated with hepatitis C in the 
prisoner population in Ireland
Hep C +ve Hep C -ve Unadjusted abc Adjusted d
Characteristic n (n=100) (n=677) p value p value or 95% CI
n (%) n (%)
Current Age (yrs) 762 18–24 7 7.1 232 35.0 Reference 1.0
25–34 51 51.5 256 38.6 p<0.001 p<0.05 3.6 1.3–9.7
35–64 41 41.4 175 26.4 p<0.001 7.8 2.7–22.5
Gender 777 Male 90 90.0 642 94.8
Female 10 10.0 35 5.2 ns p+0.04 4.5 1.04–20.0
Educational Level 761 None – Some 2° 71 74.0 463 69.6
Attained Full 2° – Higher 25 26.0 202 30.4 ns ns*
Time spent in Prison 
(preceeding 10 yrs)
695 < 1 yr 10 10.9 124 20.3 Reference 1.0
1–3 yrs 15 16.3 177 29.4 p<0.001 ns*
> 3 yrs 67 72.8 302 50.1 ns*
Prison Category 777 Low/Medium 22 22.0 345 51.0 Reference 1.0
(based on 12/12 
drug use)
High 52 52.0 268 39.6 p<0.01 ns 1.6 0.8–3.3
Very High 26 26.0 64 9.5 ns* p<0.01 9.8 3.1–31.1
IV Drug Use
History of IV Drug Use 768 Yes 83 83.0 117 17.5 p<0.001 p<0.001 8.3 3.5–20.0
Sharing IV Drug Works 739 Yes 60 63.2 39 6.1 p<0.001 p<0.001 4.5 2.0–10.4
Drugs Used IV 758 Benzodiazepines 42 42.4 26 4.0 p<0.001 **
755 Amphetamines 30 31.3 16 2.4 p<0.01 **
760 Heroin 80 80.0 69 10.5 p<0.001 **
754 Methadone 15 15.5 5 0.8 p<0.001 **
750 Other Opiates 35 37.2 17 2.6 p<0.001 **
759 Cocaine Powder 66 66.7 34 5.2 p<0.001 **
752 Mephedrone 16 16.7 14 2.1 p<0.001 **
751 Methylone 9 9.5 9 1.4 p<0.001 **
751 Crystal Meths 9 9.5 3 0.5 p<0.001 **
763 Steroids 14 14.4 52 7.2 p<0.05 **
741 Any Other Drug 20 22.5 13 2.0 p<0.001 **
Years using Drugs IV 194 (n=81) (n+113)
Median (Range) 14 (1–32) 4 (0–29) p<0.001 ns*
Tattoos n (%) n (%)
Any Tattoo 768 Yes 88 88.9 437 65.3 p<0.001 ns*
Tattoo done in Prison 752 Yes 42 45.7 139 21.1 p<0.001 p<0.01 2.6 1.4–5.1
Sexual Practices
Sexual Orientation 736 Heterosexual 90 98.9 631 97.8 ns ns*
MSM 1 1.1 14 2.2
Sex in Prison 719 Yes 15 16.9 63 10.0 ns **
Safe Sex usually 
practiced
664 Yes 41 50.0 263 45.2 ns **
Sexual Partners 
(last 12mths)
290 (n+39) (n=251)
Median (Range) 1 (0–30) 1 (0–30) ns **
2 0 = Secondary; MSM = Male-to-male sexual contact; a Pearson Chi-squared Test; b Fisher's Exact Test; c Wilcoxon Rank Sum (Mann W-U)Test; 
d Logistic Regression; ns* = Not significant and excluded from multivariate model following assessment; ** = Not included in multivariate model
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Factors associated with HIV 
There were 15 participants who tested positive for HIV in this study. The comparisons were made between these 
and the 762 who tested negative. The following variables were significantly associated with HIV in univariate 
analysis: female gender (p<0.001), longer time (>3 years) in prison in the last 10 years (p<0.05), greater 
likelihood of being in a very high use prison (p<0.001), a history of IV drug use ever (p<0.001), the sharing of IV 
drug equipment (p<0.001), IV use of all of the drugs enquired about (p<0.05 to p<0.001) except steroids, the 
number of years using drugs IV (p<0.001), the presence of a tattoo acquired while in prison (p<0.05) and certain 
sexual practices such as male-to-male sexual contact (p<0.001) and sex in prison (p<0.05).
Each of the variables significant in univariate analysis (except the individual IV drugs used) was entered into the 
logistic model. In addition, age-group, educational level attained and any tattoo were added to the initial model as 
potentially important variables. Examination of the model identified several variables that were not associated with 
HIV in this study. These included educational level attained, time spent in prison in the last 10 years, prison category 
and tattoos, whether acquired in prison or elsewhere. Age was retained in the final logistic model which included 
complete data on all remaining variables for 657 participants. The following variables emerged as independently 
and significantly associated with HIV: female gender [p<0.05, OR=7.8 (1.6–37.4)], ever having used drugs 
intravenously [p<0.001, OR=14.3 (2.8–71.4)], ever having shared IV drug equipment [p<0.001, OR=12.5 
(2.9–50.0)] and male-to-male sexual contact [p<0.001, OR=3.7 (4.0–164.50)]. A particular point of note in 
this analysis is that ‘ever having used drugs IV’ and ‘ever having shared IV drug equipment’ are not independently 
associated with HIV. The values shown occurred when each was added alone to the model. They are clearly strongly 
correlated in relation to HIV and it was deemed appropriate to report them in this way.
It must be noted that, while this analysis was based on 657 participants, only 15 participants were HIV positive. 
Therefore, findings are limited by very small numbers in some categories and this also impacts on the width of the 
confidence intervals derived.
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Table 4.61 Socio-demographic, behavioural and drug-related factors associated with HIV in the 
prisoner population in Ireland
Hep C +ve Hep C -ve Unadjusted abc Adjusted d
Characteristic n (n=100) (n=677) p value p value or 95% CI
n (%) n (%)
Current Age (yrs) 762 18–24 1 7.1 238 31.8 Reference 1.0
25–34 6 42.9 301 40.2 ns ns 2.1 0.05–4.5
35–64 7 50.0 209 27.9 ns 7.9 0.01–1.2
Gender 777 Male 11 73.3 721 94.6
Female 4 26.7 41 5.4 p<0.001 p<0.05 7.8 1.6–37.4
Educational Level 761 None – Some 2° 9 60.0 525 70.4
Attained Full 2° – Higher 6 40.0 221 29.6 ns ns*
Time spent in Prison 
(preceeding 10 yrs)
695 < 1 yr 1 7.1 133 19.5 Reference 1.0
1–3 yrs 1 7.1 191 28.1 p<0.001 ns*
> 3 yrs 12 85.7 357 52.4 ns*
Prison Category 777 Low/Medium 1 6.7 366 48.0 Reference 1.0
(based on 12/12 
drug use)
High 8 53.3 312 40.9 p<0.001 ns*
Very High 6 40.0 84 11.0 ns*
IV Drug Use
History of IV Drug Use 768 Yes 12 80.0 188 25.0 p<0.001 p<0.001 14.3 28–71.4
Sharing IV Drug Works 739 Yes 10 66.7 89 12.3 p<0.001 p<0.001 12.5 29–50.0
Drugs Used IV 758 Benzodiazepines 7 46.7 61 8.2 p<0.001 **
755 Amphetamines 3 20.0 43 5.8 p<0.05 **
760 Heroin 11 73.3 138 18.5 p<0.001 **
754 Methadone 2 13.3 18 2.4 p<0.01 **
750 Other Opiates 6 40.0 46 6.3 p<0.001 **
759 Cocaine Powder 10 66.7 90 12.1 p<0.001 **
752 Mephedrone 4 30.8 26 3.5 p<0.001 **
751 Methylone 4 40.8 14 1.9 p<0.001 **
751 Crystal Meths 2 15.4 10 1.4 p<0.001 **
763 Steroids 2 15.4 64 8.5 ns **
741 Any Other Drug 4 36.4 29 4.0 p<0.001 **
Years using Drugs IV 194 (n+11) (n-183)
Median (Range) 17 (14–30) 6 (0–32) p<0.001 ns*
Tattoos n % n (%)
Any Tattoo 768 Yes 12 80.0 513 68.1 ns ns*
Tattoo done in Prison 752 Yes 7 50.0 174 23.6 p<0.05 ns*
Sexual Practices
Sexual Orientation 736 Heterosexual 10 76.9 711 98.3 p<0.001 p<0.001 3.7 4.0–164.5
MSM 3 23.1 12 1.7
Sex in Prison 719 Yes 4 33.3 74 10.5 p<0.01 **
Safe Sex usually 
practiced
664 Yes 7 58.3 297 45.6 ns **
Sexual Partners 
(last 12mths)
290 (n=3) (n=287
Median (Range) 1 (1–4) 1 (0–30) ns **
2 0 = Secondary; MSM = Male-to-male sexual contact; a Pearson Chi-squared Test; b Fisher's Exact Test; c Wilcoxon Rank Sum (Mann W-U)Test; 
d Logistic Regression; ns* = Not significant and excluded from multivariate model following assessment; ** = Not included in multivariate model 
x Each of these variables is highly significant when modelled separately, but not simultaneously. OR's and CI's shown are from the separate models
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Factors associated with BBV co-infection 
There were just 11 participants who tested positive for more than one BBV in this study. The comparisons were 
made between these and the 766 who did not have co-infection, though some had one BBV. By definition the 
results were constrained by such small numbers and also by the fact that risk factors for co-infection were likely to 
be ‘over’ represented in the comparison group.
The following variables were significantly associated with co-infection in univariate analysis: longer time (>3 years) 
in prison in the last 10 years (p<0.05), greater likelihood of being in a very high use prison (p<0.01), a history of 
IV drug use ever (p<0.001), the sharing of IV drug equipment (p<0.001), IV use of all the drugs enquired about 
(p<0.01 to p<0.001) except steroids, the number of years using drugs IV (p<0.001) and the presence of a tattoo 
acquired while in prison (p<0.01). Sexual orientation or sexual practices did not appear to be related to co-infection.
Each of the variables significant in univariate analysis (except the individual IV drugs used) was entered into the 
logistic model. In addition, age-group, gender, educational level attained and any tattoo were added to the initial 
model as potentially important variables. Examination of the model identified only one variable, ever having 
shared IV drug equipment that was significantly associated with co-infection [p<0.001, OR=62.5 (7.5–500.0)].
It must be noted that, while this analysis was based on 658 participants, only 11 participants were BBV co-infected. 
Therefore, findings are limited by very small numbers and the confidence interval for the only significant factor was 
extremely wide.
Summary 
From the multivariate analyses carried out in this study, it would appear that by far the most important factors 
associated with infection with blood-borne viruses in the prison population are ever having used drugs intravenously 
and ever having shared IV drug equipment. Older age appears to be associated with hepatitis C, as does having 
had a tattoo done in prison. Female prisoners appear to be at greater risk of having hepatitis C and HIV in this 
population and male-to-male sexual contact is confirmed as a risk factor for HIV. It is hoped that these findings will 
focus attention on the most important factors associated with blood-borne viruses in the prison population.
86
Study on the prevalence of drug use, including intravenous drug use,  
and blood-borne viruses among the Irish prisoner population
Chapter 4 Results
Table 4.62 Socio-demographic, behavioural and drug-related factors associated with BBVs co-infection 
in the prisoner population in Ireland
Co-Infection infection Unadjusted abc Adjusted d
Characteristic n (n=11) (n=766) p value p value or 95% CI
n (%) n (%)
Current Age (yrs) 762 18–24 0 0.0 239 31.8 Reference
25–34 5 50.0 302 40.2 ns ns*
35–64 5 50.0 211 20.1 ns*
Gender 777 Male 9 81.8 723 94.4
Female 2 18.2 43 5.6 ns ns 1.1 0.22–6.0
Educational Level 761 None – Some 2° 9 81.8 525 70.0
Attained Full 2° – Higher 2 18.2 225 30.0 ns ns*
Time spent in Prison 
(preceeding 10 yrs)
695 < 1 yr 0 0.0 134 19.6 Reference
1–3 yrs 1 9.1 191 27.9 p<0.05 ns*
> 3 yrs 10 90.9 359 52.5 ns*
Prison Category 777 Low/Medium 0 0.0 367 47.9 Reference 
(based on 12/12 
drug use)
High 8 72.7 312 40.7 p<0.01 ns*
Very High 3 27.3 87 11.4 ns*
IV Drug Use
History of IV Drug Use 768 Yes 11 100.0 189 25.0 p<0.001 ns*
Sharing IV Drug Works 739 Yes 10 90.9 89 12.2 p<0.001 p<0.001 62.5 7.5–500.0
Drugs Used IV 758 Benzodiazepines 7 63.6 61 8.2 p<0.001 **
755 Amphetamines 3 27.3 43 5.8 p<0.01 **
760 Heroin 11 100.0 138 18.4 p<0.001 **
754 Methadone 2 18.2 18 2.4 p<0.01 **
750 Other Opiates 6 54.6 46 6.2 p<0.001 **
759 Cocaine Powder 10 90.0 90 12.0 p<0.001 **
752 Mephedrone 4 40.0 26 3.5 p<0.001 **
751 Methylone 4 40.0 14 1.9 p<0.001 **
751 Crystal Meths 2 20.0 10 1.4 p<0.001 **
763 Steroids 1 10.0 65 8.6 ns **
741 Any Other Drug 4 50.0 29 4.0 p<0.001 **
Years using Drugs IV 194 (n=10) (n=184)
Median (Range) 17.5 (14–32) 6 (0–31) p<0.001 ns*
Tattoos n (%) n (%)
Any Tattoo 768 Yes 9 81.8 516 68.2 ns ns*
Tattoo done in Prison 752 Yes 6 60.0 175 23.6 p<0.01 ns*
Sexual Practices
Sexual Orientation 736 Heterosexual 10 100.0 711 97.9 ns **
MSM
Sex in Prison 719 Yes 1 12.5 77 10.8 ns **
Safe Sex usually 
practiced
664 Yes 5 62.5 299 45.6 ns **
Sexual Partners 
(last 12mths)
290 (n=2) (n=288)
Median (Range) 1 (1–1) 1 (0–30) ns **
2 0 = Secondary; MSM = Male-to-male sexual contact; a Pearson Chi-squared Test; b Fisher's Exact Test; c Wilcoxon Rank Sum (Mann W-U)Test; 
d Logistic Regression; ns* = Not significant and excluded from multivariate model following assessment; ** = Not included in multivariate model
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4.10 Prison Drug Treatment and Harm Reduction Services
Results throughout Chapter 4 have included an analysis by prison category for drug use. A summary of the findings 
of those analyses is useful at this point as the results for the prisoners’ perception of their need for and use of drug 
treatment and harm reduction services in prison is also presented by prison drug use category. In this way the need 
for tailored service delivery requirements may be assessed.
In the low drug-use prison category it is notable that the lifetime (table 4.17), last year (table 4.19) and last month 
use (table 4.22) of cannabis is almost as high as it is in the other prison categories, as is the lifetime use of cocaine 
powder. In respect of all other drugs at all time points use in low drug-use prisons is substantially lower, as would 
be expected. It is also notable that the results of oral fluid sampling reveal that recent use (24–48 hour use) of 
cannabis and benzodiazepines is significantly higher in the low drug-use prisons than in any other category (table 
4.24).
The gradations in use of individual drugs from the medium use to the very high use prisons show a generally 
increasing pattern. For lifetime use this applies to heroin, methadone, other opiates and crack cocaine (table 4.17). 
For last year use it applies to all drugs except benzodiazepines (table 4.19). This is hardly surprising since the use 
of selected drugs in the last 12 months was the basis for assigning prison category. For last month use the use 
increases for benzodiazepines, other sedatives and tranquillisers, methadone and crack cocaine with increasing 
level of prison category, and decreases in the very high use prisons for cannabis, heroin, other opiates and cocaine 
powder (table 4.22). The results of oral fluid testing for drugs support the trend of self-reported use of last month 
use of cannabis and benzodiazepines and all use of methadone (table 4.24).
In relation to IV drugs, the numbers and proportions in the low drug use prisons who ever injected (table 4.26), 
injected in the last year (table 4.28) or injected in the last month (table 4.31) are negligible across all 11 drugs.  
The proportions who used IV drugs in the medium, high and very high use prisons increases across categories 
almost without exception, for ever use, last year use and last month use.
Among ever IV drug users, sharing of any IV drug equipment (table 4.49) was lowest in the low drug use prisons 
(approximately one-third of a very few users in this category). Approximately half of ever IV drug users in medium 
and high use prisons shared IV drug equipment; the highest propensity to sharing occurred in the very high use 
prisons where over 80% of participants reported ever having shared. These data may be of value in the allocation 
of selected services to prisons in selected categories.
It is noteworthy that the prevalence of BBVs, specifically HIV and hepatitis C, increases across the prison categories 
with the highest prevalence of both being in the very high use prison category (table 4.57). The nature of this 
relationship between sharing of IV works and hepatitis C and HIV was examined in multivariate analysis and is 
reported in detail in the preceding section.
Respondents were asked a series of questions about their need for drug treatment and harm reduction services  
in prison, availability of the service when they needed it, and, in cases where it was available, whether they used  
it. Results are presented for the prison population in the table and figure below and presented by prison categories 
for drug use in subsequent tables and figures in this section. When interpreting these results it should be noted that 
prisoners can move between prisons and it is possible that some respondents were at times referring to needing a 
service or its availability in a prison other than that in which they were in custody during the study.
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Table 4.63 Prison drug treatment and harm reduction services: Need, availability and use of services 
in prison
Reported needing the 
service in prison
(Of those who needed 
the service while in 
prison) availability 
of the service when 
needed
(Of those who needed 
the service and for 
whom it was available 
in prison) use of 
service while in prison
n % n % n %
Narcotics Anonymous 279 35.0 116 43.9 95 84.1
Alcoholics Anonymous 191 24.1 120 66.7 95 81.2
Detox from alcohol 113 14.4 28 26.9 21 77.8
Detox from benzodiazepines 154 19.4 32 22.1 26 83.9
Detox from opiates (Prison Detox) 153 19.3 80 54.4 64 85.3
Detox from opiates (Slow Detox) 120 15.4 38 33.0 33 94.3
Addiction Psychiatrist 215 27.4 99 48.8 82 87.2
Addiction Nurses 195 24.8 70 37.6 57 87.7
Addiction GP 249 32.7 100 42.2 91 92.9
Addiction Counsellor 336 43.5 202 62.5 184 93.9
Methadone Maintenance 196 24.7 136 72.7 126 94.7
Drug-free wing or landing 316 40.6 127 42.6 112 91.1
Drug-free treatment programme 253 33.2 82 33.2 73 92.4
Listeners’ Service 168 22.0 70 44.0 46 70.8
Information on drugs 250 32.4 110 46.8 93 89.4
Information on addiction 266 34.5 120 47.2 106 89.8
Information on infectious diseases 242 31.4 93 40.3 76 86.4
Information on overdose prevention 180 23.5 42 24.6 36 87.8
Range 15–44% 22–73% 71–95%
Overall, the need for services varied across the system, ranging from a low of 14% reporting having needed 
detoxification from alcohol to 44% reporting having needed addiction counselling.
Those who had indicated a need for drug treatment and harm reduction services were asked whether the service 
was available to them. At every session in the first prison visited during fieldwork, prisoners asked that the question 
be qualified; the majority felt that while they may eventually gain access to a service, they often had to wait for 
what they considered to be unreasonable periods of time. Following review, instructions in the presentation at all 
subsequent sessions were amended to ask if services were available to those that needed them ‘when they needed 
them’, or within a reasonable timeframe. Availability (for those who had expressed having needed the service) 
varied across the services, ranging from 22% for detoxification from benzodiazepines to 73% for methadone 
maintenance.
Finally those who had expressed a need and who had reported the service as available were asked whether they 
had used the service. Uptake ranged from over 70% to 95%. This high uptake once a service is available is shown 
graphically in figure 4.26 below.
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Figure 4.26 Prison drug treatment and harm reduction services: Need, availability and use of services 
in prison
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Service need, availability and utilisation were reviewed using the prison categories, which were derived as described 
earlier and are presented in the table below.
Table 4.64 Prison drug use categories
Low use (n = 91) Medium use (n = 289) High use (n = 341) Very high use (n = 96)
Arbour Hill Castlerea Limerick Male Cloverhill
Loughan House Cork Mountjoy Dóchas
Shelton Abbey Midlands Portlaoise Limerick Female
St. Patrick’s Institution Wheatfield
Training Unit
Note: within categories prisons are presented in alphabetical order, not in order of severity of drug use
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Table 4.65 Prison drug treatment and harm reduction services: Need for services in prison by prison 
drug use category
Low use Medium use High use Very High use
n % n % n % n %
Narcotics Anonymous 25 28.1 91 31.9 116 35.3 47 49.5
Alcoholics Anonymous 17 19.3 85 29.8 66 20.2 23 25.0
Detox from alcohol 6 6.9 52 18.4 33 10.2 22 23.7
Detox from benzodiazepines 5 5.7 53 18.7 65 19.8 31 33.3
Detox from opiates (Prison Detox) 5 5.7 45 15.8 77 23.5 26 28.3
Detox from opiates (Slow Detox) 4 4.7 36 12.9 57 17.6 23 25.6
Addiction Psychiatrist 13 14.9 74 26.1 95 29.3 33 36.3
Addiction Nurses 14 16.1 64 22.6 82 25.4 35 38.0
Addiction GP 17 20.2 76 27.7 114 36.3 42 46.7
Addiction Counsellor 33 37.9 117 41.5 137 43.5 49 55.7
Methadone Maintenance 5 5.7 42 14.8 106 32.3 43 45.7
Drug-free wing or landing 29 33.3 100 35.5 146 45.5 41 46.1
Drug-free treatment programme 21 24.4 85 30.8 109 34.8 38 43.2
Listeners’ Service 18 20.9 67 24.4 52 16.6 31 34.4
Information on drugs 21 24.1 86 30.8 104 32.9 39 43.8
Information on addiction 23 26.4 94 33.6 106 33.5 43 48.9
Information on infectious diseases 18 20.7 85 30.4 102 32.5 37 41.6
Information on overdose 
prevention
15 17.2 68 24.4 68 21.7 29 33.0
Range 5–38% 13–42% 17–46% 24–56%
Figure 4.27 Prison drug treatment and harm reduction services: Need for services in prison (1)  
by prison drug use category
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In figure 4.27 there is a clear trend of the reported need for drug treatment and harm reduction services increasing 
across the prison categories from low drug use prisons to higher use prisons, with the exception of the need for 
Alcoholics Anonymous and detoxification from alcohol. This is despite high prevalence rates for alcohol use and high 
median drinks taken on a drinking day in the 12 months before coming into prison, suggesting a lack of insight that 
excessive drinking is a problem of addiction.
Figure 4.28 Prison drug treatment and harm reduction services: Need for services in prison (2)  
by prison drug use category
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Among addiction services, the need for addiction counselling services is relatively high across all the categories.  
The need for drug-free wings or landings is expressed by at least a third of prisoners resident in all prison categories, 
highlighting the importance of a drug-free environment to many prisoners.
Figure 4.29 Prison drug treatment and harm reduction services: Need for services in prison (3)  
by prison drug use category
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Between a fifth and a third of all prisoners expressed a need for information services, with an increasing trend from 
low use to very high use prison category.
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Table 4.66 Prison drug treatment and harm reduction services: Reported availability of services 
(among those who needed them) by prison drug use category
Low use Medium use High use Very High use
n % n % n % n %
Narcotics Anonymous 10 43.5 44 50.6 50 45.9 12 26.7
Alcoholics Anonymous 16 100.0 59 72.0 36 59.0 9 42.9
Detox from alcohol 1 20.0 9 18.0 9 31.0 9 45.0
Detox from benzodiazepines 0 0 9 17.3 7 11.9 16 55.2
Detox from opiates (Prison Detox) 0 0 15 34.1 48 66.7 17 65.4
Detox from opiates (Slow Detox) 0 0 7 20.0 21 39.6 10 43.5
Addiction Psychiatrist 5 41.7 34 47.9 47 53.4 13 40.6
Addiction Nurses 3 25.0 20 31.7 35 44.9 12 36.4
Addiction GP 5 29.4 24 32.0 54 50.9 17 43.6
Addiction Counsellor 16 50.0 72 64.3 85 64.4 29 61.7
Methadone Maintenance 0 0 20 48.8 80 79.2 36 87.8
Drug-free wing or landing 13 48.1 30 31.9 73 52.9 11 28.2
Drug-free treatment programme 7 35.0 23 27.4 40 38.1 12 31.6
Listeners’ Service 10 71.4 23 34.8 26 53.1 11 36.7
Information on drugs 6 33.3 31 38.3 53 53.0 20 55.6
Information on addiction 8 40.0 37 40.7 56 55.4 19 45.2
Information on infectious diseases 8 47.1 25 30.1 41 43.2 19 52.8
Information on overdose prevention 4 33.3 14 20.9 17 26.6 7 25.0
Range 0–100% 17–72% 12–79% 25–88%
Figure 4.30 Prison drug treatment and harm reduction services: Reported availability of services (1) 
(among those who needed them) by prison drug use category
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Availability of services (to those who had expressed a need) ranged from not available for some of the detoxification 
services in low use prisons to 100% for AA in the low use prisons.
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Figure 4.31 Prison drug treatment and harm reduction services: Reported availability of services (2) 
(among those who needed them) by prison drug use category
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There was a lot of variation in the reported availability of one-to-one services with addiction professionals. One 
would not necessarily expect the availability rates to follow an increasing trend from the low to very high prison 
drug use categories as analysis was based only on those who had expressed a need. Availability of methadone 
maintenance was at its peak in the high and very high use prisons (80–88%).
Figure 4.32 Prison drug treatment and harm reduction services: Reported availability of services (3) 
(among those who needed them) by prison drug use category
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Availability of information services (to those who expressed a need) was reasonably consistent across the categories.
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Table 4.67 Prison drug treatment and harm reduction services: Reported use of services when 
available, by prison drug use category
Low use Medium use High use Very High use
n % n % n % n %
Narcotics Anonymous 9 90.0 31 73.8 45 91.8 10 83.3
Alcoholics Anonymous 14 87.5 50 87.7 27 77.1 4 44.4
Detox from alcohol 1 100.0 7 77.8 7 87.5 6 66.7
Detox from benzodiazepines – – 5 55.6 5 83.3 16 100.0
Detox from opiates (Prison Detox) – – 12 85.7 38 84.4 14 87.5
Detox from opiates (Slow Detox) – – 5 83.3 18 94.7 10 100.0
Addiction Psychiatrist 2 50.0 29 90.6 39 86.7 12 92.3
Addiction Nurses 2 66.7 13 72.2 30 93.8 12 100.0
Addiction GP 3 60.0 22 95.7 50 92.6 16 100.0
Addiction Counsellor 14 93.3 68 95.8 76 92.7 26 92.9
Methadone Maintenance – – 18 94.7 74 94.9 34 94.4
Drug-free wing or landing 13 100.0 30 100.0 62 88.6 7 70.0
Drug-free treatment programme 5 71.4 23 100.0 35 89.7 10 100.0
Listeners’ Service 6 66.7 17 77.3 14 58.3 9 90.0
Information on drugs 5 100.0 26 89.7 46 86.8 16 94.1
Information on addiction 7 87.5 31 86.1 51 91.1 17 94.4
Information on infectious diseases 8 100.0 21 87.5 34 82.9 13 86.7
Information on overdose prevention 3 75.0 12 92.3 14 82.4 7 100.0
Range 50–100% 56–100% 59–95% 44–100%
Among those who reported a need for a service and who reported that it was available to them, uptake of services 
was very high, with uptake rarely (8/72) falling below 70% in any prison drug use category.
Figure 4.33 Prison drug treatment and harm reduction services: Reported use of services when 
available (1), by prison drug use category
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Figure 4.34 Prison drug treatment and harm reduction services: Reported use of services when 
available (2), by prison drug use category
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Figure 4.35 Prison drug treatment and harm reduction services: Reported use of services when 
available (3), by prison drug use category
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The views of prisoners who had ever injected (IDUs) on their prison drug treatment and harm reduction service 
needs, availability and use was also analysed and are shown in the next three tables. A similar pattern of need 
emerges as for the general prison population, but, not unexpectedly, the proportions tend to be higher. However, 
when looking at availability of services, while the numbers are much lower, the proportions in the case of most 
services are not very different than those for the general prisoner population in any prison drug use category, 
suggesting a consistency in reporting of availability of services. The pattern of extremely high uptake, where services 
are available, persists for IDUs and is very high for the high drug use category.
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Table 4.68 Prison drug treatment and harm reduction services: Reported need for injecting drug users 
by prison drug use category
Low use Medium use High use Very High use
n % n % n % n %
Narcotics Anonymous 6 54.5 25 59.5 61 54.5 30 76.9
Alcoholics Anonymous 0 0.0 14 33.3 19 17.3 12 32.4
Detox from alcohol 1 9.1 15 35.7 12 11.0 10 26.3
Detox from benzodiazepines 3 27.3 15 35.7 38 33.9 21 55.3
Detox from opiates (Prison Detox) 4 36.4 18 42.9 56 50.0 18 47.4
Detox from opiates (Slow Detox) 3 27.3 13 31.0 39 35.8 19 51.4
Addiction Psychiatrist 5 45.5 22 52.4 53 48.6 19 52.8
Addiction Nurses 5 45.5 21 50.0 45 42.1 20 54.1
Addiction GP 6 54.5 23 56.1 64 59.3 23 65.7
Addiction Counsellor 8 72.7 30 71.4 66 62.3 28 82.4
Methadone Maintenance 4 36.4 20 47.6 74 65.5 30 78.9
Drug-free wing or landing 7 63.6 20 47.6 64 58.7 21 61.8
Drug-free treatment programme 7 63.6 25 59.5 57 53.3 26 74.3
Listeners’ Service 3 27.3 14 33.3 26 25.0 16 45.7
Information on drugs 7 63.6 13 31.0 45 42.5 22 64.7
Information on addiction 7 63.6 18 42.9 51 48.1 24 70.6
Information on infectious diseases 5 45.5 20 47.6 48 45.3 25 73.5
Information on overdose prevention 7 63.6 17 40.5 34 32.1 21 61.8
Range 0–64% 33–72% 11–66% 26–82%
Table 4.69 Availability of drug treatment and harm reduction services in prison for injecting drug users 
(who said they needed them) by prison drug use category
Low use Medium use High use Very High use
n % n % n % n %
Narcotics Anonymous 2 40.0 13 52.0 22 40.0 11 37.9
Alcoholics Anonymous – – 11 78.6 10 55.6 6 50.0
Detox from alcohol 0 0.0 3 21.4 5 45.5 6 60.0
Detox from benzodiazepines 0 0.0 1 6.7 3 8.6 11 52.4
Detox from opiates (Prison Detox) 0 0.0 7 41.2 34 65.4 12 66.7
Detox from opiates (Slow Detox) 0 0.0 3 23.1 15 41.7 9 47.4
Addiction Psychiatrist 1 25.0 9 42.9 24 49.0 11 57.9
Addiction Nurses 1 33.3 7 33.3 17 40.5 9 45.0
Addiction GP 1 16.7 6 26.1 34 56.7 13 59.1
Addiction Counsellor 3 42.9 23 76.7 39 61.9 19 67.9
Methadone Maintenance 0 0.0 9 47.4 53 76.8 25 86.2
Drug-free wing or landing 2 33.3 5 26.3 31 49.2 5 23.8
Drug-free treatment programme 2 33.3 9 36.0 18 33.3 9 34.6
Listeners’ Service 1 50.0 6 42.9 13 54.2 5 33.3
Information on drugs 1 20.0 4 30.8 21 48.8 10 45.5
Information on addiction 1 20.0 7 38.9 23 46.9 11 45.8
Information on infectious diseases 2 50.0 5 25.0 21 45.7 12 50.0
Information on overdose prevention 1 20.0 4 23.5 8 25.0 7 33.3
Range 0–43% 7–79% 9–77% 33–87%
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Table 4.70 Use of drug treatment and harm reduction services in prison by injecting drug users by 
prison drug use category
Low use Medium use High use Very High use
n % n % n % n %
Narcotics Anonymous 2 100.0 8 61.5 20 95.2 9 81.8
Alcoholics Anonymous – – 9 81.8 6 60.0 2 33.3
Detox from alcohol – – 3 100.0 5 100.0 5 83.3
Detox from benzodiazepines – – 0 0.0 2 66.7 11 100.0
Detox from opiates (Prison Detox) – – 5 71.4 27 84.4 10 90.9
Detox from opiates (Slow Detox) – – 1 50.0 12 92.3 9 100.0
Addiction Psychiatrist 0 0.0 7 77.8 20 87.0 10 90.9
Addiction Nurses 1 100.0 4 57.1 13 92.9 9 100.0
Addiction GP 0 0.0 5 83.3 30 88.2 13 100.0
Addiction Counsellor 3 100.0 22 100.0 34 91.9 16 88.9
Methadone Maintenance – – 8 100.0 50 96.2 24 96.0
Drug-free wing or landing 2 100.0 5 100.0 24 80.0 3 60.0
Drug-free treatment programme 1 50.0 9 100.0 16 94.1 9 100.0
Listeners’ Service 0 0.0 4 80.0 5 45.5 5 100.0
Information on drugs 1 100.0 3 100.0 19 90.5 9 90.0
Information on addiction 1 100.0 6 85.7 22 95.7 10 90.9
Information on infectious diseases 2 100.0 4 80.0 19 90.5 9 81.8
Information on overdose prevention 1 100.0 3 75.0 7 87.5 7 100.0
Range 0–100% 0–100% 45–100% 33–100%
4.10.1 Other Harm-Reduction Services
4.10.1.1 Blood-Borne Virus Screening
About two fifths of prisoners reported that they had been tested for hepatitis B (42%), hepatitis C (43%) and 
HIV (44%). This appears to show a moderate improvement on the previous study (Allwright et al., 1999) when 
29% had been tested for hepatitis B, 30% for hepatitis C and 38% for HIV, although it should be noted that three 
prisons considered low risk for BBVs were not included in that study. In Scottish prisons, 32% of prisoners reported 
having previously been tested for hepatitis C virus (Scottish Prison Service, 2009).
Among those who had been tested, the median number of years since they were first tested was three years 
(range 0–31 and interquartile range 1–8 years for hepatitis B; range 0–27 and interquartile range 1–8 years for 
hepatitis C; and range 0–25 and interquartile range 1–7 years for HIV); the median number of years since last 
tested was one year (range 0–20 years and interquartile range 1–3 years) for all three blood-borne viruses. Two 
thirds of those who had been tested had been in prison for their last test (hepatitis B 66%; hepatitis C 66% and 
HIV 67%).
4.10.1.2 Hepatitis B Vaccination
Two hundred and eighty two respondents (37%) reported that they had received one or more doses of hepatitis B 
vaccine and among these 67% had received all three doses (24% of all prisoners). This is a lower proportion than 
in the 1999 study (Allwright et al., 1999) when 48% had been vaccinated and 29% of all prisoners had received 
three doses. In the current study more than one in ten (13%) did not know whether they had been vaccinated 
or not. A higher proportion of women (55%) had received the vaccine than men (36%, marginally significant at 
p=0.053), but a lower proportion of women had completed the course than men. IDUs were significantly more 
likely to have been vaccinated (54%) than non-IDUs (54% vs 34%, p<0.001) and 72% of vaccinated IDUs had 
completed the full course. These latter results may be a consequence of injectors coming into contact with health 
services more so than non-injectors.
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Table 4.71 Harm Reduction Services: Hepatitis B vaccination status
All Males Females IDUs Non-IDUs
n % n % n % n % n %
Received one or more doses of hepatitis B 
vaccine?
283 37.1 261 36.1 22 55.0 106 53.5 176 31.2
Vaccinated individuals who had completed 
a course of at least 3 injections?
187 66.8 174 67.4 13 59.1 76 72.4 110 63.2
When reviewed by the category of prison, 75% of the residents in the low drug use prisons were not vaccinated, 
70% in the medium use prisons, and about 55% of those in the high and very high use prisons have not, to their 
knowledge, received any vaccination doses. Among those who had been vaccinated, completion rates were fairly 
consistent across the categories (65% to 69%).
Table 4.72 Blood-borne viruses: Hepatitis B vaccination status by prison drug use category
Low use Medium use High use Very High 
use
n % n % n % n %
Received one or more doses of hepatitis B vaccine 20 25.0 88 31.7 138 42.6 37 45.7
(Among vaccinated) completed three doses of vaccination 13 65.0 60 69.0 90 66.2 24 64.9
Among the 190 vaccinated individuals who responded to the question about where they were vaccinated, 73% 
reported that they were vaccinated in prison. One in ten of those who were vaccinated received their vaccination 
in a combination of in prison and in the community. Among IDUs, 61% were vaccinated in prison and 6% in 
combined prison and community setting. Overall, results suggest that being in custody has provided an opportunity 
for identifying and providing vaccination to this at-risk group. In the UK, Hope et al. (2007) found that the prison 
vaccination programme made a substantive contribution to achieving national vaccination coverage targets among 
IDUs.
Table 4.73 Blood-borne viruses: Hepatitis B vaccination location (among those who were vaccinated)
All Males Females IDUs Non-IDUs
n % n % n % n % n %
In prison 139 73.2 131 74.0 8 61.5 47 61.0 92 82.1
Outside of prison 33 17.4 31 17.5 2 15.4 19 24.7 13 11.6
Combination of both 18 9.5 15 8.5 3 23.1 11 14.3 7 6.3
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Figure 4.36 Blood-borne viruses: Location of hepatitis B vaccination (among those who had at least 
one dose of vaccination)
Place of Hepatitis B vaccination n = 190
139 (73.2%)
18 (9.5%)
33 (17.4%)
In prison
Outside of prison
Not to scale
4.11 Summary
This chapter has identified high prevalence rates for lifetime, last year and last month drug use among prisoners. It 
has shown the nature and patterns of drug use including drug use initiating in prison as well as use in prison within 
the last year. Methods of use for different drugs have been explored with relatively high injecting drug prevalence 
rates, but little evidence of current injecting in prison among the prisoner population. The prevalence rates for 
both hepatitis B and C have reduced since last assessed and the prevalence rate for HIV has not changed. Socio-
demographic, behavioural and drug-related factors significantly associated with hepatitis C, HIV and co-infection have 
been identified. The need for and availability of a range of drug treatment and harm reduction services in the prison 
setting have been described and a pattern of high uptake when services are available is evident.
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5.1 Discussion
This was a meticulously planned and executed survey with clearly set out aims and objectives and overseen by 
a Research Advisory Group appointed by the project commissioners, NACD. It provides up to date information 
on drug prevalence and related morbidity for prison inmates, which is of planning relevance to the stakeholders, 
including prisoners themselves. This is the first time a dedicated and very detailed predominantly drug-related 
prevalence survey, including biological sampling for drugs, has been carried out in Ireland in a prison context. It 
will provide a benchmark for future similar studies. It portrays a stark picture of a highly disadvantaged section of 
modern Irish society and the findings are in keeping with the international scientific literature on the topic.
5.2 Generalisability of the Findings
How confident can we be in the credibility of the findings given the response rate achieved? It is worth considering 
this question carefully because of the importance of the survey for planning purposes. We have described in more 
detail in the technical report the operational factors we think were potential influences on participation. Of 1,666 
eligible participants, 824 actually participated. The sample estimates were based on precision and ability to compare 
key groups and had sufficient power to do so. Relatively few decided not to participate (7%) once they had heard 
the rationale from the study team. The datasets were virtually complete, with relatively few missing values. A small 
number of biological samples were either not provided or lost in the laboratory system. There was no breach in 
confidentiality in this latter instance as samples were fully anonymised, though the NACD, the data protection 
commissioners and the prison based research ethics committee were informed and consulted. Individuals who gave 
samples can be reassured that these were used for the purpose intended, retained in an anomymised format and 
small numbers of missing data made no difference to the prevalence estimates.
A number of possible influences on the response rate were anticipated. Firstly, while previous Irish studies included 
questions about drug use, the emphasis was on either health or ill-health, whereas crucially the present study 
focused specifically on drug use, evidenced by its primary aim and primary funder. The last Irish prison hepatitis 
prevalence study (Allwright et al., 1999) included an oral fluid test for blood-borne viruses but not a test for 
drugs. It was anticipated that prisoners with a tendency to mistrust authority might not believe assurances about 
confidentiality and anonymity and might perceive that they would have more to lose in a study on drugs than in a 
study on health.
Secondly, the IPS introduced mandatory drug testing (MDT) under the 2007 Prison Rules. MDT is carried out on 
a random basis, and is not popular. MDT utilises oral fluid samples, and some prisoners may have made incorrect 
assumptions about the purpose of oral fluid sampling in this study.
Because these factors were known, while a response rate of 80% (slightly lower than previous Irish studies) 
was targeted by the study team, it was recognised from the outset this might be difficult to achieve. To obtain as 
high a rate as possible, every effort was made to highlight the above factors and dispel concerns transparently. 
To overcome the potential impact on participation, prisons were saturated with advance information (for both 
staff and prisoners) about the voluntary nature of each component of the study (including the drug test), and 
about anonymity and confidentiality, and the team engaged with Governors, Chiefs, Assistant Chief Officers, 
Nurse Managers, chaplains and teachers to help disseminate this message. The team tried to dispel concerns and 
misconceptions in advance of the study commencing and during information sessions, however, anecdotally the IPS 
acknowledge that prisoners now have a much greater awareness and suspicion of any swab taken for BBV or DOA 
because of increased exposure to issues around DNA and the use of DNA sampling in criminal cases.
While a number of studies have been carried out in prisons internationally on the prevalence of one or more 
blood-borne viruses, which generally included collecting data on risk behaviour such as drug use, and some studies 
have been carried out on drug use specifically, most studies are not directly comparable. Twelve prison studies that 
focused on blood-borne viruses, and nine that focused on drug use were reviewed with a range of response rates 
from 24% (Sleiman, 2004 in Belgium) to 94% (Radun et al., 2008, in Germany).
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A number of differences were found in aspects of these studies that can affect response. There are differences in 
methodologies for ascertaining data, such as clinical assessment interviews (Fotiadou et al., 2004; Lukasiewicz et al., 
2007), semi-structured or structured one-to-one interviews (Dye and Isaacs, 1991; Power et al., 1992), interviewer 
or self-administered questionnaires (Koulierakis, 2000; Sleiman, 2004; Zakaria et al., 2010), extracting data from 
medical records (Singleton et al., 1999; Saiz de la Hoya et al., 2011) and biological sampling (Butler et al., 1997; 
Malliori et al., 1998; Ford et al., 2000; Radun et al., 2008). There are also differences in the sample targeted, 
with seven national random samples (Power et al., 1992; Singleton et al., 1999; Koulierakis, 2000; Lukasiewicz 
et al., 2007; Radun et al., 2008; Zakaria et al., 2010; Saiz de la Hoya et al., 2011), and in the type of prisoner 
approached, whether inmates or entrants or both. Some studies lack sufficient detail on sampling procedures to 
make a valid comparison (Singleton et al., 1999; Power et al., 1992; Ford et al., 2000; Sleiman, 2004), and the 
response rate is not provided in others, or no denominator information is available (Kirwan et al., 2011; Saiz de la 
Hoya et al., 2011). In terms of those studies that looked specifically at drug use amongst prisoners, some did not 
ask about drug use in prison (Fazel et al., 2006), while others employed a measurement that was not temporally 
specific (‘ever use in prison’) and avoided asking about use within the last month, with the explicit aims of both 
alleviating fear of disciplinary action and of increasing participation (Power et al., 1992; Sleiman, 2004). Finally, no 
studies were found that collected biological samples for drug testing.
At 49.5%, the response rate in this study is lower than in two methodologically comparable previous Irish studies, 
both national cross-sectional studies carried out 12–13 years ago in prisons using a random sampling strategy. 
In a study on the prevalence of blood-borne viruses among a national sample of prison inmates, Allwright et al. 
(1999) achieved an 85% response rate in 1998, and the only national general healthcare study of the Irish prison 
population (Centre for Health Promotion Studies, 2000) achieved an 88% response rate in 1999. Each study was 
carried out using a methodology broadly similar to the current study (both used a self-completion questionnaire 
and Allwright used oral fluid sampling), and while asking about some drug-related questions, including injecting 
drug use, neither included a biological test for drugs. The Long et al. (2000) study of prevalence of blood-borne 
viruses amongst committals (entrants) to Irish prisons employed the same measurements of drug use as that of 
Allwright et al. (1999) and achieved a 96% response. This response rate is in line with other studies which looked 
specifically at committals. The Fazel et al. (2006) systematic review of substance abuse and dependence amongst 
prison entrants on reception into prison included thirteen studies that had a response rate above 75%, three of 
which were 100%; one study was excluded because of a non-participation rate of greater than 50%.
In a broadly comparable study of 8% of the prison population in eight selected prisons in England and Wales in 
1998, Weild et al. (2000) achieved an 83% participation rate in a census sample of eligible prisoners; a question 
was asked about ever injecting drugs in prison but drug testing was not part of the study. A hepatitis C incidence 
study, using a cohort study design at 0 and 6 months, a self-completion survey and saliva sampling, in a single 
prison in Scotland in 1999/2000 achieved an 85% participation rate, but it is not clear how participants were 
recruited (Champion et al., 2004). Following the methodologies and adapting the survey instruments used in the 
Republic of Ireland and in England and Wales, Danis et al. (2007) collected data in Northern Ireland’s three prisons 
in 2004, and achieved a 62% response rate. The lowest response rate in the Northern Ireland study was 41% in a 
medium security prison. In Scotland, an annual census survey of all Scottish prisoners is undertaken, and includes 
health questions (including BBV and drug-related questions); it achieved a response rate of 73% in 2006 (Graham, 
2007), 62% in 2008 (Scottish Prison Service, 2008) and 62% in 2009 (Scottish Prison Service, 2009). A National 
Inmate Infectious Diseases and Risk-Behaviour Survey undertaken in Canada in 2007 (Zakaria, 2010), using a self-
administered questionnaire but no biological sampling, achieved an estimated 48% response rate. Notwithstanding 
the differences in sampling and data being collected, there appears to be a downwards trend over time in the 
proportion of prisoners willing to participate in this type of research.
In a scenario of a 50% response a number of considerations must be taken into account. First, it is in fact possible 
that the sample is reliably representative. As outlined in detail in chapter 4, the selected sample has a demographic 
profile that is really remarkably similar to the known demographic profile of the prisoner population in prison during 
the survey period in terms of age, sex, region and prevalence of both reported and measured methadone use. The 
non-responders might have been unavailable for random reasons, which would not affect accuracy or generalisability, 
and this is what was anecdotally reported, in that prisoners were otherwise engaged, informed with short notice 
without having had time to think through all the implications of participating, or not interested in the topic.
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Systematic bias might arise if either a) users knowingly stayed away or b) non users were more likely to turn 
up. This was a formidable commitment for Prisoners as they had to understand what was required, trust in the 
anonymity process, give information about potentially illicit behaviour that they knew was being verified and give 
a simultaneous biological sample. There is increasing evidence of fall-off in survey participation worldwide, even 
in the decade since the last round of Prisoner surveys in Ireland. The last SLAN survey rounds in 2002/3 and 
2007 achieved just over a majority of respondents. The recent (2010) All Ireland Traveller Health Study (AITHS) 
had a remarkable 80% response rate to the general census survey but it fell to just over 50% for the birth cohort 
component where mothers had to agree to linkage to their health data. Accordingly this survey presents the 
problems seen with any health examination survey, in this context or otherwise.
We can be confident that the reported rates here are much higher than in the general population and were verified 
by samples, both for drugs and blood-borne viruses with a high degree of concordance. The variations seen by 
demographic group and type of institution are also in keeping with both the known scientific literature and what 
one might expect based on previous studies. Accordingly we conclude that we can be relatively robust in our 
interpretation of the findings. These set a benchmark against which to measure trends and to plan for focused 
service planning, and for any future research in this area.
5.3 Prevalence of Drug Use
The first objective was to describe the nature, extent and pattern of consumption for different drugs among the 
prisoner population. We report the rate of prevalence of use of individual drugs surveyed from 33% to 87%, which 
greatly exceeds that of the general population of comparable age. Cannabis is indeed, as expected, the most 
commonly reported drug, but any lifetime heroin use, at 43% overall, is very high indeed and peaks in the mid age-
group of 25–34 year olds. Gender differences emerge from the outset. Women prisoners, albeit with much lower 
numbers incarcerated than men, are more likely to use drugs, to have used heroin or methadone, in their lifetime, 
in the last 12 months and the last 30 days. This translates also into differences in service needs, which we discuss 
further below. The directionality of this relationship is difficult to ascertain, but it has long been established that a 
drug lifestyle predisposes to being jailed and previous studies of Irish women prisoners show that this translates into 
very poor health generally (Mooney et al., 2002, Comiskey et al., 2006).
We employed a data-driven so-called dendritic classification system to categorise the prisons surveyed into groups, 
based on a composite measure of drugs consumption patterns, using criteria based on the EMCDDA recent 
problem drug use definition. To our knowledge this is the first study in Ireland or the UK in which prison category 
has been defined as described and has been used to report use of drugs and BBVs by category. Accordingly there 
are four categories of prison, with low, medium, high and very high associated drug use. Trends of prevalence can 
be seen then across these four categories, from the low use prisons where drugs are not an especial problem, 
to the two higher category groups where cannabis experience is almost ubiquitous and half or more of surveyed 
prisoners have had experience of heroin use. Numbers who report using drugs in the last 12 months drop off 
appreciably, but are still much higher than expected for the general population. Over 40% of all prisoners had 
used cannabis in the last 30 days, and a tenth had used heroin, again a pattern related to age, gender and type of 
prison. Direct comparisons of our results with other prison studies is problematic due to the methodological issues 
previously described and because this study probed more deeply than any previous study. From the comparisons 
that can be made there is no strong evidence to suggest that the drug problem in prisons is reducing. The short 
answer to the first objective therefore is that drugs consumption is a significant problem in our prison service, both 
in statistical prevalence and public health terms.
5.4 Methods of Drug Use
The second objective was to describe methods of drugs use. Again, in the literature review, we highlighted the 
fact that prisoner patterns differ from those of general addicts, in that smoking scarce drug material is considered 
more wasteful than injecting and there is a culture of sharing equipment in such injectors. We found that a quarter 
of prisoners had a lifetime history of drug injection, other than for medical reasons, and the predominant drug 
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injected was heroin. Again, the pattern peaked in the 25–34 year age-group, was more likely for the small group of 
women than for men and showed a strong positive trend by category of prison. Self-injection in the last 12 months 
was lower, and of especial importance for prison management purposes, current injection, i.e. injection in the last 
30 days, was very low (2%). Whilst this might translate into an appreciable case load across the service, it would 
appear nonetheless that prison needle exchange schemes may not be especially warranted in this country given the 
relatively high rates of methadone use, which is the predominant policy strategy in place.
Prisoners reporting drug ingestion started in their teens, were introduced first to cannabis, and if heroin users, had 
a relatively high likelihood of having been introduced to drugs in prison. Again, this fits the pattern of drug use 
reported in the general population, though clearly on a higher scale than the norm. Of cannabis users in the last 
12 months, high numbers reported they did so in prison and as the majority were in jail within that time period 
the pattern seems clear. Prison authorities should recognise that drugs, particularly cannabis, are making their way 
through the security checks into prison. Whilst the prevalence of drug injecting is low, there is a culture of sharing 
(58% among ever injectors), which could have serious health consequences for prisoners, in particular for the small 
group of women prisoners. How accurate are these self-report data? Certainly the figures for methadone agree with 
both the prisoners’ self-report and objectively recorded prison service data and the concordance was high between 
data sources, so we can have reasonable confidence in the accuracy of the findings.
Findings on excessive alcohol use, and the high rates of use for benzodiazepines and other sedatives and 
tranquillisers, whether with or without prescription, also need consideration taking account of the known prevalence 
of substance abuse and mental health issues among prisoners (Duffy et al., 2006), and suggest that drugs other 
than the typical ones require intervention.
5.5 Prevalence of Blood-Borne Viruses
The third objective was to estimate the prevalence of blood-borne viruses amongst the prisoner population and 
to identify associated risk behaviours. Prevalence of hepatitis B and HIV, whilst clearly higher than in the general 
population, are still thankfully found in relatively small numbers of prisoners and in the case of hepatitis C, 
prevalence has certainly seemed to fall since the last surveys. This may well reflect concerted prison health policy in 
the interval since, which is a positive finding for service providers. There was again a high concordance rate between 
the self-reported data and the actual measured data, with only a small number of people misclassified in either 
direction. There were a small number of true positives among the missing data group but most respondents were 
correct in their self-assessment, especially for hepatitis B. By far the most important factors associated with blood-
borne viruses in this prison population are the drug-related factors of ‘ever having used drugs IV’ and ‘ever having 
shared IV drug equipment’. Other significant factors, e.g. older age and having had a tattoo done in prison associated 
with hepatitis C, female gender associated with hepatitis C and HIV and male-to-male sexual contact as a risk factor 
for HIV, fall into the socio-demographic and behavioural factors and may be less amenable to intervention.
The demographic characteristics of the prisoner population are both similar to that found in previous surveys 
(Hannon et al., 2007) and in keeping with the international scientific literature. Prisoners are much more likely to 
be male, in their thirties, with very poor levels of education and using one indicator of lifestyle disadvantage, very 
heavy smokers. Self-rated health is a well-established subjective indicator that relates well to objective health status 
and to longer-term prediction of measurable health problems. This very young population of people report relatively 
poor levels of health, much higher than their counterparts in the general population and when viewed as a social 
gradient, the worst for any social group. One particularly disadvantaged group are Irish Travellers. The recently 
published All Ireland Traveller health study, in a series of reports, charts the poor health expectancy of Travellers and 
while noting that the vast majority of the 40,000 strong population is not in prison, the present survey shows that 
11% of the survey sample were in fact Travellers. This is an inordinately high representation for this population, and 
prison may provide an opportunity for access to healthcare and related services for this disadvantaged group, which 
might otherwise not engage with such services.
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We cannot again assess the directionality of the relationship between being imprisoned and having limited life 
chances but we can be clear that these characteristics of social and lifestyle disadvantage certainly limit prospects 
of rehabilitation and reintegration into mainstream society following release and highlight once again the need for 
step-down facilities, adequate training and positive lifestyle health promotion initiatives. The rates of re-offence 
and re-incarceration are also problematic for prisoner populations. This reinforces the vicious, cyclical circle of the 
situation. Those who are disadvantaged are more likely to slip into an adverse lifestyle including exposure to drugs, 
in turn are at higher risk of crime and consequent imprisonment, are exposed to the drug culture in prison and face 
serious challenges in achieving rehabilitation afterwards.
5.6 Utilisation of Services
The fourth objective was to measure the uptake of individual drug treatment and harm reduction interventions 
whilst in prison. For this objective, our prison group categorisation strategy proved particularly useful, both because it 
assisted in precision of estimates by grouping institutions to improve sample size, helped to preserve anonymity for 
respondents and service providers and also because it shows that service availability and utilisation patterns differ for 
different institution types. We listed a number of services potentially available to prisoners. The gradations in use of 
individual drugs from the low use to the very high use prisons show a generally increasing pattern. Services such as 
methadone maintenance were much more germane to the high and very high use category prisons and in general 
were available, especially to the high drug-use group. However, some services, such as addiction counselling, 
whilst needed by 40% of prisoners, were available only 60% of the time and had almost universally high uptake 
when they were available. There were issues of timeliness of availability also that merit planning exploration by 
providers. Other types of service, such as alcoholics anonymous, displayed a relatively similar pattern of need 
according to category of prison, at about a fifth of respondents overall. This is not surprising, given the young age 
of the respondents and the high rates of binge drinking culture seen generally in Irish society. This is a problem 
not conceptualised strongly by prisoners as an unmet need. Participants’ willingness to use services if available 
suggests rehabilitative solutions can be effective in reducing drug use. These data may be of value in the allocation 
of selected services to prisons in selected categories.
5.7 Strengths and Limitations
The strengths of this study include the fact that it was a national study involving inmates in all prisons in Ireland. 
Participants were selected randomly within prisons, albeit following exclusions of selected prisoners by the IPS. 
Cooperation from and working relationships with the IPS executive was excellent throughout the study. The 
comprehensive survey was based on an internationally validated set of questions, primarily from the EMCDDA, 
and included very detailed questions regarding lifetime, last year and last month use and injecting use of a wide 
range of individual drugs (thirteen in total), many of which are also asked in general population drug prevalence 
surveys. Results will therefore be suitable for comparison with any future prison studies that follow the EMCDDA 
methodology. Biological sampling for drugs of abuse has not previously been carried out in this context. Among 
prisoners who agreed to participate, component participation was extremely high. Despite the length and the 
sensitive and detailed nature of the questionnaire, completion rates were very high with minimal missing data. On 
analysis it became clear that prisoners engaged with the questions in a serious manner and internal consistency was 
very high. A trained and dedicated research team remained unchanged throughout the study.
The primary limitation of this study is likely to be the response rate, although this has been examined thoroughly 
and the potential impact on final results assessed in so far as possible. It must be emphasised that the final study 
sample was representative of the prisoner population in terms of demographic variables, length of time in prison 
and methadone use. The detailed account of the logistics and methods used for recruitment and sampling provided 
in the technical report published separately to this document will be useful for future Irish researchers in this area. It 
is recognised that certain relevant factors may have contributed to non-response, but it was not possible to quantify 
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what level of bias, if any, these introduced to the results. A limitation over which there was no control was the 
number of females in the sample. This is reflective of the total population of women in prison, approximately  
4%. Lack of direct access to the study participants for recruitment purposes could also be regarded as a limitation, 
but is related to security arrangements within the current prison environment and associated IPS staff and 
researcher safety.
5.8 What are the Policy Implications?
Clearly, this survey was commissioned in the context of on-going policy strategy for prisons and we can only 
comment to the extent that we have collected the data that will help to inform that process. However some 
important points come to mind. Firstly, this finding of drug use in prison is both a big and a small problem, in that 
it clearly poses an unacceptable health hazard and yet is occurring in a contained environment of relatively few 
people. Ireland as a society shows strong social gradients in health inequality and we have allowed the familiar 
patterns of area disadvantage seen in larger more industrialised countries to become endemic in our larger urban 
areas. Prisoner populations reflect that more general profile of social disadvantage. The Minister for Health is leading 
a cross-sectoral policy strategy review at present in 2011, entitled “Your Health is your Wealth”, and many of the 
patterns seen in prisoners, such as poor educational attainment and chronic unemployment, need to be tackled at 
root cause to address this life-course trajectory.
At a more specific level in relation to substance misuse, there are some signs that more concerted policing and 
community development strategies may be influencing drug supply, particularly of the harder drugs, and this may 
mean there is a real effect at play here, in that adverse drug use is peaking in the 25–34 year old group. As this 
study is based on the current prison ‘inmate’ population, this means that there are relatively few hard core users 
among them. While it is recognised that different patterns of drug use may exist among the larger throughput of 
committals (17,000 in 2010) these were not part of this study.
In relation to services within prisons, there was a demonstrated willingness on the part of surveyed prisoners to 
engage with relevant one to one services in prisons. The prison population thus includes a discrete sub-group of 
the national drug-using population, who may or may not engage with drug treatment and harm reduction services 
in the community. This could be capitalised upon in the 14 institutions to reach and engage those prisoners with 
various effective strategies, either already in place or with potential for development, such as brief intervention, 
motivational interviewing and cognitive behavioural therapy as well as treatment provision. In health promotion 
terms, empowerment to change is critical and the five key components are healthy public policy, personal skills 
development, community engagement, supportive environments and re-oriented services. The Health Promoting 
Prison concept has been advocated by the World Health Organisation (2005). Strategies such as control of 
drug supply, management of existing addiction and random policing of drug consumption form a necessary 
but only partial component of that picture. Prisoners, by contrast with the general perception by some of being 
uncooperative, are in fact often willing to engage effectively and it is a judgement call for service providers whether 
to take the carrot or stick approach to policy, e.g. voluntary surveillance rather than punitive random sampling with 
punishment for non-compliance.
In regard for instance to supportive environments, there are also signs in this survey that the prisoners who are 
not drug users would wish to be placed on drug-free wings, though this does not always happen. Effective triage 
strategies on prison entry could contain exposure to drugs while in prison and target more effectively those most 
in need. Morbidity and premature mortality are the established reality for modern prisoners in studies that have 
engaged in longitudinal follow-up of cohort members. Everything we have identified about the vulnerability of this 
group in society suggests that effective step-down intervention might help longer term health gain which would help 
the affected individuals and reduce the costs to society that are caused by criminality. The evidence base in the 
present survey should assist in that policy development.
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Please note for all age-group sub-categories that 10 participants did not provide their age.
Table A.1 NACD Irish Prison Study 2011: Lifetime Prevalence of Tobacco (Cigarettes) and Alcohol use
All Male Female 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Cigarettes 
(tobacco)
n = 808 n = 763 n = 45 n = 253 n = 318 n = 228
Prevalence 725 89.7 684 89.6 41 91.1 232 91.7 288 90.6 196 86.0
Upper 95% CI 91.5 91.4 96.0 94.3 93.1 89.6
Lower 95% CI 87.7 87.5 80.7 88.0 87.2 81.3
Alcohol n = 806 n = 761 n = 45 n = 252 n = 317 n = 227
Prevalence 777 96.4 738 97.0 39 86.7 249 98.8 303 95.6 216 95.2
Upper 95% CI 97.4 97.9 93.0 99.6 97.2 97.1
Lower 95% CI 95.0 95.6 75.4 96.8 93.0 91.8
In prevalence tables A2 to A7 below ‘other opiates’ refers to having taken opiates other than heroin or methadone. 
These were described to participants as ‘Diffs, Dikes, Peach, Napps, Pethidine, DF’s, Morphine, Opium or Codeine’.
115
Study on the prevalence of drug use, including intravenous drug use, 
and blood-borne viruses among the Irish prisoner population
Appendix: Prevalence Tables
Table A.2 NACD Irish Prison Study 2011: Self-reported Lifetime Prevalence of Drug Use
All Males Females 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Cannabis n = 815 n = 770 n = 45 n = 254 n = 321 n = 230
Prevalence 708 86.9 670 87.0 38 84.4 241 94.9 297 92.5 162 70.4
Upper 95% CI 88.8 89.0 91.4 96.8 94.7 75.5
Lower 95% CI 84.6 84.7 72.9 91.8 89.4 64.8
Sedatives or 
Tranquillisers
n = 808 n = 763 n = 45 n = 253 n = 320 n = 225
Prevalence 572 70.8 540 70.8 32 71.1 210 83.0 239 74.7 117 52.0
Upper 95% CI 73.6 73.6 81.0 86.7 78.8 57.9
Lower 95% CI 67.9 67.7 58.5 78.4 70.1 46.0
Benzodiazepines 
only
n = 807 n = 762 n = 45 n = 253 n = 319 n = 225
Prevalence 547 67.8 516 67.7 31 68.9 203 80.2 229 71.8 109 48.4
Upper 95% CI 70.6 70.7 79.1 84.3 76.0 54.4
Lower 95% CI 64.8 64.6 56.2 75.4 67.1 42.5
Sedatives or 
Tranquillisers 
(excl. Benzos)
n = 801 n = 756 n = 45 n = 250 n = 318 n = 223
Prevalence 466 58.2 435 57.5 31 68.9 166 66.4 196 61.6 100 44.8
Upper 95% CI 61.2 60.7 79.1 71.4 66.4 50.9
Lower 95% CI 55.0 54.3 56.2 60.9 56.7 39.0
Heroin n = 803 n = 758 n = 45 n = 249 n = 317 n = 227
Prevalence 348 43.3 319 42.1 29 64.4 94 37.8 159 50.2 90 39.7
Upper 95% CI 46.5 45.3 75.3 43.3 55.2 45.6
Lower 95% CI 40.3 38.9 51.7 32.5 45.2 34.0
Methadone n = 803 n = 758 n = 45 n = 249 n = 317 n = 227
Prevalence 262 32.6 235 31.0 27 60.0 60 24.1 128 40.4 69 30.4
Upper 95% CI 35.6 34.1 71.4 29.2 45.4 36.2
Lower 95% CI 29.8 28.1 47.3 19.7 35.6 25.2
Other Opiates n = 800 n = 755 n = 45 n = 246 n = 317 n = 227
Prevalence 260 32.5 241 31.9 19 42.2 54 22.0 131 41.3 72 31.7
Upper 95% CI 35.5 35.0 54.9 27.0 46.3 37.5
Lower 95% CI 29.6 29.0 30.6 17.7 36.5 26.5
Crack Cocaine n = 797 n = 753 n = 44 n = 248 n = 313 n = 226
Prevalence 284 35.6 258 34.3 26 59.1 74 29.8 134 42.8 72 31.9
Upper 95% CI 38.7 37.4 70.7 35.2 47.9 37.7
Lower 95% CI 32.7 31.3 46.2 25.0 37.9 26.6
Cocaine Powder n = 809 n = 765 n = 44 n = 251 n = 320 n = 228
Prevalence 600 74.2 571 74.6 29 65.9 210 83.7 262 81.9 121 53.1
Upper 95% CI 76.8 77.3 76.7 87.4 85.4 58.9
Lower 95% CI 71.3 71.7 53.0 79.1 77.7 47.1
Cocaine 
(including Crack 
and Powder)
n = 810 n = 766 n = 44 n = 251 n = 320 n = 229
Prevalence 605 74.7 574 74.9 31 70.5 211 84.1 265 82.8 122 53.3
Upper 95% CI 77.3 77.6 80.5 87.7 86.2 59.1
Lower 95% CI 71.9 72.0 57.6 79.5 78.7 47.3
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Table A.3 NACD Irish Prison Study 2011: Self-reported Last Year Prevalence of Drug Use
All Males Females 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Cannabis n = 808 n = 763 n = 45 n = 250 n = 318 n = 230
Prevalence 554 68.6 523 68.6 31 68.9 210 84.0 231 72.6 105 45.7
Upper 95% CI 71.4 71.5 79.1 87.7 76.9 51.6
Lower 95% CI 65.6 65.5 56.2 79.4 67.9 39.9
Sedatives or 
Tranquillisers
n = 797 n = 753 n = 44 n = 250 n = 316 n = 221
Prevalence 472 59.2 442 58.7 30 68.2 185 74.0 200 63.3 81 36.7
Upper 95% CI 62.3 61.9 78.6 78.6 68.0 42.7
Lower 95% CI 56.1 55.5 55.3 68.8 58.3 31.1
Benzodiazepines n = 795 n = 750 n = 45 n = 251 n = 314 n = 220
Prevalence 434 54.6 406 54.1 28 62.2 174 69.3 188 59.9 68 30.9
Upper 95% CI 57.7 57.4 73.4 74.2 64.7 36.8
Lower 95% CI 51.4 50.9 49.5 63.9 54.8 25.6
Sedatives or 
Tranquillisers 
(excl. Benzos)
n = 793 n = 749 n = 44 n = 245 n = 316 n = 222
Prevalence 367 46.3 337 45.0 30 68.2 136 55.5 158 50.0 69 31.1
Upper 95% CI 49.5 48.3 78.6 61.0 55.0 36.9
Lower 95% CI 43.1 41.8 55.3 49.9 45.0 25.8
Heroin n = 791 n = 746 n = 45 n = 249 n = 311 n = 221
Prevalence 233 29.5 212 28.4 21 46.7 74 29.7 112 36.0 45 20.4
Upper 95% CI 32.4 31.5 59.1 35.1 41.0 25.7
Lower 95% CI 26.7 25.6 34.7 24.9 31.3 16.0
Methadone n = 799 n = 754 n = 45 n = 249 n = 314 n = 226
Prevalence 167 20.9 142 18.8 25 55.6 36 14.5 83 26.4 44 19.5
Upper 95% CI 23.6 21.5 67.4 18.9 31.1 24.7
Lower 95% CI 18.5 16.4 43.0 11.0 22.3 15.2
Other Opiates n = 793 n = 748 n = 45 n = 246 n = 313 n = 224
Prevalence 103 13.0 94 12.6 9 20.0 29 11.8 52 16.6 21 9.4
Upper 95% CI 15.3 14.9 32.0 16.0 20.7 13.5
Lower 95% CI 11.0 10.6 12.0 8.7 13.2 6.5
Crack Cocaine n = 790 n = 746 n = 44 n = 247 n = 309 n = 224
Prevalence 92 11.7 78 10.5 14 31.8 26 10.5 47 15.2 18 8.0
Upper 95% CI 13.9 12.7 44.7 14.5 19.2 12.0
Lower 95% CI 9.8 8.6 21.4 7.6 11.9 5.4
Cocaine Powder n = 791 n = 748 n = 43 n = 247 n = 313 n = 221
Prevalence 226 28.6 208 27.8 18 41.9 96 38.9 101 32.3 26 11.8
Upper 95% CI 31.5 30.8 54.9 44.5 37.2 16.3
Lower 95% CI 25.8 25.0 30.0 33.6 27.8 8.4
Cocaine 
(including Crack 
and Powder)
n = 794 n = 
750
n = 44 n = 247 n = 314 n = 223
Prevalence 248 31.2 225 30.0 23 52.3 100 40.5 114 36.3 31 13.9
Upper 95% CI 34.2 33.1 64.5 46.1 41.3 18.6
Lower 95% CI 28.4 27.1 39.7 35.1 31.6 10.3
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Table A.4 NACD Irish Prison Study 2011: Self-reported Last Month Prevalence of Drug Use
All Males Females 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Cannabis n = 804 n = 760 n = 44 n = 250 n = 316 n = 228
Prevalence 349 43.4 332 43.7 17 38.6 128 51.2 148 46.8 67 29.4
Upper 95% CI 46.5 46.9 51.5 56.7 51.9 35.1
Lower 95% CI 40.3 40.5 27.3 45.6 41.9 24.3
Sedatives or 
Tranquillisers
n = 794 n = 750 n = 44 n = 250 n = 315 n = 219
Prevalence 273 34.4 251 33.5 22 50.0 95 38.0 119 37.8 55 25.1
Upper 95% CI 37.5 36.6 62.4 43.6 42.8 30.8
Lower 95% CI 31.5 30.5 37.6 32.8 33.1 20.2
Benzodiazepines n = 791 n = 746 n = 45 n = 251 n = 312 n = 218
Prevalence 229 29.0 211 28.3 18 40.0 79 31.5 106 34.0 43 19.7
Upper 95% CI 31.9 31.3 52.7 36.9 38.9 25.1
Lower 95% CI 26.2 25.4 28.6 26.6 29.4 15.4
Sedatives or 
Tranquillisers 
(excl. Benzos)
n = 788 n = 744 n = 44 n = 244 n = 314 n = 220
Prevalence 195 24.8 173 23.3 22 50.0 65 26.6 82 26.1 44 20.0
Upper 95% CI 27.6 26.1 62.4 32.0 30.8 25.3
Lower 95% CI 22.1 20.6 37.6 22.0 22.0 15.6
Heroin n = 785 n = 740 n = 45 n = 248 n = 310 n = 217
Prevalence 87 11.1 81 11.0 6 13.3 27 10.9 40 12.9 19 8.8
Upper 95% CI 13.3 13.2 24.5 14.9 16.7 12.9
Lower 95% CI 9.3 9.1 7.1 7.9 9.9 5.9
Methadone n = 798 n = 753 n = 45 n = 249 n = 314 n = 225
Prevalence 106 13.3 90 12.0 16 35.6 13 5.2 57 18.2 34 15.1
Upper 95% CI 15.6 14.2 48.3 8.4 22.4 20.0
Lower 95% CI 11.3 10.0 24.8 3.3 14.6 11.3
Opiates other 
than heroin or 
methadone
n = 791 n = 746 n = 45 n = 245 n = 313 n = 223
Prevalence 35 4.4 35 4.7 0 0.0 6 2.5 17 5.4 12 5.4
Upper 95% CI 5.9 6.3 6.8 5.0 8.3 8.9
Lower 95% CI 3.3 3.5 0.0 1.2 3.6 3.3
Crack Cocaine n = 788 n = 744 n = 44 n = 247 n = 308 n = 223
Prevalence 15 1.9 13 1.8 2 4.6 2 0.8 7 2.3 6 2.7
Upper 95% CI 3.0 2.9 13.7 2.7 4.4 5.5
Lower 95% CI 1.2 1.1 1.5 0.3 1.2 1.3
Cocaine Powder n = 781 n = 739 n = 42 n = 242 n = 310 n = 219
Prevalence 41 5.3 40 5.4 1 2.4 11 4.6 19 6.1 10 4.6
Upper 95% CI 6.9 7.1 11.1 7.6 9.1 7.9
Lower 95% CI 4.0 4.1 0.5 2.7 4.1 2.7
Cocaine (including 
Crack and Powder)
n = 783 n = 740 n = 43 n = 242 n = 310 n = 221
Prevalence 45 5.8 43 5.8 2 4.7 11 4.6 20 6.5 13 5.9
Upper 95% CI 7.4 7.6 14.1 7.6 9.5 9.5
Lower 95% CI 4.4 4.5 1.6 2.7 4.4 3.7
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Table A.5 NACD Irish Prison Study 2011: Self-reported Lifetime Prevalence of Injecting Drug Use
All Males Females 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Any drug n=813 n= 768 n=45 n=253 n=320 n=230
Prevalence 207 25.5 187 24.4 20 44.4 46 18.2 109 34.1 51 22.2
Upper 95% CI 28.3 27.2 57.0 22.9 38.9 27.5
Lower 95% CI 22.9 21.7 32.6 14.3 29.5 17.7
Benzodiazepines n=804 n=760 n=44 n=250 n=315 n=229
Prevalence 71 8.8 64 8.4 7 15.9 9 3.6 36 11.4 25 10.9
Upper 95% CI 10.8 10.4 27.6 6.4 15.1 15.2
Lower 95% CI 7.2 6.8 8.8 2.1 8.6 7.8
Amphetamines n=799 n=756 n=43 n=249 n=313 n=227
Prevalence 47 5.9 43 5.7 4 9.3 7 2.8 21 6.7 18 7.9
Upper 95% CI 7.6 7.4 20.0 5.4 9.8 11.8
Lower 95% CI 4.6 4.4 4.3 1.5 4.6 5.3
Heroin n=805 n=761 n=44 n=251 n=315 n=229
Prevalence 154 19.1 135 17.7 19 43.2 26 10.4 83 26.4 44 19.2
Upper 95% CI 21.7 20.4 56.0 14.3 31.0 24.3
Lower 95% CI 16.8 15.4 31.3 7.5 22.2 15.0
Methadone n=799 n=756 n=43 n=248 n=315 n=226
Prevalence 22 2.8 21 2.8 1 2.3 3 1.2 9 2.9 10 4.4
Upper 95% CI 4.0 4.1 10.8 3.3 5.1 7.7
Lower 95% CI 1.9 1.9 0.5 0.5 1.6 2.6
Opiates other 
than heroin or 
methadone
n=793 n=751 n=42 n=248 n=310 n=225
Prevalence 54 6.8 48 6.4 6 14.3 7 2.8 24 7.7 22 9.8
Upper 95% CI 8.6 8.2 26.2 5.4 11.0 14.0
Lower 95% CI 5.4 5.0 7.5 1.5 5.5 6.8
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Table A.5 NACD Irish Prison Study 2011: Self-reported Lifetime Prevalence of Injecting Drug Use
All Males Females 18–24 Years 25–34 Years 35–64 Years
n % n % n % n %
Cocaine Powder n=803 n=759 n=44 n=250 n=314 n=229
Prevalence 104 13.0 90 11.9 14 31.8 13 5.2 56 17.8 34 14.9
Upper 95% CI 15.2 14.1 44.7 8.3 22.0 19.6
Lower 95% CI 11.0 9.9 21.4 3.3 14.3 11.1
Mephedrone n=797 n=752 n=45 n=250 n=313 n=224
Prevalence 34 4.3 27 3.6 7 15.6 11 4.4 16 5.1 6 2.7
Upper 95% CI 5.8 5.0 27.0 7.4 7.9 5.5
Lower 95% CI 3.2 2.6 8.7 2.7 3.3 1.3
Methylone n=794 n=749 n=45 n=250 n=312 n=222
Prevalence 20 2.5 15 2.0 5 11.1 7 2.8 9 2.9 4 1.8
Upper 95% CI 3.7 3.2 21.8 5.4 5.2 4.3
Lower 95% CI 1.7 1.3 5.5 1.5 1.6 0.8
Crystal Meth n=795 n=750 n=45 n=250 n=312 n=223
Prevalence 13 1.6 12 1.6 1 2.2 2 0.8 5 1.6 5 2.2
Upper 95% CI 2.7 2.7 10.3 2.7 3.5 4.9
Lower 95% CI 1.0 1.0 0.5 0.3 0.8 1.1
Steroids n=807 n=762 n=45 n=253 n=317 n=227
Prevalence 69 8.6 68 8.9 1 2.2 22 8.7 33 10.4 13 5.7
Upper 95% CI 10.5 11.0 10.3 12.4 13.9 9.2
Lower 95% CI 7.0 7.3 0.5 6.1 7.8 3.6
Any Other Drug n=784 n=742 n=42 n=248 n=304 n=222
Prevalence 35 4.5 29 3.9 6 14.3 3 1.2 20 6.6 11 5.0
Upper 95% CI 6.0 5.4 26.2 3.3 9.7 8.4
Lower 95% CI 3.3 2.8 7.5 0.5 4.5 3.0
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Table A.6 NACD Irish Prison Study 2011: Self-reported Last Year Prevalence of Injecting Drug Use
All Male Female 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Benzodiazepines n=803 n=759 n=44 n=250 n=315 n=228
Prevalence 23 2.9 18 2.4 5 11.4 7 2.8 13 4.1 3 1.3
Upper 95% CI 4.1 3.6 22.3 5.4 6.7 3.6
Lower 95% CI 2.0 1.6 5.7 1.5 2.6 0.5
Amphetamines n=797 n=754 n=43 n=249 n=312 n=226
Prevalence 12 1.5 9 1.2 3 7.0 4 1.6 6 1.9 2 0.9
Upper 95% CI 2.5 2.2 17.1 3.8 3.9 3.0
Lower 95% CI 0.9 0.7 2.8 0.7 1.0 0.3
Heroin n=797 n=754 n=43 n=251 n=311 n=225
Prevalence 55 6.9 46 6.1 9 20.9 20 8.0 27 8.7 8 3.6
Upper 95% CI 8.7 7.9 33.4 11.6 12.0 6.6
Lower 95% CI 5.5 4.7 12.5 5.5 6.3 1.9
Methadone n=798 n=755 n=43 n=248 n=315 n=225
Prevalence 6 0.8 5 0.7 1 2.3 2 0.8 3 1.0 1 0.4
Upper 95% CI 1.6 1.5 10.8 2.7 2.6 2.3
Lower 95% CI 0.4 0.3 0.5 0.3 0.4 0.1
Opiates other 
than heroin or 
methadone
n=789 n=748 n=41 n=248 n=308 n=223
Prevalence 8 1.0 7 0.9 1 2.4 2 0.8 5 1.6 1 0.5
Upper 95% CI 1.9 1.8 11.4 2.7 3.6 2.3
Lower 95% CI 0.6 0.5 0.5 0.3 0.8 0.1
Cocaine Powder n=797 n=754 n=43 n=250 n=313 n=224
Prevalence 25 3.1 19 2.5 6 14.0 7 2.8 13 4.2 5 2.2
Upper 95% CI 4.5 3.8 25.6 5.4 6.7 4.9
Lower 95% CI 2.2 1.7 7.4 1.5 2.6 1.0
Mephedrone n=796 n=751 n=45 n=250 n=312 n=224
Prevalence 18 2.3 12 1.6 6 13.3 7 2.8 9 2.9 2 0.9
Upper 95% CI 3.4 2.7 24.5 5.4 5.2 3.0
Lower 95% CI 1.5 1.0 7.1 1.5 1.6 0.3
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Table A.6 NACD Irish Prison Study 2011: Self-reported Last Year Prevalence of Injecting Drug Use
All Male Female 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Methylone n=795 n=750 n=45 n=250 n=312 n=223
Prevalence 9 1.1 6 0.8 3 6.7 3 1.2 5 1.6 1 0.5
Upper 95% CI 2.1 1.7 16.4 3.2 3.5 2.3
Lower 95% CI 0.6 0.4 2.7 0.5 0.8 0.1
Crystal Meth n=795 n=750 n=45 n=250 n=312 n=223
Prevalence 3 0.4 3 0.4 0 0.0 0 0.0 2 0.6 1 0.5
Upper 95% CI 1.0 1.1 6.8 1.4 2.2 2.3
Lower 95% CI 0.2 0.2 0.0 0.0 0.2 0.1
Steroids n=805 n=760 n=45 n=252 n=317 n=226
Prevalence 19 2.4 19 2.5 0 0.0 5 2.0 12 3.8 2 0.9
Upper 95% CI 3.5 3.8 6.8 4.3 6.3 3.0
Lower 95% CI 1.6 1.7 0.0 1.0 2.3 0.3
Any Other Drug n=783 n=741 n=42 n=248 n=303 n=222
Prevalence 11 1.4 9 1.2 2 4.8 2 0.8 5 1.7 4 1.8
Upper 95% CI 2.4 2.2 14.4 2.7 3.6 4.3
Lower 95% CI 0.8 0.7 1.6 0.3 0.8 0.8
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Table A.7 NACD Irish Prison Study 2011: Self-reported Last Month Prevalence of Injecting Drug Use
All Male Female 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Benzodiazepines n=802 n=758 n=44 n=249 n=315 n=228
Prevalence 4 0.5 3 0.4 1 2.3 1 0.4 2 0.6 1 0.4
Upper 95% CI 1.2 1.1 10.6 2.1 2.1 2.3
Lower 95% CI 0.2 0.2 0.5 0.1 0.2 0.1
Amphetamines n=797 n=753 n=44 n=249 n=311 n=227
Prevalence 2 0.3 1 0.1 1 2.3 1 0.4 1 0.3 0 0.0
Upper 95% CI 0.9 0.7 10.6 2.1 1.7 1.5
Lower 95% CI 0.1 0.0 0.5 0.1 0.1 0.0
Heroin n=794 n=750 n=44 n=249 n=309 n=226
Prevalence 7 0.9 5 0.7 2 4.6 2 0.8 3 1.0 2 0.9
Upper 95% CI 1.7 1.5 13.7 2.7 2.7 3.0
Lower 95% CI 0.5 0.3 1.5 0.3 0.4 0.3
Methadone n=797 n=754 n=43 n=248 n=314 n=225
Prevalence 3 0.4 2 0.3 1 2.3 1 0.4 2 0.6 0 0.0
Upper 95% CI 1.0 0.9 10.8 2.1 2.2 1.5
Lower 95% CI 0.2 0.1 0.5 0.1 0.2 0.0
Opiates other 
than heroin or 
methadone
n=788 n=747 n=41 n=247 n=308 n=223
Prevalence 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Upper 95% CI 0.4 0.5 7.5 1.4 1.1 1.6
Lower 95% CI 0.0 0.0 0.0 0.0 0.0 0.0
Cocaine Powder n=796 n=752 n=44 n=248 n=313 n=225
Prevalence 8 1.0 7 0.9 1 2.3 1 0.4 6 1.9 1 0.4
Upper 95% CI 1.9 1.8 10.6 2.1 3.9 2.3
Lower 95% CI 0.6 0.5 0.5 0.1 1.0 0.1
Mephedrone n=796 n=751 n=45 n=250 n=312 n=224
Prevalence 2 0.3 1 0.1 1 2.2 1 0.4 1 0.3 0 0.0
Upper 95% CI 0.9 0.7 10.3 2.1 1.7 1.6
Lower 95% CI 0.1 0.0 0.5 0.1 0.1 0.0
Methylone n=794 n=749 n=45 n=250 n=311 n=223
Prevalence 1 0.1 1 0.1 0 0.0 0 0.0 1 0.3 0 0.0
Upper 95% CI 0.7 0.7 6.8 1.4 1.7 1.6
Lower 95% CI 0.0 0.0 0.0 0.0 0.1 0.0
Crystal Meth n=796 n=751 n=45 n=250 n=312 n=224
Prevalence 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Upper 95% CI 0.4 0.5 6.8 1.4 1.1 1.6
Lower 95% CI 0.0 0.0 0.0 0.0 0.0 0.0
Steroids n=805 n=760 n=45 n=252 n=317 n=226
Prevalence 4 0.5 4 0.5 0 0.0 0 0.0 3 1.0 1 0.4
Upper 95% CI 1.2 1.3 6.8 1.4 2.6 2.3
Lower 95% CI 0.2 0.2 0.0 0.0 0.4 0.1
Any Other Drug n=782 n=740 n=42 n=248 n=302 n=222
Prevalence 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Upper 95% CI 0.5 0.5 7.3 1.4 1.2 1.6
Lower 95% CI 0.0 0.0 0.0 0.0 0.0 0.0
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Table A.8 NACD Irish Prison Study 2011: Self-reported Prevalence of HIV, hepatitis B and hepatitis C*
All Male Female 18–24 Years 25–34 Years 35–64 Years
n % n % n % n % n % n %
Hepatitis B n = 793 n = 749 n = 44 n = 248 n = 314 n = 222
Prevalence 9 1.1 9 1.2 0 0.0 2 0.8 3 1.0 3 1.4
Upper 95% CI 2.1 2.2 7.0 2.7 2.6 3.7
Lower 95% CI 0.6 0.7 0.0 0.3 0.4 0.5
Hepatitis C n = 781 n = 737 n = 44 n = 245 n = 309 n = 218
Prevalence 67 8.6 60 8.1 7 15.9 2 0.8 37 12.0 27 12.4
Upper 95% CI 10.6 10.2 27.6 2.7 15.7 17.0
Lower 95% CI 7.0 6.5 8.8 0.3 9.1 8.9
HIV n = 777 n = 733 n = 44 n = 243 n = 309 n = 216
Prevalence 11 1.4 9 1.2 2 4.6 0 0.0 5 1.6 5 2.3
Upper 95% CI 2.4 2.2 13.7 1.4 3.6 5.1
Lower 95% CI 0.8 0.7 1.5 0.0 0.8 1.1
* Based on those who tested positive to either their first or their last test
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Table A.9 NACD Irish Prison Study 2011: Prevalence of HIV, hepatitis B and hepatitis C based on Oral 
Fluid Sample Testing
All Male Female 18–24 Years 25–34 Years 35–64 Years
n = 777 n = 732 n = 45 n = 239 n = 307 n = 216
n % n % n % n % n % n %
Hepatitis B (HBsAg)
Prevalence 2 0.3 2 0.3 0 0.0 0 0.0 1 0.3 1 0.5
Upper 95% CI 0.9 0.9 6.8 1.4 1.7 2.4
Lower 95% CI 0.1 0.1 0.0 0.0 0.1 0.1
Hepatitis C (Anti-HCV)
Prevalence 100 12.9 90 12.3 10 22.2 7 2.9 51 16.6 41 19.0
Upper 95% CI 15.2 14.7 34.4 5.6 20.8 24.3
Lower 95% CI 10.9 10.3 13.7 1.6 13.2 14.7
HIV (Anti-HIV)
Prevalence 15 1.9 11 1.5 4 8.9 1 0.4 6 2.0 7 3.2
Upper 95% CI 3.1 2.6 19.1 2.2 4.0 6.3
Lower 95% CI 1.2 0.9 4.1 0.1 1.0 1.7
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Table A.10 NACD Irish Prison Study 2011: Prevalence of Drug Use in the 24–72 Hours Prior to the Study 
Based on Oral Fluid Sample Testing*
All Male Female 18–24 Years 25–34 Years 35–64 Years
n = 775 n = 730 n = 45 n = 240 n = 308 n = 212
n % n % n % n % n % n %
Cannabis
Prevalence 31 4.0 31 4.2 0 0.0 9 3.8 14 4.5 8 3.8
Upper 95% CI 5.5 5.8 6.8 6.7 7.2 7.0
Lower 95% CI 2.9 3.1 0.0 2.1 2.9 2.1
All Male Female 18–24 Years 25–34 Years 35–64 Years
n = 777 n = 732 n = 45 n = 241 n = 309 n = 212
n % n % n % n % n % n %
Benzodiazepines
Prevalence 83 10.7 74 10.1 9 20.0 25 10.4 40 12.9 18 8.5
Upper 95% CI 12.8 12.3 32.0 14.4 16.8 12.7
Lower 95% CI 8.9 8.3 12.0 7.4 9.9 5.7
Methadone
Prevalence 103 13.3 88 12.0 15 33.3 11 4.6 55 17.8 35 16.5
Upper 95% CI 15.6 14.4 46.0 7.7 22.1 21.7
Lower 95% CI 11.2 10.0 22.8 2.7 14.3 12.4
Opiates
Prevalence 2 0.3 2 0.3 0 0.0 0 0.0 1 0.3 0 0.0
Upper 95% CI 0.9 0.9 6.8 1.4 1.7 1.6
Lower 95% CI 0.1 0.1 0.0 0.0 0.1 0.0
Cocaine
Prevalence 1 0.1 1 0.1 0 0.0 0 0.0 1 0.3 0 0.0
Upper 95% CI 0.7 0.7 6.8 1.4 1.7 1.6
Lower 95% CI 0.0 0.0 0.0 0.0 0.1 0.0
* Oral fluid tests can detect the presence of drug metabolites for drugs taken up to 72 hours prior to the survey
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